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MASTL is a Ser/Thr kinase first identified in Drosophila and Xenopus as a protein required for 
mitosis. MASTL inhibits, through phosphorylation of ENSA and ARPP19, the phosphatase PP2A 
in complex with the B55 family of regulatory subunits. In this work, we describe that Mastl is 
essential for mitotic progression in mouse embryonic fibroblasts (MEFs) derived from a 
conditional loss-of-function mouse model for Mastl, through inhibition of PP2A/B55 complexes. 
Mastl mediated inhibition of PP2A/B55 prevents premature dephosphorylation of CDK1 
phosphosubstrates that are essential for chromosome condensation and segregation, and proper 
progression through mitosis. This proliferative role of Mastl is essential in vitro in cell culture and 
in vivo. Work done in a mouse model for Mastl shows that ablation of Mastl in young mice results 
in mitotic aberrations, severe proliferative defects and rapid death after Mastl depletion. Deletion 
of Mastl in elder mice, in contrast, causes less severe proliferative problems and improved 
survival. Nevertheless, Mastl depletion in adult mice also leads, in the long term, to impaired 
tissue regeneration, altered tissue homeostasis and eventual death of the mice. 
Although PP2A/B55 is a phosphatase that regulates multiple cellular processes, the only 
function attributed so far to the PP2A/B55-inhibitory kinase MASTL in mammals is its role in 
mitosis. Aiming to identify new functions of MASTL, we have explored other potential cell cycle-
dependent and independent functions of MASTL. Whereas Mastl was not required for S-phase 
entry or maintenance of the quiescence state, we have found a new and unexplored role for the 
MASTL-PP2A/B55 pathway in the control of insulin signaling downstream of mTORC1.  
The mTORC1/S6K1 axis triggers a negative feedback loop that inhibits the upstream 
PI3K pathway, which in turn, is also important for controlling mTORC1 activity. We have found 
that MASTL-mediated PP2A/B55 inhibition prevents the activating dephosphorylation of the 
feedback target proteins, IRS1 and GRB10, and is required to fine-tune the feedback-mediated 
inhibition of the PI3K/AKT pathway and its metabolic consequences. Interestingly, MASTL activity 
is also modulated downstream of the mTORC1/S6K1 axis in conditions of feedback activity. 
This feedback loop is physiologically relevant in vivo for metabolic diseases involving 
insulin resistance, such as obesity or type 2 diabetes. Importantly, we have found that depletion 
of Mastl improves glucose tolerance in a mouse model of high fat diet-induced obesity, and 
lowers basal glycaemia in old mice. This data together indicate that MASTL, through the inhibition 
of PP2A/B55, has a new mitotic-independent function in mammals in the control of PI3K/AKT-
mTORC1 signaling and cooperates to control glucose homeostasis in vivo. 
  Summary/Resumen   
	   16	  
 MASTL fue identificada por primera vez en Drosophila y Xenopus como una quinasa requerida 
para mitosis. MASTL inhibe, a través de la fosforilación de ENSA y ARPP19, los complejos de la 
fosfatasa PP2A con subunidades reguladoras de la familia B55. En este trabajo hemos 
demostrado que MASTL también es esencial para la progresión a través de mitosis en 
fibroblastos embrionarios de ratón del modelo condicional de pérdida de función de Mastl, 
mediante la inhibición de PP2A/B55. La inhibición de PP2A/B55 por MASTL previene la 
desfosforilación prematura de los epítopos fosforilados por CDK1, los cuales son esenciales para 
la condensación y segregación de los cromosomas, y la progresión a través de mitosis. Los 
estudios realizados en el modelo condicional demostraron que la eliminación de Mastl en ratones 
jóvenes resulta en aberraciones mitóticas y defectos proliferativos severos que comprometen la 
supervivencia rápidamente después de la eliminación de Mastl. Por el contrario, la depleción de 
Mastl en ratones adultos, resulta en defectos proliferativos menos severos y mayor 
supervivencia. La eliminación de Mastl a largo plazo resulta, sin embargo, en pérdida de 
capacidad regenerativa y homeostasis de los tejidos que finalmente provoca la muerte. 
 Aunque PP2A/B55 es una fosfatasa que regula múltiples procesos, la única función 
atribuida hasta la fecha a su quinasa inhibitoria, MASTL, es por ahora su papel en mitosis. 
Mientras que MASTL no es esencial para la entrada en fase S o para el mantenimiento de 
quiescencia, hemos encontrado una nueva función de la vía MASTL-PP2A/B55 en el control de 
la ruta de señalización de insulina regulada por mTORC1. 
 El módulo PI3K/AKT-mTORC1 acopla la presencia de nutrientes, energía y factores de 
crecimiento con el crecimiento, proliferación y metabolismo celular. mTORC1/S6K1 lanza un 
circuito de retroalimentación negativo (negative feedback loop) que inhibe la vía de PI3K/AKT 
después de su activación. Hemos descubierto que la inhibición de PP2A/B55 mediada por 
MASTL previene la desfosforilación de las proteínas fosforiladas por mTORC1/S6K1, IRS y 
GRB10, y es necesaria para regular la inhibición de AKT mediada por mTORC1 y sus 
consecuencias metabólicas. Además, la actividad catalítica de MASTL está regulada de manera 
dependiente de mTORC1/S6K1 en condiciones de inhibición de AKT. 
La regulación retroactiva de la ruta PI3K/AKT-mTORC1 es importante in vivo, dado que 
su desregulación está implicada en enfermedades metabólicas de resistencia a la insulina, como 
obesidad o diabetes tipo 2. Nuestros resultados muestran que la eliminación de Mastl mejora la 
tolerancia a la glucosa en un modelo de ratón de obesidad inducida por dieta grasa y disminuye 
la glicemia basal en ratones adultos. En conjunto, estos resultados indican que MASTL 
desarrolla una función independiente de mitosis en mamíferos, en la que regula la vía de 
señalización de PI3K/AKT/mTORC1 y ayuda a mantener la homeostasis de la glucosa in vivo. 
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1.1 MASTL-PP2A/B55 pathway in mammals 
1.1.1 MASTL/Greatwall: a PP2A-inhibitory kinase with critical roles in mitosis 
Cell cycle progression is controlled by multiple enzymatic activities including protein 
phosphorylation, which are coordinated by a network of kinases and phosphatases. Mitotic entry 
is driven by the activation of the cyclin-dependent kinase 1 (CDK1)-cyclin B complexes, which are 
activated at the G2-M transition and promote a broad range of protein phosphorylations that 
result in ordered structural rearrangements in the cell, such as nuclear envelope breakdown 
(NEB), chromosome condensation, and spindle formation. Entry and maintenance of the mitotic 
state depends on the inhibition of phosphatases to promote CDK1-cyclinB activity through an 
autocatalytic amplification loop, and to prevent the premature dephosphorylation of CDK 
substrates (Álvarez-Fernández & Malumbres, 2014; Lindqvist et al., 2009). In mammals, protein 
phosphatase 2A (PP2A) is the main phosphatase that dephosphorylates CDK1-cycB target 
proteins, including those involved in the CDK1 auto-amplification loop. Mitotic exit, on the 
contrary, requires inhibition of mitotic kinases, activation of phosphatases, and degradation of 
other critical regulators. PP2A/B55 activity as a major phosphatase that counteracts CDK-
substrate phosphorylation, is essential for mitotic exit (Wurzenberger & Gerlich, 2011) (Figure 1). 
PP2A is a major proline-directed Ser/Thr phosphatase involved in cell cycle regulation. It is a 
heterotrimeric complex composed of a catalytic subunit C, a structural subunit A, and a regulatory 
subunit B that confers substrate specificity. In mammals there are 4 subfamilies of B regulatory 
subunits (B55, B56, PR72 and PR93). The B55 family of regulatory subunits is composed of four 
isoforms (α, β, γ, and δ), and in vitro confers specificity toward CDK substrate consensus 
sequences (proline-directed Ser/Thr sites). PP2A/B55δ is essential for dephosphorylation of 
CDK1 substrates and mitotic exit in Xenopus extracts (Castilho et al., 2009; Mochida et al., 
2009). Depletion of B55α in HeLa cells delays mitotic exit and the re-assembly of postmitotic 
structures, such as nuclear envelope and Golgi apparatus (Schmitz et al., 2010), whereas 
depletion of both B55α and B55δ induces mitotic exit of metaphase-arrested cells in mouse 
embryonic fibroblasts (MEFs) (Manchado et al., 2010). 
Rencently, a new cell cycle kinase has emerged linking CDK1 and PP2A activities in mitosis. 
MASTL (microtubule-associated Ser/Thr kinase-like protein), also known as Greatwall (Gwl) in 
Xenopus and Drosophila, is activated by CDK1 during mitotic entry and inhibits the activity of 
PP2A/B55 complexes in mitosis to prevent premature dephosphorylation of CDK1 substrates and 
maintain the mitotic state (Castilho et al., 2009; Mochida et al., 2009) (Figure 1).  
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MASTL/Gwl was originally identified in Drosophila as a protein required for DNA 
condensation and normal progression through mitosis (Yu et al., 2004). Gwl mutant cells 
displayed a delayed entry into mitosis, with spindle aberrations and chromosome condensation 
and segregation defects, a function that was later on shown to be conserved in mammalian cells. 
RNA interference studies in cultured HeLa cells showed that depletion of MASTL results in 
inefficient mitotic entry, mitotic defects and deficient phosphorylation of CDK1 substrates, which 
can be partially rescued by PP2A inhibition (Burgess et al., 2010; Voets & Wolthuis, 2010). In 
contrast to fly and mammals, depletion of Gwl from Xenopus extracts prevents mitotic entry (J. 
Yu et al., 2006), and the concomitant inhibition of PP2A/B55 rescues defective mitotic entry 
(Vigneron et al., 2009). Additionally, studies in Xenopus oocytes and other organisms reported 
the involvement of Gwl in meiosis, as activation of Gwl promotes meiotic resumption through 
inhibition of PP2A/B55 (Vigneron et al., 2016). 
 
 
Figure 1. Regulatory interactions between CDK1 and PP2A and their control by 
MASTL/Gwl. CDK1 is inhibited by WEE1/MYT1-dependent phosphorylation and activated by 
CDC25 phosphatases that counteract inhibitory phosphorylation. Activity of these proteins is 
controlled by CDK1 and PP2A. CDK1 activate its activators and inhibits its inhibitors, and these 
processes are reverted by PP2A/B55 activity. MASTL, which is activated by CDK1 and 
inactivated by PP2A/B55, is able to inhibit PP2A/B55 complexes through direct phosphorylation 
of endosulfines. All these regulatory loops modulate the phosphorylation of a wide spectrum of 
substrates whose phosphorylation controls mitotic entry and progression. Adapted from (Álvarez-
Fernández & Malumbres, 2014). 
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1.1.2 MASTL inhibits PP2A through phosphorylation of ENSA and ARPP19 
Studies in Xenopus egg extracts showed that MASTL/Gwl inhibits PP2A/B55 indirectly through 
phosphorylation of two substrates of the endosulfine family, α-endosulfine (ENSA) and cAMP-
regulated phosphoprotein (ARPP19) (Aicha Gharbi-Ayachi et al., 2010; Mochida et al., 2010) 
(Figure 1). These two 20-kDa proteins share high homology and are phosphorylated by MASTL 
on a unique serine residue (S67 and S62 of human ENSA and ARPP19, respectively), in turn, 
this phosphorylation is counteracted by PP2A/B55. MASTL-mediated phosphorylation of ENSA 
and ARPP19 promotes their binding to the active site of PP2A/B55 complexes, and inhibits its 
phosphatase activity through a mechanism termed ‘inhibition by unfair competition’. That means 
that ENSA/ARPP19, when phosphorylated, bind very efficiently but are very slowly 
dephosphorylated by PP2A/B55 compared to other substrates, until progressive 
dephosphorylation reduces its affinity and allow reactivation of the phosphatase and complete 
dephosphorylation and release of its inhibitor (Williams et al., 2014). 
Besides MASTL/Gwl-dependent phosphorylation, ENSA and ARPP19 can be also 
phosphorylated by protein kinase A (PKA) and CDK1-cycB at different sites. In Xenopus egg 
extracts phosphorylation of endosulfines by CDK1 alone does not generate inhibitory activity 
against PP2A/B55 (Mochida, 2014), and mitotic entry is impaired in the absence of Gwl. In 
Starfish oocytes, by contrast, Cdk1-dependent phosphorylation of Arpp19 inhibits PP2A/B55 via a 
Gwl independent mechanism and is sufficient to promote mitotic entry. Whereas the role of PKA-
mediated phosphorylation is not well understood, it is proposed that PKA-mediated 
phosphorylation of endosulfines could impair MASTL-mediated phosphorylation or decrease its 
binding affinity to PP2A/B55, since PKA inhibition promotes Cdk1-cyclinB re-activation and 
meiotic resumption (Dupre et al., 2014). Although the relative contribution of Cdk1 and PKA to the 
regulation of ENSA and ARPP19 is yet not fully understood, they might participate in the fine 
modulation of PP2A to confer the correct timing of inhibition under different in vivo conditions 
(Lorca & Castro, 2012; Mochida, 2014). 
1.1.3 Regulation of MASTL activity 
MASTL and its close relatives MAST1-4 constitute a poorly studied branch of the AGC kinase 
family. MASTL is an atypical member of the AGC family as it contains a non-conserved insertion 
of around 550 amino acids (termed non conserved middle region; NCMR) splitting the catalytic 
kinase domain into two separate N-terminal and C-terminal lobes. The mechanism by which 
MASTL is activated at mitotic entry is poorly understood (Blake-Hodek et al., 2012) (Figure 2).  
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 Activating phosphorylations in MASTL are located within its N-terminal region, including the 
T194 and T207, which probably function as activating T-loop phosphorylation and are targeted by 
CDKs, explaining at least in part how MASTL is turned on at mitotic entry (Blake-hodek et al., 
2012). The C-terminal tail (known as the turn motif in PKA or the tail/Z site in growth factor-
stimulated AGC kinases) is a critical region whose phosphorylation is normally required for 
conformational changes and kinase activity. In fact, autophosphorylation at S875 is considered a 
major pre-requisite for full activation of MASTL, and mutations of this residue to alanine impairs 
MASTL activity (Blake-Hodek et al., 2012; Vigneron, Gharbi-ayachi, et al., 2011). This 
phosphorylated residue in the C-tail probably interacts with a basic patch on the enzyme’s N-
terminal lobe to help stabilize the active conformation. Apart for the already described regulation 
of MASTL by CDKs in a mitotic context, nothing is known about the putative contribution of other 
kinases to MASTL regulation in other cellular contexts. Due probably to the fact that MASTL is a 
large kinase, many different phosphorylated sites in MASTL have been detected, event though 
little is known about their relative contribution to the regulation of MASTL activity or the putative 
kinases upstream of MASTL regulating these sites (Blake-Hodek et al., 2012). 
 
Figure 2. Model of MASTL activation. MASTL is depicted with four domains: the N-terminal 
lobe (N lobe), the C-terminal lobe (C lobe), the nonconserved middle region (NCMR), and the C-
terminal tail (thick black line). During M phase entry, CDK1-cyclinB phosphorylates MASTL at the 
presumptive activation T-loop sites T194 and T207. After MASTL is primed by phosphorylation at 
the T-loop, S875 in the C-terminal tail can be autophosphorylated. It is likely that phosphorylated 
S875 can subsequently interact with a patch of basic residues in the N-lobe (dark triangle) to help 
stabilize active MASTL. The round hole in the N lobe depicts the putative conserved hydrophobic 
binding pocket, whose role is not yet clear. Adapted from (Blake-Hodek et al., 2012). 
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 At least three phosphatases, protein phosphatase 1 (PP1), Fcp1 and PP2A-B55 itself, 
have been reported to be involved in the inactivation of MASTL during mitotic exit, although the 
precise mechanism of MASTL inactivation is not understood yet (Vigneron et al., 2016). 
1.1.4 Role of the MASTL-PP2A/B55 pathway in physiology and disease 
Besides its essential function in the control of mitosis and meiosis, the only additional function 
attributed to MASTL so far is in the DNA-damage checkpoint recovery (Peng et al., 2010). 
Probably due to the fact that all these data emerged relatively recently, little is known about the 
physiologycal relevance of MASTL in mammals or its implications in human disease.  
The first association of MASTL with disease was the discovery of a missense mutation in the 
human gene (MASTL, FLJ14813) on chromosome 10 that linked MASTL to a novel form of 
autosomal dominant inherited thrombocytopenia (Gandhi et al., 2003). In addition, MASTL has 
been recently related to cancer as it is overexpressed in specific tumors types, such as oral 
squamous carcinoma, colon cancer and neuroblastoma (Dahlhaus et al., 2016; Vera et al., 2015; 
Wang et al., 2014),	   and MASTL inhibition might have a therapeutic benefit (Anania et al., 2015; 
Nagel et al., 2015). A recent study also suggested that MASTL might promote cell transformation 
in an ENSA/ARPP19-PP2A-independent manner by hyperactivating AKT (Vera et al., 2015). 
 PP2A is considered a major tumor suppressor in multiple malignancies. Aberrant 
expression, mutations and somatic alterations of the PP2A scaffold and regulatory subunits have 
been detected in several tumor types (Eichhorn et al., 2009). For instance epigenetic silencing by 
hypermethylation of B55β subunit, encoded by PPP2R2B, occurs in almost all colorectal cancer 
samples analyzed (Tan et al., 2010). Similarly, deletions of PPP2R2A, the gene encoding B55α, 
have been found in a significant fraction of luminal breast tumors (Curtis et al., 2012). On the 
contrary, B55α has been shown to be overexpressed in pancreatic ductal adenocarcinoma tissue 
and required for sustained hyperactivity of the AKT, ERK and WNT oncogenic pathways in 
pancreatic cancer (Hein et al., 2016). In a different work, PP2A/B55α is required for HIF1α 
stabilization and promotes survival under hipoxia and glucose starvation in different breast cancer 
cell lines (Conza et al., 2017; Di Conza et al., 2017).  
PP2A/B55 complexes function in many different pathways in the cell and, as such, 
control other cellular or physiological functions in addition to cell cycle progression. Nevertheless, 
it is not known to what extent all these PP2A/B55-dependent functions are also mediated by  
MASTL, and, therefore, MASTL might also be relevant for other biological processes beyond cell 
cycle regulation.  
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1.2 Role of Rim15 and Ppk18, the yeast MASTL kinases 
1.2.1 Conservation of the MASTL-endosulfine-PP2A/B55 pathway  
The MASTL-ENSA/ARPP19-PP2A/B55 pathway is evolutionary conserved from yeast to 
mammals. Rim15, the budding yeast orthologous of MASTL kinase, phosphorylates the 
endosulfine proteins Igo1/2, the two orthologous of human ENSA and ARPP19, at the site 
equivalent of their vertebrate counterparts to promote binding to and directly inhibit the 
phosphatase PP2A/Cdc55, the yeast orthologous of PP2A/B55 proteins (Bontron et al., 2013; 
Talarek et al., 2010) (Figure 3). The evolutionary conservation of the pathway is further 
strengthened by the finding that Rim15 phosphorylates in vitro human ENSA and ARPP19 
endosulfines in their equivalent site, and that human ENSA and ARPP19 are able to partially 
replace Igo1/2 function in budding yeast (Juanes et al., 2013; Talarek et al., 2010). In addition, 
yeast endosulfines can be phosphorylated by MASTL/Gwl and promote mitotic entry in Xenopus 
egg extracts (Juanes et al., 2013). The MASTL-endosulfine-PP2A regulatory module appears to 
be conserved in all organisms analyzed to date, with the notable exception of the nematode C. 
elegans where and obvious MASTL-like kinase seems to be missing (M. Y. Kim et al., 2012) 
(Figure 3). 
 
 
1.2.2 Regulation of Rim15 and Ppk18 by nutrient-regulated pathways  
Eukaryotic cell proliferation is controlled by growth factors and essential nutrients, in the absence 
of which cells cease growing, reversible arrest cell division and enter into a quiescent state (also 
known as G0 state) (Malumbres & Barbacid, 2001). In yeast, the decision of cells to initiate, or 
 
Figure 3. Conservation of the 
MASTL-ENSA/ARPP19-
PP2A/B55 pathway from yeast 
to mammals. MASTL/Gwl 
inhibits PP2A/B55 complexes 
through phosphorylation of Ensa 
and Arpp19 proteins.  
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not, the quiescence program relies on the conserved nutrient signaling pathways of TORC1 and 
PKA, which are responsive to the abundance in the media of nitrogen and/or carbon, and 
glucose, respectively. Rim15 integrates signals from these nutrient-dependent protein kinases, 
and initiates a program to mediate entry into quiescence (de Virgilio, 2012). Rim15 is activated 
upon nutrient limitation, and its activation requires its nuclear accumulation and Rim15 
autophosphorylation (Pedruzzi et al., 2003) (Figure 4). Rim15 amino acid sequence has five 
consensus sites for PKA, and Rim15 kinase activity is under the direct and negative control of 
Ras2/PKA pathway in vitro (Reinders et al., 1998). Rim15 is also inhibited by TORC1, which 
retains Rim15 in the cytoplasm and impairs its kinase activity (Pedruzzi et al., 2003). However, 
TORC1-mediated inhibition of Rim15 is indirect through the inhibition of a phosphatase and/or 
activation of a alternative kinase (Wanke et al., 2005). Sch9, the yeast orthologous of AKT and/or 
S6K1, signals the combined presence of glucose and nitrogen and negatively regulates Rim15, 
even though the mechanism is not fully understood (Fabrizio et al., 2001). Sch9, like TOR, is 
required for the cytoplasmic retention of Rim15. However, unlike rapamycin-induced 
hyperphosphorylation of Rim15, Rim15 was not hyperphosphorylated in the absence of Sch9, 
suggesting that TOR and Sch9 are likely to regulate Rim15 function via two different mechanisms 
(Pedruzzi et al., 2003). 
As in budding yeast, the fission yeast MASTL kinase, Ppk18, is also negatively regulated 
by TORC1 and PKA pathways, and links nutrient status to mitotic size control. Ppk18 protein 
sequence contains several phosphorylation sites for fission yeast S6K1 kinase, which 
phosphorylates Ppk18 in nitrogen-rich medium and inhibit its activity (Chica et al., 2016).  
 
Figure 4. Control of Rim15 
activity by PKA, TORC1 and 
Sch9 pathways in budding 
yeast. PKA phosphorylates and 
inhibits Rim15, whereas TORC1 
and Sch9 retain Rim15 in the 
cytoplasm. Dashed lines 
indicate indirect regulation by a 
not fully understood 
mechanism. Adapted from 
(Pedruzzi et al., 2003) 
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1.2.3 Role of the Rim15-Igo1/2-PP2A/Cdc55 pathway in the control of quiescence in 
budding yeast 
Rim15 was described for first time in S. cerevisiae, as a protein essential to promote initiation of 
the quiescence program and ensure maximal survival in the stationary phase (e.g. following 
growth for 5 days), also known as chronological life span (CLS). Cells that lack Rim15 failed to 
properly enter quiescence after entry into stationary phase and nutrient limitation, had reduced 
survival, defects in glycogen accumulation and lower capacity to resume proliferation(Fabrizio et 
al., 2001; Pedruzzi et al., 2003; Reinders et al., 1998). Rim15 ensures this function by controlling 
the expression of specific stress- and nutrient-regulated genes implicated in G0 arrest through a 
dual role of Rim15 (Figure 5). The first one involves direct activation of gene transcription 
through phosphorylation of Igo1/2 and inhibition of the phosphatase PP2A/Cdc55 (Bontron et al., 
2013). Inhibition of PP2A/Cdc55 activates the transcription factor Gis1 and induces the 
expression of specific nutrient-regulated genes. Rim15 also up-regulates expression of genes 
involved in stress response through the transcription factors Msn2/4 (Cameroni et al., 2004). The 
second mechanism is mediated by Rim15-dependent phosphorylation of Igo1/2 proteins 
independently of PP2A/Cdc55 and involves the stabilization of specific mRNAs by preventing its 
degradation via 5’-3’ mRNA decay pathway (Luo et al., 2011; Talarek et al., 2010).  
Altogether these data places Rim15 as critical mediator downstream of nutrient regulated 
pathways, to control entry into quiescence and CLS after nutrient deprivation. Because 
orthologous of many genes in this network are known to affect aging in higher eukaryotes, these 
results might point to similar mechanisms in mammalian cells (M. Wei et al., 2008). 
 
Figure 5. Role of Rim15 in the control of 
quiescence and stress resistance. In budding 
yeast nitrogen and carbon limitation causes 
activation of the Rim15 kinase to promote the 
transcription of genes required for G0 program 
initiation through two mechanisms: i) Rim15 
through inhibition of PP2A/Cdc55 promotes Gis1-
mediated transcription. ii) Rim15-mediated 
phosphorylation of Igo1/2 proteins license 
specific mRNAs to evade de 5’-30 mRNA decay 
pathway (Bontron et al., 2013). 
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1.2.4 Other functions of the MASTL-endosulfine-PP2A/BB5 pathway in yeast 
New targets of the Rim15-Igo1/2-PP2A/Cdc55 pathway have been recently described in yeast 
suggesting the involvement of Rim15 in other aspects of nutrient regulated pathways. Rim15 
promotes autophagy under nutrient-limiting conditions and TORC1 inhibition through the 
inhibition of Rph1, a transcriptional repressor of autophagy-related genes, whose function is also 
conserved in mammals (Bernard et al., 2015). 
The Rim15 pathway also coordinates the phosphorylation status of the CDK inhibitor Sic1, 
p27Kip1 in mammals, to couple TORC1 signaling with cell cycle progression. Following TORC1 
inactivation, Rim15-mediated PP2A/Cdc55 inhibition stabilizes Sic1 and ensures G1 arrest 
(Moreno-torres et al., 2015). 
In budding yeast, Rim15 controls timely mitotic progression through the conserved Igo1/2-
PP2A/Cdc55 axis but with some remarkable differences compared to multicellular organisms 
(Juanes et al., 2013). In mitosis Rim15 activates, rather than inhibits PP2A/Cdc55, which in turn 
promotes mitotic entry, as PP2A/Cdc55 positively regulates the autocatalytic amplification of 
CDK1. Rim15 or Igo1/2 deletion had no significant effect in unperturbed mitosis, however under 
stress conditions delayed mitotic entry and mitotic defects become apparent (Juanes et al., 
2013). 
The MASTL-endosulfine-PP2A/B55 pathway is equally conserved in fission yeast, where 
Ppk18 and Pab1 are the fission yeast orthologous of MASTL and B55, respectively, and connect 
nutritional environment to the cell cycle machinery to control cell size (Chica et al., 2016). Fission 
yeast is a good model for studying mechanisms coupling cell growth and cell division, as the 
threshold of cell size necessary for cell division is determined by growth conditions. In the 
presence of nutrients, inhibition of Ppk18 by TORC1/S6K1 activates PP2A/Pab1 activity to 
prevent the activation of mitotic Cdk1, and cells increase in size before they divide. By contrast, in 
nutrient limiting conditions, TORC1 inhibition relieves Ppk18 activity and decreases PP2A/Pab1 
activity therefore promoting Cdk1 activation and accelerated entry into mitosis with a smaller cell 
size (Chica et al., 2016).  
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1.3 Nutrient- and growth factor- regulated pathways in mammals 
1.3.1 The mTOR signaling pathway 
The mammalian target of rapamycin (mTOR) is a master regulator of cell growth, proliferation 
and metabolism and responds to a variety of extracellular and intracellular stimuli, including 
growth factors, nutrients, and energy. All cells must coordinate their metabolic activity with 
changes in their nutrient environment to grow and proliferate when nutrients are abundant. In this 
condition mTOR is activated and stimulates anabolic processes to synthetize essential building 
blocks such as proteins, lipids and nucleotides. As a central controller of organism growth and 
homeostasis, aberrant regulation of mTOR signaling has been implicated in cancer, metabolic, 
neurological, inflammatory and autoimmune diseases (Saxton & Sabatini, 2017).  
mTOR belongs to the phosphoinositide 3-kinase (PI3K)-related protein kinases (PIKK) family, 
and exists in two functionally and structurally distinct complexes, mTORC1 and mTORC2 (Saxton 
& Sabatini, 2017). mTORC1 is comprised of three essential and evolutionary conserved core 
subunits: mTOR, RAPTOR (regulatory protein associated with mTOR) and mLST8 (mammalian 
lethal with Sec13 protein 8). RAPTOR facilitates substrate recruitment to mTORC1 through 
binding to the TOR signaling (TOS) motif found on several canonical mTORC1 substrates, and is 
 
Figure 6. mTORC1 and mTORC2. Subunits of mTOR complexes, upstream regulators and major 
processes downstream mTOR signaling to help the cell coordinate nutrient input with biosynthetic 
output. 
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required for the correct subcellular localization of mTORC1. In addition to these three 
components, mTORC1 also contains two inhibitory subunits, PRAS40 and DEPTOR (Figure 6).  
mTORC2 complex is distinguished by having RICTOR (rapamycin insensitive companion of 
mTOR) instead of RAPTOR, which also function as scaffold for assembling complexes and 
binding substrates. Additionally mTORC2 contains: mLST8, the regulatory subunits mSin1 and 
PROTOR1/2, and the inhibitory subunit DEPTOR (Figure 6). mTORC1 activity is sensitive to the 
rapamycin-FKB12 complex, which function as allosteric inhibitor. In contrast, rapamycin-FKB12 
complex cannot interact with mTORC2, which is characterized by its insensitivity to acute 
rapamycin treatment, even though prolonged rapamycin treatment also abrogates mTORC2 
signaling (Saxton & Sabatini, 2017). 
1.3.2 Processes regulated downstream of mTOR 
When activated, mTORC1 phosphorylates a number of substrates, the best characterized of 
which are S6K1 and 4E-BP1 that promote protein synthesis when phosphorylated at T389 and 
T36/47-S65, respectively (Saxton & Sabatini, 2017). Through phosphorylation of different 
substrates, mTORC1 promotes anabolic processes, including de novo lipid and nucleotide 
synthesis, and also inhibits autophagy (Figure 6). mTORC1 controls metabolism by enhancing 
glycolysis and the activity of the pentose phosphate pathway, thereby promoting the production of 
ATP and NADPH to support anabolic processes. mTORC1 signaling favors glycolysis by 
increasing the translation of hypoxia-inducible factor 1 (HIF1α), which induces the expression of 
the glucose transporter GLUT1 and glycolytic enzymes such as phospho-fructo kinase (PFK). In 
addition, mTORC1 and S6K1 have several substrates, including growth factor receptor-bound 
protein 10 (GRB10) and insulin receptor substrate proteins (IRS), which restrain insulin pathway 
activation upstream of mTORC1 forming a negative feedback loop. 
mTORC2 instead controls proliferation and survival primarily by phosphorylating several 
members of the AGC family of protein kinases (Saxton & Sabatini, 2017). The most important 
function of mTORC2 is likely the phosphorylation and activation of the S/T AKT kinase, a key 
effector of insulin-PI3K signaling (Figure 6). mTORC2 also controls remodeling of the actin 
cytoskeleton and cell migration through phosphorylation of PKCs. 
1.3.3 Signal integration by mTORC1 
Systemic changes in the organism are sensed by mTORC1 through pathways activated by 
secreted growth factors, cytokines and hormones, and nutrients, as activation of mTORC1 is also 
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dependent on sufficient levels of intracellular amino acids, glucose and oxygen. Nutrients seem to 
be the more ancient input for mTORC1, as its activation in yeast depends exclusively on nutrient 
availability. In higher eukaryotes, cell culture experiments suggest that intracellular nutrients only 
basally activate mTORC1, but are essential for its robust stimulation by extracellular growth 
factors (Dibble & Manning, 2013).  
In comparison to mTORC1, mTORC2 regulation is poorly understood. Growth factors and 
PI3K signaling stimulate mTORC2 activity, which is in part mediated through PI3K-dependent 
mTORC2-ribosome association (Zinzalla et al., 2011).  
Below there is a description of the signaling pathways upstream of mTORC1 and the 
mechanisms through which they control mTORC1 activation: 
a) Growth factors 
 Growth factor signaling pathways stimulate an acute and robust increase in mTORC1 
activity. mTORC1 is activated by insulin and most other growth factors through either receptor 
tyrosine kinases (RTKs) or G-protein-coupled receptors (GPCRs) at the cell surface (Dibble & 
Manning, 2013; Saxton & Sabatini, 2017). Downstream of these receptors, two major signaling 
pathways are involved in mTORC1 activation: the phosphatidylinositol-3-OH kinase (PI3K)-AKT 
and RAS-ERK pathways (Figure 7), which are differentially activated downstream of specific 
receptors, with the PI3K/AKT pathway dominating downstream of the insulin and insulin-like 
growth factor (IGF) receptors. Growth-factor-dependent pathways stimulate mTORC1 signaling 
by inhibiting the tuberous sclerosis heterotrimeric complex (TSC) composed of TSC2, TSC1 and 
TBC1D7, whereby TSC1 stabilizes TSC2, and TSC2 acts as GTPase-activating protein (GAP). 
The TSC complex is a GAP for Rheb (Ras homolog enriched in brain), which is an essential 
mTORC1 activator present in the lysosomal membrane. Rheb activates mTORC1 when it is in its 
GTP-bound state, although the precise mechanism of how Rheb activates mTORC1 remains 
unknown. In response to growth factors, AKT-mediated phosphorylation of TSC2 on T1462 and 
S939 inhibits the TSC complex by inducing its dissociation from the lysosomal membrane, where 
Rheb localizes, without altering its GAP activity (Inoki et al., 2002; Manning et al., 2002; Menon et 
al., 2014). TSC inhibition relieves Rheb activity and allows mTORC1 activation at the lysosomal 
membrane. Downstream of the growth factor receptors, activation of RSK and ERK can also 
inhibit TSC2 by inducing its phosphorylation. RSK can phosphorylate TSC on the AKT sites, as 
well as other sites (Roux et al., 2004). Although, TSC complex is essential to inhibit mTORC1 
signaling in the absence of growth factors, parallel mechanisms can also contribute to mTORC1 
regulation, such as AKT-mediated phosphorylation and inhibition of PRAS40 on T246 (Vander 
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Haar et al., 2007). Additional growth factor pathways upstream of TSC include Wnt and the 
inflammatory cytokine TNFα pathways, both of which activate mTORC1 through the 
phosphorylation of TSC1 and the inhibition of the TSC complex (Saxton & Sabatini, 2017). 
 Of note, the TSC complex has also been linked to mTORC2 function. TSC complex 
interacts with mTORC2 and positively regulates its kinase activity by yet undefined mechanisms 
(Huang et al., 2008). 
b) Amino acids 
Amino acids are essential nutrients for mTORC1 activation. The primary amino acid 
sensing pathway involves the Rag GTPases, which are heterodimeric components that are 
tethered to the lysosomal membrane through their association to the Ragulator complex (Saxton 
& Sabatini, 2017).  Amino acid stimulation converts the Rags to their active GTP-bound state, 
allowing them to bind RAPTOR and recruit mTORC1 to the lysosomal surface, where Rheb is 
located (Figure 7). This mechanism allows a very thigh control of mTORC1 activation by 
nutrients, whereby mTORC1 signaling is only on when both the Rags and Rheb are activated, 
explaining why both amino acids and growth factors are required for mTORC1 activation. 
c) Glucose, oxygen and cellular energy levels 
mTORC1 also responds to intracellular and environmental stresses that are incompatible 
with growth such as low cellular energy levels as a consequence of reduced glucose or oxygen 
availability (Dibble & Manning, 2013; Saxton & Sabatini, 2017). Cells respond to such changes by 
tipping the metabolic balance from anabolic to catabolic processes that produce energy, and as a 
major promoter of anabolic processes, mTORC1 is a key target in this metabolic adaptation.  
Glucose controls mTORC1 through different mechanisms and is required for its activation. A 
reduction in energy levels, such as during glucose deprivation, activates AMPK, which promotes 
catabolic metabolism and activates autophagy. AMPK inhibits mTORC1 both indirectly, through 
phosphorylation and activation of TSC2 on T1387, as well as directly through phosphorylation 
and inhibition of RAPTOR on S792 (Figure 7) (Gwinn et al., 2008; Inoki et al., 2003). 
Interestingly, glucose deprivation still inhibits mTORC1 in cells lacking AMPK, through inhibition 
of the Rag GTPases and impaired lysosomal localization of mTORC1 (Efeyan et al., 2013; 
Kalender et al., 2010). MEFs that are homozygous for a constitutively active mutant of RagA are 
resistant to the inhibitory effects of either amino acid or glucose withdrawal on mTORC1 signaling 
(Efeyan et al., 2013), although the precise mechanism of glucose sensing upstream Rag 
GTPases is unknown.  
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Similarly, hypoxia inhibits mTORC1, in part through AMPK activation, but also through the 
induction of REDD1 mediated by HIF1α, which activates TSC (Figure 7) (Brugarolas et al., 
2004). REDD1 is also required for the inhibitory effects of glucose starvation on mTORC1 activity 
(Sofer et al., 2005), but rather this effects result from the deletereous effects of glucose starvation 
on protein maturation and activation of the unfolded protein response in the endoplasmatic 
reticulum (ER), and ATF4-mediated transcription of REDD1.  
In addition to the mechanisms discussed above, the p38-regulated/activated kinase (PRAK) is 
activated under energetic stress and is required to supress mTORC1 signaling through inhibition 
of Rheb (Zheng et al., 2011). 
 
 
Figure 7. mTORC1 signaling network. Signaling pathways upstream of mTORC1. Growth 
factors and nutrients (e.g. glucose and amino acids) positively regulate mTORC1 signaling mainly 
through regulation of TSC complex and Rag GTPases, respectively. Low energy such as in 
conditions of glucose starvation or hypoxia inhibits mTORC1 signaling through different 
mechanisms, which are depicted in red. Inhibitory and activating phosphorylations are shown in 
grey and black, respectively. 
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1.3.4 The PI3K-AKT pathway 
AKT activation is initiated by growth factors and the stimulation of RTKs and GPCRs on the 
cell surface (Manning & Toker, 2017). Once activated, RTKs autophosphorylate, creating 
phosphotyrosine binding sites for the IRS family of scaffolding proteins, among others. IRS1 and 
IRS2 proteins are subsequently phosphorylated by the insulin and insulin-like growth factor (IGF-
I) receptors on several tyrosine residues, which initiate signaling cascades by acting as binding 
sites for proteins containing src homology 2 domains, including the p85 regulatory subunit of 
PI3K. IRS-mediated activation of PI3K at the plasma membrane leads to the generation of the 
lipid second messenger phosphatidylinositol-3,4,5-triphosphate (PIP3), which recruits a subset of 
proteins with pleckstrin homology domains, like AKT and PDK1. AKT is then activated upon 
recruitment to the plasma membrane by subsequent phosphorylation by mTORC2 at S473 in the 
hydrophobic motif and PDK1 at T308 in the T-loop (Figure 9). Phosphorylation of both residues 
is required for maximal activation of the kinase. Signal termination of PI3K-PIP3 signaling is 
achieved by the phosphatase PTEN, which dephosphorylates PIP3 converting it back to PIP2. 
The initial synthesis of PI3K lipid products is observed within minutes after growth factor 
stimulation, exhibits a peak, and is then down regulated with a timing that depends on the cell 
type and stimulus. The transient nature of this signal is largely achieved by PTEN combined with 
other inactivation of PI3K (Manning & Toker, 2017). In addition to PTEN, two other phosphatases 
have been shown to inhibit AKT by inducing its direct dephosphorylation. PP2A in complex with 
B55α binds and dephosphorylates the T308 on AKT in murine lymphoid cells (Kuo et al., 2008), 
whereas the PH domain leucine-rich repeat protein phosphatases (PHLPP1 and PHLPP2) are 
responsible for S473 dephosphorylation (Gao et al., 2005). 
AKT is a central node downstream of growth factors, and contributes to diverse cellular roles, 
which includes cell survival, growth, proliferation, migration, angiogenesis and metabolism 
(Manning & Toker, 2017). Aberrant loss or gain of AKT activation underlies the 
pathophysiological properties of a variety of diseases, including type-2 diabetes and cancer. 
Given the complexity and diversity of signaling downstream AKT, we will focus on AKT targets 
involved in this work, mostly related to glucose metabolism.  
One of the most important physiological functions of AKT is to acutely stimulate glucose 
uptake in response to insulin through the induction of GLUT4 translocation to the plasma 
membrane (Sano et al., 2003) (Figure 8). The mechanism by which AKT stimulates GLUT4 
translocation involves phosphorylation of the Rab-GAP AS160 (Sano et al., 2003), although other 
studies have suggested AS160-independent mechanisms and other AKT substrates involved in 
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this process (L. Bai et al., 2007). AKT can also positively regulate glucose uptake by upregulating 
the levels of GLUT1, which is the main glucose transporter in most cell types, and unlike GLUT4, 
it appears to be regulated through alterations in expression levels. AKT-mediated activation of 
mTORC1 contributes to HIF1α-dependent transcription of GLUT1 gene and cap-dependent 
translation of GLUT1 mRNA (Zelzer et al., 1998). 
Upon entry into the cells glucose can be stored by conversion to glycogen or catabolized to 
produce energy through glycolysis, and AKT can regulate both processes. AKT increases the 
rate of glycolysis (Elstrom et al., 2004) due, at least in part, to its ability to promote expression of 
glycolytic enzymes through mTORC1-dependent induction of HIF1α transcription factor (Lum et 
al., 2007; Majumder et al., 2004). AKT phosphorylates and inhibits glycogen synthase kinase 
(GSK3) (Cross et al., 1995), which regulates a large set of targets, among them glycogen 
synthase activity whose activity is relieved by AKT stimulating glycogen synthesis, a process 
particularly important in muscle and liver. AKT phosphorylates and inhibits the	   Forkhead Box O 
(FoxO) family of transcription factors (Brunet et al., 1999), which are involved in diverse 
processes including induction of apoptosis, cell-cycle arrest, or gluconeogenesis, a process 
specially important in hepatocytes (Manning & Toker, 2017).  
1.3.5 Feedback regulation of PI3K/AKT signaling by mTORC1/S6K1 
The PI3K/AKT axis is subjected to negative feedback regulation after its activation, reflecting the 
necessity of putting a brake to excessive or chronic activation of the pathway. A very important 
negative feedback loop involves the inhibition of PI3K/AKT signaling by mTORC1/S6K1, which is 
also important for mTORC1 regulation itself (Efeyan & Sabatini, 2010). Apart from the inhibition of 
PI3K/AKT, this feedback loop is also responsible for inhibiting the activity of the Ras-ERK 
pathway (Carracedo et al., 2008). Feedback regulation occurs at different levels and restrains 
upstream signaling through insulin/IGF-I receptors as well as other receptor tyrosine kinases 
 
Figure 8. Substrates and functions of AKT involved in glucose uptake and metabolism. 
Positive and negative regulation of AKT is shown with arrows and flat bars, respectively. 
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(Rodrik-Outmezguine et al., 2011). Studies done in TSC-null MEFs, which show constitutive 
mTORC1 activation, uncovered a strikingly inability of serum, platelet-derived growth factor 
(PDGF), and specially insulin and IGF-I, to activate the PI3K/AKT. The insensitivity to PDGFR 
was due to a loss of expression of both PDGF receptors alpha and beta, and was mediated by 
S6K1 (Zhang et al., 2007). Two different studies showed that the mechanism of insulin/IGF-I 
resistance was consequence of constitutive down-regulation of IRS1 and IRS2 proteins due to 
sustained mTORC1 signaling, as rapamycin treatment of TSC2-deficient MEFs completely 
restored IRS protein levels and the sensitivity to insulin and IGF-I (Harrington et al., 2004; Shah 
et al., 2004). mTORC1 hyperactivation in TSC2 null MEFs promotes multisite serine 
phosphorylation of IRS and triggers its degradation (Harrington et al., 2004; Shah et al., 2004) 
(Figure 9). Knockdown of S6K1 could restore the expression of IRS1 in TSC2-null MEFs 
(Harrington et al., 2004), and a kinase dead version of S6K1 blocked the negative feedback loop 
and restored the levels of activated AKT (Shah et al., 2004), further suggesting that S6K1 activity 
downstream of mTORC1 is involved in IRS phosphorylation and inhibition of AKT signaling.  
 
Figure 9. The PI3K/AKT signaling pathway and mTORC1-mediated feedback regulation. 
Growth factors stimulate activation of the receptors and signal transduction mediated by adaptor 
proteins containing SH2 domains to the PI3K/AKT signaling. Subsequent mTORC1/S6K1 
activation triggers negative feedback loops to inhibit the PI3K pathway after its activation. 
Phosphatases counteract activating phosphorylations on events of the pathway, and are depicted 
in gray. Negative feedback loops are shown with red lines. Inhibitory phosphorylations are in red 
and activating phosphorylations in black. 
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Activation of mTORC1 by amino acids has been shown to attenuate insulin signaling through 
mTORC1-dependent effects on IRS1, which imply changes in phosphorylation, localization 
and/or degradation (Takano et al., 2001; Tremblay & Marette, 2001). Similarly, PI3K/AKT-
mediated activation of mTORC1 in response to insulin or PDGF, also leads to multisite serine 
phosphorylation on IRS which induces its proteosomal degradation in a rapamycin sensitive 
manner (Carlson et al., 2004; Greene et al., 2003; Haruta et al., 2000) (Figure 9).  
IRS-independent feedbacks have been also proposed, including mTORC1-dependent 
phosphorylation of GRB10, a negative adaptor protein of insulin and IGF-I signaling (Hsu et al., 
2011a; Y. Yu et al., 2011). mTORC1 phosphorylates GRB10 at multiple sites stabilizing the 
protein and enhancing its ability to block PI3K/AKT activation. Additionally, a new non-cell 
autonomous mechanism of mTORC1-dependent feedback inhibition of the IGF-I pathway has 
been recently described. It involves mTORC1-HIF1α-dependent transcription of IGF binding 
protein 5 (IGFBP5), which blocks IGFR-I activation in the extracellular space, and synergizes with 
GRB10 (Ding et al., 2016). Interestingly, GRB10 and IGFBP5 expression is frequently down 
regulated in various cancers (Ding et al., 2016; Yonghao et al., 2011). 
There are also points of cross talk between mTORC1 and mTORC2 that influence full 
activation of AKT. S6K1-mediated phosphorylation of the mTORC2 components RICTOR and 
Sin1 decreases mTORC2-dependent phosphorylation of AKT on S473, but curiously not other 
substrates (Dibble, Asara, & Manning, 2009). These regulatory loops point toward a cellular 
mechanism that prevents simultaneous activation of mTORC1 and mTORC2 and influence full 
activation of AKT.   
Although the involvement of feedback phosphatases has been far less studied, evidences 
suggest that the action of mTOR in the phosphorylation and degradation of IRS1 results from 
inhibition of PP2A. Interestingly, rapamycin treatment increased PP2A activity and IRS1 protein 
stability was shown to be regulated by PP2A, since treatment of cells with okadaic acid, a PP2A 
inhibitor, increased the phosphorylation of IRS1 and induced IRS1 degradation (Clark, Molero, & 
James, 2000; Hartley & Cooper, 2002) (Figure 9).  
1.3.6 Role of the mTORC1/S6K1-dependent feedback loop in insulin resistance 
According to the mTORC1/S6K1-dependent feedback loop described above, high levels of 
constitutive mTORC1 activity leads to insulin desensitization and attenuated AKT activation in 
cells. Insulin resistance is a pathological state of obesity and type 2 diabetes that occurs, at least 
in part, through chronic activation of mTORC1/S6K1 by nutrients and constitutive feedback 
activity that blocks AKT activation, disrupting the key metabolic actions of insulin (Zoncu et al., 
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2011) (Figure 10). This state is characterized by high levels of circulating glucose as 
consequence of reduced glucose uptake and impaired glycogen synthesis in the muscle, adipose 
tissue and liver, and concomitant increased gluconeogenesis and glucose release by the liver. 
Insulin is produced and secreted by pancreatic β-cells in response to glucose, and stimulates 
adaptive signaling events in liver, fat and muscle. β-cells in the pancreas have a specialized role 
in sensing systemic glucose levels. Glucose is imported by GLUT2 in murine pancreas and 
through glycolysis increases the ratio ATP/ADP. ATP induces the closure of KATP channels and 
causes membrane depolarization that results in a transient rise in intracellular calcium 
concentration that facilitates insulin release to systemic circulation (Efeyan et al., 2015).  
Insulin induces post-prandial glucose uptake and storage specially, in skeletal muscle where 
it takes place around 75% of glucose uptake, and also in adipose tissue (Leto & Saltiel, 2012; 
Saltiel & Kahn, 2001). GLUT4 is the predominant glucose transporter expressed in skeletal 
muscle and adipose tissue, where insulin-stimulated PI3K/AKT activation leads to the rapid 
 
Figure 10. The mTORC1-dependent feedback loop in physiology and disease. a) In conditions 
of nutrient balance, activation of AKT by insulin triggers the translocation of GLUT4 contained in 
intracellular vesicles to the plasma membrane, where GLUT4 allows glucose uptake. b) 
Constitutive high activity of mTORC1/S6K1 axis triggers a negative feedback loop that is 
responsible of the detrimental effects associated to insulin resistance.  Under nutrient overload or 
pathological conditions of obesity, high blood levels of amino acids sustain constitutive mTORC1 
hyperactivation, despite of insulin resistance.  
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translocation of GLUT4 to the plasma membrane allowing glucose uptake. Subsequently, the 
newly acquired glucose is stored as glycogen in skeletal muscle through the action of glycogen 
synthase that is activated by AKT through inhibition of GSK3. AKT signaling in skeletal muscle 
attenuates protein breakdown while enhances protein synthesis through mTORC1 activation, and 
drives muscle hypertrophy. It has been shown that by promoting an increase in muscle mass, 
AKT signaling in skeletal muscle can improve systemic metabolism and overcome diet-induced 
obesity (Izumiya et al., 2008).  
Adipose tissue accounts for only a small fraction of insulin-stimulated glucose uptake that is 
stored as triglycerides. Insulin, through mTORC1 activation, also suppresses lipolysis and fatty 
acid release. The most important function of the adipose tissues in this context is, however, to 
sense the energy status and communicate with other tissues by secreting cytokines and 
chemokines, which in turn regulate metabolism in muscle, liver, and brain (Leto & Saltiel, 2012). 
In the liver, insulin is essential for suppression of hepatic glucose production, and stimulation of 
glycogen and lipid synthesis. Inhibition of gluconeogenesis in hepatocytes occurs via AKT-
mediated phosphorylation and inhibition of FoxO1, which control expression of the key enzymes 
controlling this process, phosphoenolpyruvate carboxykinase (PEPCK) and glucose 6-
phosphatase (G6PD) (Manning & Toker, 2017). Hepatic insulin resistance and glucose 
intolerance is associated with the inability of insulin to inhibit glucose production.  
Insulin secretion is itself affected by AKT and mTORC1 pathways. Reduced AKT activity in 
pancreatic β-cells resulted in impaired insulin secretion and impaired glucose tolerance (Bernal-
Mizrachi et al., 2004). On the other hand, AKT activation in pancreatic islet cells increased β-cell 
mass and insulin production likely through mTORC1 activation, as specific activation of mTORC1 
in islet cells in a TSC2-/- model, results in a robust expansion of islets, hyperinsulemia and 
improved glucose tolerance (Rachdi et al., 2008). 
Supporting the role of the mTORC1/S6K1 feedback loop in the pathogenesis of type 2 
diabetes, S6K1-deficient mice displayed enhanced sensitivity when chronically maintained on 
high fat diet and were protected from age- and obesity-induced insulin resistance in the presence 
of reduced IRS-1 phosphorylation (Um et al., 2004). In addition, GRB10-deficient mice also 
exhibited enhanced glucose tolerance and insulin sensitivity (Lixin Wang et al., 2007), whereas 
IRS1-deficient mice developed insulin resistance (Saltiel & Kahn, 2001). These evidences 
suggests that mTORC1 or S6K1 inhibitors could improve glucose tolerance and could be an 
effective treatment for certain metabolic disorders characterized by insulin resistance, such as 
type 2 diabetes (Um et al, 2004). 
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MASTL/Greatwall is a kinase responsible for inhibiting the phosphatase PP2A in complex 
with the B55 family of regulatory subunits. A role for MASTL-PP2A/B55 pathway has been widely 
described in mitosis, and an additional function for MASTL in recovery from the DNA damage-
induced G2 checkpoint has also been suggested. In budding yeast, the role of its orthologous 
Rim15 in the establishment of the quiescence program after nutrient deprivation has been 
extensively characterized. Whether the mammalian protein plays similar roles remain unknown, 
and no additional functions for mammalian MASTL have been described to date. The major aim 
of the project was therefore to identify new functions of MASTL in mammals. We aim to 
accomplish the following objectives: 
 
1. Characterize the implications of MASTL-PP2A/B55 pathway in cell cycle regulation. 
2. Identify new cell cycle-independent functions of MASTL and characterize the underlying 
molecular mechanism. 
3. Study the physiological relevance of Mastl in vivo using a conditional loss-of-function 
mouse model for Mastl.  
  
  	  
2. Material and Methods 
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2.1 Cell culture and cellular biology 
2.1.1 Cell culture, synchronizations and starvation and re-stimulation of cells 
Conditional knockout (cKO) mouse embryonic fibroblasts (MEFs) of Mastl, referred to as Mastl 
(lox/lox) MEFs, were obtained at E13.5 following the classical protocol for MEFs extraction. MEFs 
were immortalized using the first 121 amino acids of the SV40 T large antigen (T121), and have 
been previously reported (Álvarez-Fernández et al., 2013). MEFs were grown in (DMEM) 
Dulbecco’s modified Eagle’s medium supplemented with 10% fetal bovine serum (FBS; Sigma) 
and gentamycin at 37ºC and 5% CO2. To stop cell proliferation and synchronize cells in 
quiescence, or G0, subconfluent immortal MEFs (iMEFs) or primary MEFs (pMEFs) were arrested 
in G0 by serum starvation (0.1% FBS) for 72 or 48 hours, respectively. For quantification of S-
phase entry, MEFs synchronized in G0 were trypsinized and split in complete media containing 
10% FBS for the indicated time points, cells were incubated with 10 µM EdU for 30 minutes 
before harvesting and DNA replication was analyzed by flow cytometry. To analyze entry into 
quiescence in MEFs, asynchronous cultures were serum starved for the indicated times and cells 
were incubated with 10 µM EdU for 30 min to monitor the decrease in DNA replication. To assess 
the maintenance of quiescence, 10,000 MEFs were seeded on µCLEAR bottom 96-well plates 
(Greiner Bio-One) 24 h before serum starvation for 72h. Loss of staining of the proliferative 
markers Ki67 and EdU staining was scored using high throughput microscopy (HTM), 10 µM EdU 
was added 2 h before fixation. 
All human cancer cell lines were grown in DMEM supplemented with 10% FBS and 
gentamycin at 37ºC 5% CO2. MDA-MB231, BT549, and MCF7 breast cancer cell lines were 
kindly provided by M.A. Quintela (Breast Cancer Clinical Unit, CNIO).  Human embryonic kidney 
(HEK) 293-T cell line was obtained from American Type Culture Collection (ATCC). The MDA-
MB231 cell line has been DNA fingerprinted using the GenePrint 10 System (Promega). All of 
these cell lines are mycoplasma-free. Single cell clones of the MDA-MB231 cell line stables for 
the inducible CRISPR-Cas9 system for MASTL ablation, named isgMASTL, and control isgCas9, 
have been described (Álvarez-Fernández et al., submitted). Stable cell lines for the expression of 
determined genes were generated using constructs described below according to established 
protocols. Unless otherwise indicated, the MDA-MB231 cell line was used in all the experiments. 
For starvation experiments, cells were seeded into 6 well plates at a density of 300,000 cells per 
well 24 h before. For glucose or amino acid starvation, actively proliferating cells were rinsed 
twice with Hank’s balanced salt solution (HBSS) and incubated in DMEM without glucose or 
DMEM/Ham’s F-12 without amino acids supplemented with 10% dialyzed FBS (dFBS) for 1 h, 
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unless otherwise indicated. Stimulation with 25 mM glucose was performed for 10 min, unless 
otherwise noted. For serum withdrawal, cells were rinsed twice with HBSS and incubated in 0.1% 
FBS DMEM for 6 h and, when specified stimulated with 100 nM insulin, 50 ng/mL human 
epidermal growth factor (hEGF) or 10% FBS for 30 min, unless otherwise indicated. For oxygen 
starvation cells were treated with the hypoxic mimetic CoCl2 for 22 h in complete media. Glucose-
free media (11966) and dFBS were from Gibco; amino acids free DMEM/Ham’s F-12 (D9811-01) 
was from USBiological, glucose, insulin and hEGF were purchased from Sigma-Aldrich. 
2.1.2 Protein knockout and knockdown 
The Mastl conditional allele was knocked out in MEFs for the mitotic experiments following 
adenoviral-mediated Cre-recombinase (AdenoCre) delivery, AdenoFlp transduction was used as 
control. For Mastl ablation in the S-phase entry and quiescence experiments, we used the pLM-
CMV-R-Cre plasmid (Addgene #27546) for the lentiviral-mediated delivery of Cre-recombinase, 
which was tagged in the N-terminal with mCherry, to overcome the adenoviral-associated toxicity 
in quiescence (O’Shea et al., 2005). Control cells were infected with lentiviral supernatants 
expressing the mCherry protein. Media was refreshed 16 h after infection. For protein knockdown 
in MEFs using small interfering RNAs (siRNAs), iMEFs were nucleofected with Amaxa® 
Nucleofector® Technology (Lonza) following the product specifications. 
For MASTL and TSC2 knockdown in human cancer cell lines using short hairpin RNA 
sequences (shRNA), we used the TRC pLKO.1 lentiviral system obtained from Sigma (Mission 
Library), references and sequences are listed in Table 1. shRNA scramble (Scr) was used as 
control. For virus production, pLKO plasmids were co-transfected into HEK293-T cells along with 
packaging pMDL, REV and envelope (VSVG) expression plasmids using Lipofectamine 2000 
(Invitrogen) following manufacturer’s instructions. Virus-containing supernatants were collected 
24 and 48 hours after transfection, filtered to eliminate cells, and target cells were infected in the 
presence of 4 µg/mL polybrene. Cells were analyzed 64 h later, and knockdown efficiencies were 
examined by immunoblot analysis using specific antibodies against target proteins. 
Table 1. shRNAs used in this work. 
Target gene shRNA sequence Mission Library Reference 
hMASTL AGTATAAGCATAACGAAATG TRCN0000418233 
(A ́lvarez-Ferna ́ndez 
et al., submitted) 
hTSC2 CGACGAGTCAAACAAGCCAAT TRCN0000042723 (Llanos et al., 2016) 
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For conditionally knockout MASTL gene in the MDA-MB231 cell line, we generated single 
cell clones for the inducible CRISPR-Cas9 (isgRNA) system (Figure 11a). isgMASTL clones 
constitutively express the sgRNA targeting the exon 1 of MASTL (Table 2), and Cas9 expression 
is induced by doxycycline (Dox) at a concentration of 2 µg/mL. Addition of Dox to the media 
results in Cas9-mediated and sgRNA-directed specific cutting of the MASTL gene generating 
MASTL knockout cells (Figure 11b-d). Expression of MASTL protein is already undetectable 60-
72 h after Dox addition. Experiments were performed 64-72 h after Dox addition, and starvations 
and re-stimulations were performed in the absence of Dox following the specifications indicated 
above.  
 
Figure 11. Genetic ablation of MASTL using inducible CRISPR/Cas9 system. a) Schematic 
representation of the sgRNA/Cas9-inducible lentiviral vector. b) Representative flow cytometry plots 
of dsRed induction in MDA-MB231 clones expressing both Cas9 and sgRNAs against MASTL 
(isgMASTL) or control cells expressing Cas9 alone (iCas9) upon 4 days of Dox treatment (Left). 
Numbers indicate the percentage of DsRed-positive cells. Immunoblotting analysis of MASTL 
depletion in the same conditions (Right). Cas9 induction was monitored with an anti-Flag antibody. 
c-d) Genomic analysis of isgMASTL clone. sgRNA and PAM sequence are highlighted in yellow 
and blue colors, respectively. Red arrowhead denotes predicted Cas9 cutting site. Note that this 
clone is already heterozygous for MASTL before treatment due to a 15 bp deletion that leads to a 
frameshift mutation and a premature stop codon (c). Treatment with Dox results in deletion of 
MASTL in both alleles due to 1-43 bp deletions also causing frameshift mutations as indicated in 
panel d). Representative sequences are shown. 
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TSC2 gene was knocked out using the constitutive CRISPR-Cas9 system. The sgRNA 
against human TSC2 gene (Y. Bai et al., 2015) (Table 2) was subcloned into the lentiCRISPR v2 
vector (Addgene #52961). MDA-MB231 cells were transduced with supernatants containing 
lentiviral vectors and selected with 1 µg/mL puromycin for 72 h. TSC2 protein knockout was 
confirmed by immunoblotting and a TSC2 knockout cell line was established from the pool of 
puromycin selected cells and grown as usual. 
Table 2. sgRNAs used in this work. 
Target gene sgRNA sequence Reference 
hMASTL TCCTTCTTGCTTCCCGCGGT (A ́lvarez-Ferna ́ndez et al., submitted) 
hTSC2 GTGGCCTCAACAATCGCATC (Y. Bai et al., 2015) 
 
Knockdown of human ENSA, ARPP19 and B55 alpha and delta proteins was done using 
specific siRNAs (Table 3). Cell lines were transfected with Hiperfect (Qiagen), according to the 
manufacturer’s specifications. siRNA against luciferase (Luci) was used as control. 
Table 3. siRNAs used in this work.  
Target gene siRNA sequence ON-TARGET plus 
SMART pool 
(Dharmacon) 
Reference 
hENSA GCUAAAGGCCAAAUACCCA L-011852-00 (Cundell et al., 
2013) AGAGAGCUGAAGAGGCAAA 
UGAAGAGACUCCAGAAAGG 
AGGACACGCAGGAGAAAGA 
hARPP19 CAAGCUGGCUGGCUGAUUA L-015338-00 (Cundell et al., 
2013) CAACAUGGCUAAAGCAAAA 
GUUCAGAUUUCUUAAGGAA 
GCACAAGAGUUCCUACACA 
  Quiagen  
hPPP2R2A CTGCAGATGATTTGCGGATTA SI02225825 (Schmitz et al., 
2010)  hPPP2R2D TTCATCCATATCCGATGTAAA SI02759148 
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2.1.3 Treatments 
For cell culture treatment, inhibitors were added either at the same time of the starvation or 10-20 
min before re-stimulation for the indicated periods of time in each case. The following drugs were 
used in cell culture at the indicated concentrations. 
Table 4. Inhibitors used in this work and their working concentration. 
Inhibitor Target Concentration Supplier 
2-DG Hexokinase 50 mM Sigma 
AKTIV AKT 500 nM Calbiochem 
Antimycin A 
Mitochondrial electron 
transport 
1 µM Sigma 
Erlotinib EGFR 5 µM Tarceva; Roche 
FCCP H+ ionophore 0.4-0.8 µM Santa Cruz  
Fostriecin PP2A 5 µM Santa Cruz  
Linsitinib IR/IGFR-I 5 µM Selleckem  
PF-4708671 P70S6K1 10 µM Selleckem 
Okadaic acid PP2A 50 nM Calbiochem 
Oligomycin A H+-ATP-synthase 10 µM Sigma 
Rapamycin mTORC1 100 nM Santa Cruz  
Roscovitine CDK1/2/5 25 µM Selleckem 
Rotenone 
Mitochondrial electron 
transport 
1 µM Sigma 
Taxol Microtubules 1 µM Sigma 
Torin1 mTOR 250 nM Selleckem  
 
2.1.4 Protein overexpression 
For transient protein overexpression of ENSA and ARPP19 and MASTL, respective cDNAs into 
the pEGFP-C2 or pDEST 3.1-GFP vectors were used. Cells were transfected using 
Lipofectamine 2000 (Invitrogen) following manufacturer’s instructions. 
For stable overexpression of proteins, cDNAs were subcloned into the lentiviral pLVX-puro 
vector in which the cDNA is expressed under the CMV promoter. To generate lentiviral 
supernatants, pLVX vectors were co-transfected along with pMDL, REV and envelope (VSVG) 
plasmids in HEK293-T cells using Lipofectamine 2000. Virus-containing supernatants were 
recovered at 30, 48 and 72 h after transfection, and MDA-MB231 target cells were infected in 
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presence of 4 µg/mL polybrene. 48 h later, cells stably expressing the cDNA were selected with 1 
µg/mL puromycin. 
2.1.5 Cell cycle analysis by flow cytometry 
Cells were trypsinized and fixed in cold 70% ethanol at 4ºC for at least 12 h. For EdU staining we 
followed the classical azide-based EdU Click-iT protocol (Invitrogen) plus an additional step for 
signal amplification using biotin-azide and streptavidin-Alexa fluor. For cell cycle profile analysis, 
DNA was stained with propidium iodide (PI) (Invitrogen) and samples were incubated in the 
presence of RNAse at 37ºC for 30 min. To assess the mitotic index, cells were stained using 
specific antibodies for the mitotic markers S-10-H3 (Millipore; 06-570) and MPM-2 (Millipore; 05-
368), which detects mitotic proline-directed Ser/Thr-phosphoepitopes, DNA content was 
monitored using DAPI (Sigma). Samples were run on a LSR Fortesa flow cytometer (BD, San 
Jose), and 10,000 single events were acquired. Data were analyzed using the analyzer FlowJo 
v9.6.4 (Treestar, Oregon)  
2.1.6 Videomicroscopy  
MEFs expressing stable H2B-mRFP were plated on eight well glass-bottom dishes (Ibidi) at a 
density of 30,000 cells per well and imaged with a DeltaVision RT imaging system (Applied 
Precision, LLC; IX70/71; Olympus) equipped with a PI APO 20XI 1.42 NA objective lens and 
maintained at 37ºC in a humidified CO2 chamber. Images were acquired every 10 min for mitotic 
analysis and analyzed using ImageJ software. 
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2.2 Molecular biology and biochemical analysis 
2.2.1 Cloning of cDNA and mutagenesis 
Human ENSA (NCBI NM_004436.2 transcript variant 3) and ARPP19 (NCBI NM_006628.5 
transcript variant 3) cDNAs in the pOTB7 and pCMV-SPORT6, respectively, were obtained from 
the CNIO library. Both cDNAs were amplified by PCR (Expand High Fidelity PCR system, Roche) 
and tagged in the N-terminal with FLAG and HA tags, respectively using specific primers. The 
PCR product was sub-cloned into the BamHI and XhoI sites of the pLVX-puro lentiviral vector for 
stable expression, or in the same sites of the pEGFP-C2 vector for transient expression following 
classical cloning techniques. 
Human (NCBI NM_001172303.2 transcript variant 1) and mouse Mastl (NCBI NM_025979.4) 
cDNAs were sub-cloned into the pENTRY and transferred into the pDESTINY 3.1-GFP using the 
Gateway system (Invitrogen) for transient protein expression. MASTL proteins were tagged in its 
N-terminal for not to affect its kinase activity. For stably protein expression, GFP-Mastl cDNA was 
digested from the pDESTINY 3.1-GFP and sub-cloned into the BamHI and XhoI sites of the 
pLVX-puro vector. 
For rescue experiments in human cell lines, the cDNA of mouse Mastl in the pENTRY was 
mutagenized using the QuikChange Site-directed mutagenesis kit (Agilent) and specific primers 
following their specifications. Mutants used in our experiments are numbered according to NCBI 
and were verified by sequencing. Mutant forms of Mastl were subcloned into pDESTINY 3.1-GFP 
or pLVX-puro vectors as stated above.  
ENSA- and ARPP19-pEGFP-C2 sequences were mutagenized as indicated above for Mastl. 
Phosphomutant forms for ENSA and ARPP19 (S67A and S62A, respectively) are unable to be 
phosphorylated by MASTL. Conversely, phosphomimetic forms of ENSA and ARPP19 (S67D 
and S62D, respectively) mimic constitutive MASTL phosphorylation. After verification by 
sequencing, ENSA and ARPP19 cDNAs were tagged with FLAG and HA tags in the N-terminal, 
respectively, by PCR using specific primers. After restriction enzyme digestion, were subcloned 
into the pLVX-puro vector as specified above. 
2.2.2 Immunoblotting 
For immunoblot analysis, cells were extracted on ice in cold lysis buffer (50 mM Tris-HCl pH 7.5, 
1 mM EDTA, 1 mM EGTA, 0.1% Triton X-100, protease inhibitors, 1 mM sodium orthovanadate, 
50 mM sodium fluoride, 20 mM β-glycerophosphate, 0.1% 2-mercaptoethanol). Cell lysates were 
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cleared by centrifugation at 15,000 xg for 10 min at 4ºC, and protein was quantified using the 
Bradford method. Protein extracts were mixed with sample buffer (350 mM Tris-HCl pH 6.8, 30% 
glycerol, 10% SDS, 0.6 M DTT, 0.1% bromophenol blue), boiled for 5 min and subjected to 
electrophoresis using the standard SDS-method. Proteins were then transferred to a 
nitrocellulose membrane, blocked in PBS 0.1% Tween-20 buffer containing 3% non-fat dried milk, 
and probed overnight with primary antibodies (1:1000 dilution) at 4 ºC and for 1 h at room 
temperature with peroxidase-conjugated secondary antibodies. Blots were developed using 
enhanced chemiluminiscence reagent (Western Lightning Plus-ECL; Perkin Elmer), exposed to 
an autoradiograph film and developed using standard methods. Films were scanned and 
quantifications were performed using ImageJ. 
Reagents for western blot (WB) were obtained from the following sources: anti phospho-
T308 AKT (9275), phospho-S473 AKT (9271), phospho-T1462 TSC2 (3611), phospho-S939 
TSC2 (3615), phospho-T389 S6K1 (9234), phospho-S235/236 S6 (2211), phospho-S612 IRS1 
(3203), phospho-S307 IRS1 (2381), phospho-S476 GRB10 (11817), phospho-Y1068 EGFR 
(3777), phospho-Y1135/1136 IR/IGFR (3024), phospho-T202/Y204 ERK (9101), phospho-S79 
ACC (11818), phospho-S792 Raptor (2083), phospho-T246 PRAS40 (2640), phospho-S9 GSK-
3β (9336), phospho-T24/32 FoxO1/3 (9464), phospho-S67/S62 Ensa/Arpp19 (5240), total AKT 
(9272), ERK (9102) TSC (4308), S6K1 (9202), S6 (2217), IRS1 (3407), GRB10 (3702), EGFR 
(4267), IR (3025), ACC (3676), Raptor (2280), PTEN (9188) were from Cell Signaling technology. 
Anti human and mouse MASTL (MABT372), phospho-S291 PDHE (AP1062), phospho-S10 H3 
(06-570) and MPM-2 (05-368) were from Millipore. Anti mouse Mastl (AP14289c) was from 
Abgent. Anti pan-B55 (sc-81606) was from Santa Cruz. Anti phospho-T194 MASTL was a gift 
from Heldfrich. Anti HIF1α (610959) antibody was purchased from BD Biosciences. Anti PDK2 
was from Cusabio (CSB-PA618976ESR2HU). Anti ENSA/ARPP19 (180513), and HA (1424) 
were from Abcam. Anti β-Actin (5441), FLAG (F7425) and Vinculin were from Sigma. Anti GFP 
was from Roche (11814460001). Unless otherwise indicated β-actin was used as loading control. 
2.2.3 Immunofluorescence 
MEFs were cultured in 96-well plates for HTM and fixed in 4% buffered paraformaldehyde (PFA) 
for 10 min at room temperature (RT). EdU staining was performed following de Click-iT EdU 
specifications (Invitrogen; C10086), and was followed by immunofluorescence (IF) against Ki67 
(Master Diagnostica; 0003110QD). Briefly, after EdU detection, cells were permeabilized with 
0.5% Triton X-100 for 10 min and blocked with 10% FBS for 1 h at RT, Ki67 antibody was 
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incubated overnight at 4ºC and nuclei were stained with DAPI. Images were automatically 
acquired from each well by an Opera High-Content Screening system (Perkin Elmer). A 20x 
magnification lens was used and pictures were taken at non-saturating conditions. Images were 
segmented using the DAPI staining to generate masks matching cell nuclei from which mean 
EdU and Ki67 signals were calculated. 
MDA-MB231 cells cultured on glass coverslips were fixed in 4% buffered PFA for 10 min at 
RT. For GLUT4 immunodetection, PFA was first quenched with 100 mM glycine for 10 min 
followed by permeabilization using 0.2 % Triton X-100 for 10 min and blocking with 10% goat 
serum plus 1% BSA for 1 h at RT. Incubation with a specific antibody against GLUT4 (ab654) 
(Bradley et al., 2014) was done at a 1:200 dilution for 1 h at 37ºC. To have a reference of the 
plasma membrane delimitation we combined GLUT4 staining with 1 µM HCS cell mask 
(Invitrogen; H32720) that stains the entire cell, and 1 µM TO-PRO-3 Iodide 642/661 (Invitrogen; 
T3605) to visualize the nuclei. Images were captured using a laser scanning confocal microscope 
TCS-SP5 (AOBS) Leica. Image analysis was done using ImageJ software. 
2.2.4 Immunoprecipitations and proteomic analysis of phosphoresidues in Mastl 
Cells were lysed in TNN (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1% NP-40) or RIPA buffer (50 
mM Tris-HCl pH 7.5, 150 mM NaCl, 1% NP-40, 0.5% Sodium-deoxicolate, 0.1% SDS, 5 mM 
EDTA) in presence of protease inhibitors (Roche), and phosphatase inhibitors (1 mM sodium 
orthovanadate, 50 mM sodium fluoride, 20 mM β-glycerophosphate). Cell lysates were cleared 
by centrifugation at 15,000 xg for 10 min at 4ºC and protein was quantified using the bicinchoninic 
acid assay (BCA; Thermo). Proteins were immunoprecipitated (IP) from total extracts using 
specific antibodies (2 µg/1 mg protein) crosslinked to Dynabeads Protein A (Invitrogen), and 
incubated overnight at 4 ºC on a rotatory wheel. The immunoprecipitates were washed once in 
RIPA buffer, twice in high salt RIPA buffer (500 mM NaCl) followed by an additional wash in 
RIPA. Immunoprecipitates were then used with different applications as stated below. Eventually, 
for immunoblot analysis, IP samples were resuspended in 30 µL of sample buffer, boiled 5 min at 
95ºC, and subjected to electrophoresis and immunoblot analysis. 
To study specific phosphoresidues on Mastl, endogenous mouse Mastl was IP from iMEFs 
using a polyclonal antibody against Mastl (Abgent; AP14289c) crosslinked to Dynabeads Protein 
A. Total lysates were extracted in RIPA buffer following the specifications indicated above and 
samples were subjected to mass spectrometry analysis. For this, protein eluates from the IP 
samples were doubly digested using the FASP procedure with some modifications. The resulting 
peptides were analyzed by LC-MS/MS using a LTQ Orbitrap Velos mass spectrometer (Thermo 
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Scientific). Besides, the samples were subjected to TiO2 enrichment. Raw files were searched 
against a UniprotKB/TrEMBL Mus musculus database (UniProtKB/Swiss-Prot/TrEMBL 43,539 
sequences) using Sequest-HT as the search engine through the Proteome Discoverer 1.4 
(Thermo Scientific) software. Peptide identifications were filtered by Percolator at 1% FDR using 
the target-decoy strategy. Label-free quantification was performed with MaxQuant and extracted 
ion chromatograms for MASTL phosphopeptides were manually validated in Xcalibur 2.2 
(Thermo Scientific). 
2.2.5 In vitro kinase assay 
For the in vitro kinases assays, cells stably expressing either GFP-hMASTL wild type (WT) or 
kinase dead (G44S) were lysed in ELB buffer (50 mM Hepes pH 7.4, 150 mM NaCl, 5 mM EDTA, 
1% NP-40) in presence of protease and phosphatase inhibitors. GFP-hMASTL proteins were IP 
using an anti-GFP antibody (Roche; 11814460001) crosslinked to Dynabeads Protein A 
(Invitrogen) and proceeded as indicated above for routine IP. For kinase assay, IP were washed 
two times in ELB buffer, twice in high salt (500 mM NaCl) ELB buffer, followed by to additional 
washes in kinase buffer (20 mM Hepes pH 7.5, 10 mM MgCl2). Equal amounts of beads were re-
suspended in kinase buffer and mixed with 500 ng of recombinant ARPP19 purified from 
HEK293T cells (A. Castro) in a final volume of 20 µL in the presence of radioactive 32P-labeled 
ATP, and incubated for 20 min at 30ºC. Reactions were stopped by the addition of sample buffer 
and boiling for 5 min. Samples were analyzed by SDS-PAGE in a gel of 10% acrylamide, 
transferred to a nitrocellulose membrane, and revealed by exposure to a radiosensitive screen. 
Images and quantifications were performed using ImageJ. Total MASTL in the reactions was 
quantified by immunoblot against MASTL on the transferred membrane. 
For kinases assays using mTOR and p70S6K1 as kinases, active recombinant proteins were 
purchased from Sigma (SRP0364, P0066, respectively). Recombinant purified human MASTL 
protein was used as a substrate and was from Abnova (H00084930). Reaction was performed in 
a final volume of 30 µL consisting of kinase buffer (supplemented with 50 mM KCl for the mTOR 
assay), 200 ng of the upstream kinase and 500 ng of MASTL, and incubated for 30 min at 30ºC. 
Reactions were stopped by the addition of sample buffer and boiling for 5 min, and were 
analyzed by SDS-PAGE in a gel of 8% acrylamide. Proteins in the gel were stained using 
Imperial Stain (Invitrogen) following the manufacturer’s instructions, dried and revealed by 
exposure to a radiosensitive screen. 
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2.2.6 MASTL phosphorylation site mapping 
mTORC1 and S6K1 in vitro kinase assays were performed as detailed above with the exception 
that the reaction was in the presence of 500 µM cold ATP. Samples in 5 M urea were doubly 
digested using the FASP procedure with some modifications. The resulting peptides were 
analyzed by LC-MS/MS using an Impact mass spectrometer (Bruker Daltonics). Raw files were 
searched against a Uniprot Homo sapiens database (20,187 sequences) using Andromeda as 
the search engine through the MaxQuant software. Peptide identifications were filtered by 
Percolator at 1% FDR using the target-decoy strategy. Label-free quantification was performed 
and extracted ion chromatograms for MASTL phosphopeptides were manually validated. 
2.2.7 Reverse-transcription quantitative PCR (RT-qPCR) 
Total RNA was extracted from mouse tissues using the Trizol (Sigma) method, according to the 
manufacturer’s instructions. Reverse transcription from 1 µg of total RNA was performed with the 
M-MLV retrotranscriptase (Promega) followed by quantitative PCR (qPCR) using either SYBR 
Green PCR Master Mix (Applied Biosystems) with specific primers (Table 5), or TaqMan 
reagents (Applied Biosystems) for analyzing MASTL expression in murine tissues. Data were 
analyzed using the comparative Ct method and are expressed as the ratio between the 
expression of each gene and the housekeeping gene. β-2-microglobulin (B2M) was used as 
housekeeping for human cells. Primers used for the amplification of specific genes are listed 
below. 
Table 5. Primers for RT-qPCR used in this work. Forward and reverse sequences are indicated. 
 Primer sequence 
Gene Forward Reverse 
hB2M AGATGAGTATGCCTGCCGTG TCATCCAATCCAAATGCGGC 
hGlut1 AACTCTTCAGCCAGGGTCCAC CACAGTGAAGATGATGAAGAC 
 
For quantification of Mastl mRNA expression in murine tissues, TaqMan probes against Mastl 
(Mm01329243_m1) spanning exon 4 of Mastl gene, and the housekeeping genes of B2M 
(Mm00437762_m1) and hypoxanthine phosphoribosyl transferase 1 (HPRT; Mm00446968_m1) 
were used. 
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2.3 Metabolic assays in cells 
2.3.1 Seahorse metabolic profiling 
Glycolysis and mitochondrial respiration were determined as indirect measurements of the 
extracellular acidification rate (ECAR) and oxygen consumption rate (OCR) of cells, respectively, 
and were measured with an XF96 Extracellular flux analyzer (Seahorse Bioscience), following 
manufacturer’s instructions for the Glycolytic and Mitochondrial Stress kit. MDA-MB231 cells 
were plated at a density of 10,000 cells  per well, the day after cells were washed and incubated 
in buffered glucose- and sodium pyruvate-free DMEM (Seahorse Bioscience) supplemented with 
2 mM glutamine and 2% dFBS for glycolysis measurement. The same media was supplemented 
with 5 mM glucose and 1mM sodium pyruvate to assess mitochondrial capacity. Cells were 
incubated for 1 h in a CO2-free incubator at 37ºC to allow for temperature and pH equilibration 
before loading into XF96 apparatus. Assays consisted of sequential mix (3 min) and 
measurement (3 min) cycles, allowing for determination of OCR/ECAR every 6 min. To obtain the 
glycolytic-dependent ECAR and the mitochondrial-dependent OCR, only the 2-DG-sensitive 
media acidification and the antimycin A-sensitive respiration were used, respectively. ECAR and 
OCR were normalized to the cell number calculated at the end of the experiments. Cell count at 
the end of the experiment was assessed by fixing cells with paraformaldehyde 4% for 10 min at 
RT following by DAPI staining and quantification of total number of cells per well using a laser 
scanning confocal microscope TCS-SP5 (AOBS) Leica. Image analysis was done using ImageJ 
software. Data was expressed as mean ± sem of 3 independent experiments. Statistical 
significant differences were determined using paired Student’s t test. 
  
  Material and Methods  
	   68	  
2.4 Studies in vivo in Mastl mutant mice  
2.4.1 Generation of a conditional Mastl knockout mice and genotyping 
To generate a Mastl conditional loss-of-function model, Mastl(lox/lox), mouse embryonic stem 
cells carrying a neomycin resistance gene flanked by frt sites in MASTL intron 4 and loxP sites 
flanking exon 4, which contains the ATP binding site critical for the activity of the kinase, were 
microinjected into developing blastocysts. The resulting positive chimaeric mice Mastl(+/loxfrt) 
were crossed with C57BL6/J mice. Subsequently, the neo cassette was removed by mating with 
mice expressing the Flp recombinase (Tg.pCAG-Flp), generating the Mastl cKO allele, termed 
Mastl(lox) (Figure 12). To obtain a ubiquitous and constitutive depletion of Mastl, Mastl(+/lox) 
mice were crossed with animals expressing DNA recombinase Cre (Cre) under control of a 
human cytomegalovirus minimal promoter (CMV). Excision of exon 4 of the Mastl gene leads to a 
frame shift in the mRNA generating several new premature stop codons that results in loss of 
Mastl protein, and renders the Mastl(∆) allele. Mastl cKO animals were obtained by crossing 
Mastl(lox) mice with mice expressing a knock in of the CRE-ERT2 recombinase inducible by 
tamoxifen (TAM) in the locus of the ubiquitous RNA polymerase promoter (RNAP2_CreERT2). 
These mouse models have been previously described (Álvarez-Fernández et al., 2013). Liver-
specific Mastl cKO mice referred as Mastl_L(lox/lox), were obtained by crossing Mastl(lox/lox) 
mice with the serum albumin-Cre knockin mice (Schuler, Dierich, Chambon, & Metzger, 2004). 
 
Figure 12. Generation of Mastl loss-of-function mutant mice. Schematic representation of the 
murine Mastl gene and the generation of the different Mastl alleles. The exon 4 of the Mastl gene 
is flanked by loxP sites (green triangles) and intron 4 contained a neomycin selection cassette 
(orange arrow) flaked by frt sites (orange triangles) rendering the Mastl(loxfrt) allele. Site-specific 
recombination by Flp results in the conditional Mastl(lox) allele, which expresses normal levels of 
Mastl protein. Cre-mediated recombination renders the germ-line Mastl(−) or conditionally 
induced Mastl(∆) null alleles. (Álvarez-Fernández et al., 2013) 
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All animals were maintained in a C57BL6/J-129S mixed background. Mice were housed 
in the pathogen-free animal facility of the CNIO (Madrid) and maintained under a standard 12-h 
light-dark cycle, at 23ºC with free access to food and water. All animal work and procedures were 
approved by the ISCIII committee for animal care and research, and were performed in 
accordance with the CNIO Animal Care program. To induce insulin resistance, mice were fed for 
8 weeks with 60% high fat diet (HFD) (60% fat, 20% protein, 20% carbohydrate; Research Diets; 
D12492). Only males between 2 and 3 months of age were used for HFD experiments. 
Routine genotyping of the Mastl(lox) and Mastl(−)  allele was done by PCR using DNA 
from the tail of the mice. Both PCRs were done using a standard Taq Polymerase (Promega), 
and the following protocol with specific primers in each case (Table 6): i) 5 minutes at 95ºC to 
denaturalize the DNA; ii) 40 cycles of denaturing 30 s at 95ºC, annealing 30 s at 58ºC, and 
elongation 60 s at 72ºC; and iii) final elongation step 10 min 72ºC.  
Table 6. Primers used for genotyping MASTL mutant alleles. 
Primers 
Mastl(− ) 
Forward TCTTTCCACTCCCATACCACA 
Reverse GGCTGGCAGTTCCATTTTTA 
Mastl(lox) 
Forward GCCCTTTTAAAAACCCAACA 
Reverse GGCTGGCAGTTCCATTTTTA 
 
PCR products were run in 2% agarose gels and interpreted as follows: Mastl(−) PCR gave a 
band of 783 bp for Mastl(+) allele and 289 bp for Mastl(−). PCR products for Mastl(lox) were 402 
bp for Mastl(lox) and 296 bp for Mastl(+) allele. 
2.4.2 Deletion of Mastl in young and adult mice 
To excise the Mastl gene and generate the Mastl knockout mice, mice were treated with 
tamoxifen (TAM) to induce the nuclear translocation and activation of Cre-ERT2 recombinase. 
Young mice of 3 weeks (after weaning) or adult mice of between 45- and 52-weeks-old were 
treated with TAM in the diet (Envigo; TD.55125) for the whole time that the experiment lasted. 
Alternatively, mice that were under the HFD were treated with TAM by intraperitoneal injection of 
TAM (Sigma; T5648) at a dose of 200 mg/kg. Mice were injected twice each other day one week 
before each experiment.  
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2.4.3 Glucose- and insulin-tolerance tests  
For glucose tolerance test assay (GTT) mice were fasted for 16 h and then administered an 
intraperitoneal glucose injection (2 g/kg body weight). Glycaemia was measured by tail vein blood 
sampling using a glucometer and glucose strips (Bio Medical) in fasting and 15, 30, 45, 60, 90 
and 120 min after glucose injection. For insulin tolerance test (ITT) same mice were fasted for 6 h 
and intraperitoneally injected with rapid acting insulin (0.75 U/kg body weight) (Actrapid, Novo 
Nordisk) following by tail vein blood glucose sampling to measure the glycaemia at 0, 15, 30, 45 
and 60 min after insulin injection. 
2.4.4 Glucose stimulated insulin secretion 
To measure glucose-stimulated insulin secretion (GSIS), mice were fasted for 16 h and injected 
with glucose (2 g/kg body weight). Plasma insulin levels were measured at 0 and 30 min after 
glucose injection. Blood from the cheek was collected in EDTA tubes, centrifuged at 8,000 xg for 
10 min at 4ºC, and the plasma was separated and stored at -80ºC. Insulin was measured in 25 
µL of plasma using an ultrasensitive mouse insulin ELISA kit (Mercodia). 
2.4.5 Treatment of mice with a CNIO-PI3K inhibitor 
The PI3K inhibitor developed at CNIO ETP-44692 (Martínez González et al., 2012) was 
administered to the 16 h fasted mice by oral gavage in a unique dose of 20 mg/kg 1 h before 
starting the GTT. ETP-44692 was dissolved in 90% PEG-300 and 10% N-methyl-2-pyrrolidone 
(NMP). Sham-treated mice, which received only vehicle, were included in the study to discard 
any effect indirect to the inhibitor. 
2.4.6 Immunohistochemistry 
For histological analysis tissues were fixed in 10%-buffered formalin (Sigma) and embedded in 
paraffin wax. Sections of 3- or 5-µm thickness were stained with haematoxylin and eosin (HE) or 
Periodic Acid Schiff (PAS) staining. Additional immunohistochemical (IHC) examination was 
performed using specific antibodies against MASTL (Millipore; MABT372), Ki67 (Master 
Diagnostica), cleaved caspase-3 (Asp175) (Cell signaling; 9661), insulin (Dako; A 0564), and 
glucagon (Sigma; G2654). 
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2.5 Statistics 
Statistical analysis was carried out using Prism 5 (GraphPad). Statistical tests were performed 
using either two-sided, unpaired Student’s t-test, paired Student’s t-test, 1- or 2-way ANOVA 
(Bonferroni’s multiple test) according to specifications in the figures. Data with p>0.05 were 
considered not statistically significant (ns); *, p<0.05; **, p<0.01; ***, p<0.001. 
  	  
 
 
3. Results 
 
  
 
  Results  
	   74	  
3.1 Role of MASTL kinase in cell cycle regulation in mammals 
3.1.1 Mastl is essential for mitotic progression in mammalian cells 
The role of MASTL in the maintenance of the mitotic state through inhibition of PP2A has also 
been reported in mammalian cells using siRNAs against MASTL (Burgess et al., 2010). To further 
understand the role of mammalian Gwl in cell cycle progression and mitosis, our lab generated a 
Mastl conditional knock-out (cKO) mouse model, in which LoxP sites flank the exon 4 of the Mastl 
gene that contains the ATP binding site critical for the activity of the kinase (see section 2.4.1 and 
Figure 12) (Álvarez-Fernández et al., 2013). Expression of Cre under an ubiquitous and 
constitutive promoter, excises exon 4 of Mastl and induces the loss of Mastl protein, rendering 
the germ-line null Mastl(−) allele (Figure 13a). Mastl(+/−) heterozygous mice developed normally 
and are fertile. By crossing heterozygous mice it was found that germ line null mutation in Mastl 
leads to embryonic lethality at periimplantational stages comprised between E5.5 and E10.5, 
 
Figure 13. Mastl is essential for mouse embryonic development. a) Representative 
PCR products showing the Mastl(−) and WT alleles. b) The number and percentage of mice 
or embryos with the indicated genotype is shown indicating that Mastl(−/−) embryos develop 
normally until blastocyst stage. c) Immunohistochemical analysis of E14.5 embryos after 
injection of the pregnant mother with TAM. S-10-H3 staining shows an increase in M figures 
versus interphasic (I) cells in the subventricular zone in Mastl(∆/∆) respect Mastl(+/∆) 
embryos. PM figures and AT are indicated by arrows and arrowheads, respectively. i.v.c, in 
vitro culture. **p<0.01. 
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indicating that Mastl gene is essential for mouse embryonic proliferation (Figure 13b). 
To overcome this lethality, we generated a TAM-inducible cKO mouse model for Mastl, which 
expresses Cre fused to the estrogen receptor (Cre_ERT2) in the ubiquitous RNA polymerase II 
locus (Polr2a). To analyze the consequences of Mastl ablation in vivo in a highly proliferative 
stage, we treated pregnant females at E12.5 with TAM to conditionally knockout Mastl in the 
embryos, which were analyzed at E14.5 (Figure 13c). We found increased mitotic (M) figures in 
the neuroepithelium of Mastl(∆/∆) embryos compared to Mastl(+/∆) littermates with an 
enrichment in prometaphases/metaphases (P/M) compared with the more abundant 
anaphases/telophases (A/T) in control sections. This result suggested that Mastl is essential for 
proper mitotic progression in mammals in vivo (Álvarez-Fernández et al., 2013). 
To further explore the role of Mastl in mitosis in vitro we took advantage of MEFs derived 
from the Mastl cKO mouse model. AdenoCre transduction of pMEFs generated Mastl(∆/∆) cells 
and resulted in reduced proliferation accompanied by mitotic aberrations in prometaphase, 
including defective chromosome condensation and abnormal spindle (Figure 14a,b).  
To study the kinetics of mitotic entry and progression, Mastl(lox/lox) immortal MEFs 
stably expressing histone H2B fused to mRFP were followed by time-lapse videomicroscopy for 
48 h. To record the first division after Mastl ablation, MEFs were arrested in quiescence, or G0, by 
serum starvation at the same time they were transduced with adenoCre, or adenoFlp viruses as 
control. Quiescent cells were split and serum stimulated following the protocol depicted in Figure  
 
Figure 14. Mastl is required for proliferation in vitro in MEFs. a) WB showing the 
depletion of Mastl protein in Mastl(lox/lox) pMEFs after transduction with adenovirus 
expressing Cre. AdenoGFP was used as control. Bottom plot represents a cell growth curve 
over 6 days in the same cells. Mean ± SD for each time point is shown in the plot. PDL, 
population doubling levels. b) Representative immunofluorescence images of mitotic cells 
stained with DAPI (blue), a-tubulin (green), and S-10-H3 (red). 
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15a. No differences were observed in the kinetics of mitotic entry between Mastl(lox/lox) and 
Mastl(∆/∆) MEFs, as determined by cell rounding and chromosome condensation (Figure 
15b,c). In addition, no differences were detected neither in a time course of mitotic entry nor in 
the accumulation of mitotic markers, such as cyclinB1 or phospho-histone H3 proteins by WB 
(Figure 15d). However, Mastl(∆/∆) mitotic MEFs showed reduced levels of phosphorylated 
mitotic proteins scored by IF using an MPM-2 antibody, which mainly detects phosphorylated 
proline-directed Ser/Thr epitopes abundant in mitotic cells (Figure 15e), and also displayed a 
dramatic reduction in the levels of phosphorylation of CDK substrates by WB after a shake-off of 
taxol arrested pMEFs (Figure 15f).  
Video analysis also allowed us to calculate the duration of mitosis (DOM), which was 2.5 
times longer for Mastl(∆/∆) MEFs. Whereas control cultures spent approximately 73 ± 5 min in 
mitosis, most Mastl(∆/∆) MEFs arrested in prometaphase and reached DOM of 182 ± 16 min 
(Figure 16a). This delay was due to the activation of the Spindle Assembly Checkpoint (SAC), 
since knockdown of the essential SAC protein Mad2 significantly reduced DOM in Mastl(∆/∆) 
cells. Cell fate analysis showed that approximately 75% of Mastl(∆/∆) cells lack chromosome 
 
Figure 15. Mastl is not essential for mitotic entry in MEFs. a) Schematic representation of the 
protocol used in MASTL(lox/lox) iMEFs for synchronization in G0 and serum stimulation to monitor 
mitotic entry. Genetic ablation of Mastl was done using adenoCre or adenoFlp as control. b) 
Representative time-lapse images of Mastl(lox/lox) and Mastl(∆/∆) MEFs. H2B-mRFP is shown in 
red. c) Quantification of mitotic entry after analysis of time-lapse images. d) Immunodetection of 
the indicated proteins by WB in a time course after serum stimulation. e) Levels of MPM2 per cell 
scored by IF. e) Levels of the indicated proteins in a mitotic shake off extract after treatment with 
taxol. Error bars indicate SD. ns, not significant; p>0.05 (Fisher’s exact test); *p<0.05 (Student t 
test). 
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segregation whereas 5% of the cells died during mitosis (Figure 16b). In summary, we have 
shown that ablation of Mastl does not impair mitotic entry but triggers a SAC-dependent arrest in 
prometaphase, and eventually leads to lack of chromosome segregation.  
It is known that Mastl inhibits PP2A-B55 complexes to avoid early dephosphorylation of 
CDK substrates in mitosis (Vigneron et al., 2009), and we have also shown that lack of Mastl 
results in decreased phosphorylated CDK substrates (Figure 15f). Importantly, knockdown of 
B55 alpha and delta isoforms rescued the defective phosphorylation of these substrates in mitotic 
entry extracts by WB (Figure 17a-c). Mastl(∆/∆) cells also presented defective chromosome 
condensation, as observed in metaphase spreads, a phenotype that was also rescued by co-
depletion of B55 subunits (Figure 17d). PP2A/B55 inhibition also restored the reduced 
phosphorylation of CyclinB1 on S126, a phosphorylation event that is required for the stable 
association of CyclinB1 with mitotic chromosomes (Figure 17e). These results are in agreement 
with a requirement for Mastl to maintain the mitotic state after NEB through the inhibition of 
PP2A/B55 complexes. 
 
 
Figure 16. Mastl depletion leads to prolonged mitosis and chromosome segregation defects. 
a) Duration of mitosis was considered from NEB until mitotic exit and was scored based on DNA 
condensation and loss of rounded morphology, respectively. Mastl(lox/lox) and Mastl(∆/∆) iMEFs 
nucleofected with siRNAs against Mad2 or Luciferase (Luc) as control. WB shows the depletion of 
Mastl and Mad2. Vinculin was used as loading control. b) Quantification of mitotic aberrations in the 
same cells as in a). ***p<0.001 (Student’s t-test). 
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3.1.2 Mastl depletion does not affect S-phase entry 
Apart from the above-described role of Mastl in mitosis, and in the recovery from the G2 
checkpoint (Peng et al., 2010), no other implications of Mastl in the control of cell cycle have 
 
Figure 17. Mastl-mediated inhibition of PP2A/B55 prevents dephosphorylation of mitotic 
substrates and condensation defects in mitosis. a) WB of the indicated proteins in 
Mastl(lox/lox) and Mastl(∆/∆) iMEFS at the indicated time points after serum stimulation following 
the scheme represented in Figure 15a for culture synchronization and Mastl depletion. Cells were 
nucleofected with siRNAs against B55 alpha and delta subunits, or Luci as control. b) 
Quantification of the relative levels of phosphorylated CDK substrates at 24 h from a), values were 
normalized respect Mastl(lox/lox). c) Quantification of the depletion of B55 alpha and delta by RT-
qPCR in cells from a. d) Representative images of the metaphase spreads from the indicated 
cultures. Quantification of the percentage of cells per condition (Right). Condensation defects were 
determined based on the abnormal length of mitotic chromosomes and classified based on the 
number of affected chromosomes per metaphase as mild (5-10 chromosomes affected) or severe 
(more than 10). At least 50 metaphases were counted per condition. (Scale bars: 10 µm; Insets, 1 
µm). e) WB for the indicated antibodies. Depletion of B55 subunits was analyzed by RT-qPCR. 
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been described to date. Progression of cells into S phase is controlled by retinoblastoma protein 
(pRB) and relies on the functional inactivation of this tumor suppressor in late G1 via protein 
phosphorylation. Interestingly, it has been reported that PP2A/B55α counteracts CDK-mediated 
phosphorylation of pRB and the pocket proteins, p130 and 107, and restrains cell cycle 
progression at the G1/S transition (Kurimchak & Graña, 2012). Whether the control of PP2A/B55 
activity in this context depends on Mastl has not been addressed. For this purpose, we explored 
the role of Mastl in S-phase entry using the Mastl(lox/lox) iMEFs. To generate Mastl(∆/∆) cells, 
MEFs were infected with lentiviral supernatants that expressed the recombinase Cre tagged in 
the N-terminal with mCherry (LentiCre). Control cells were infected with lentiviral supernatants 
expressing mCherry alone. As expression of Cre has shown some DNA damage-associated 
toxicity in MEFs, a Mastl(+/+) clone was also included as a control. To analyze entry into S-phase 
from G0, cells were synchronized by serum starvation for 48 h and then split and stimulated with 
10% serum in a time course experiment (Figure 18a). Cells were incubated with the thymidine 
analogous, EdU, for 30 min before harvesting to monitor DNA replication. EdU incorporation was 
quantified by flow cytometry. There were no differences in the percentage of cells entering S-
phase from G0 between Mastl(lox/lox) and Mastl(∆/∆) cells as shown by the percentage of EdU 
positive cells at the different time points (Figure 18b). The Mastl(+/+) clone had no differences 
 
Figure 18. Mastl is not required for S-phase entry. a) Schematic representation of the protocol 
used for synchronization in G0 and serum stimulation to monitor S-phase entry in Mastl(lox/lox) 
and Mastl(+/+) MEFs. Asynchronous MEFs were infected with Lentiviral supernatants to generate 
Mastl(∆/∆) and control MEFs. b,c) Quantification of EdU positive cells by flow cytometry at the 
indicated time points in iMEFs b) and pMEFs c) WB at 12 h after serum stimulation shows the 
depletion of MASTL protein upon LentiCre infection of pMEFs (Right). ns, not significant p>0.05. 
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after LentiCre infection neither, indicating that expression of Cre does not alter S-phase entry in 
this setting (Figure 18b). Similar kinetic in S-phase entry was obtained in pMEFs (Figure 18c) 
confirming that Mastl is not required for S-phase entry in MEFs. 
3.1.3  Mastl is not essential for quiescence in mammals 
The budding yeast Mastl protein, Rim15, is required for entry into quiescence in conditions of 
nutrient scarcity (Pedruzzi et al., 2003). Following nitrogen and/or carbon limitation Rim15 
orchestrates the initiation of a reversible cellular quiescence program. Based on the role of 
 
Figure 19. Entry into quiescence is not altered by Mastl deletion in MEFs. a) Schematic 
representation of the protocol used for depletion of Mastl and monitor entry into quiescence in 
MEFs. Asynchronous MEFs were infected with LentiCre supernatants and 48 h later cultures 
were serum starved for the indicated points. b) Immunoblot analysis for the indicated proteins 
from total extracts of iMEFs at different time points after serum starvation. c) Quantification of 
EdU positive cells by flow cytometry in iMEFs. Representative plots of the flow cytometry profiles 
for EdU staining (Bottom). d) Quantification of EdU positive cells after serum starvation in pMEFs. 
ns, not significant p>0.05. 
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Rim15, we explored the potential role of Mastl in quiescence in mammals. We made use of 
Mastl(lox/lox) MEFs, which were infected with LentiCre supernatants to generate Mastl(∆/∆) 
MEFs. Control cells were infected with lentiviral supernatants expressing the mCherry protein 
alone. Entry into quiescence was analyzed in a time course following serum starvation (Figure 
19a). 24 h after serum starvation control cells had already decreased the levels of proliferative 
proteins like cyclinA and signaling through the mTORC1 pathway (scored by P-T389 S6K1), 
likewise they had increased the levels of the antiproliferative proteins p130 and p27, and had 
increased autophagy signals such as the appearance of the LC3B-II lipidated band. Mastl(∆/∆) 
MEFs, however, did not show any differences in any of these proteins compared to control MEFs 
(Figure 19b). Quiescence state is also characterized by the loss of proliferative markers, such as 
Ki67 or EdU staining. There were no differences either in the proportion of cells exiting the cell 
cycle across the different time points analyzed, as shown by loss of EdU staining (Figure 19c). 
We further validated these results in pMEFs, which are more sensitive to the loss of mitogenic 
signals and become fully quiescent 24 h after serum starvation. Similarly to iMEFs, Mastl(∆/∆) 
pMEFs efficiently entered quiescence, following same kinetics as controls cells (Figure 19d). 
 To evaluate if Mastl, rather than for entry into quiescence, was instead required for 
maintenance of the quiescence state, we starved cells 24 h after LentiCre infection to ensure that 
Mastl deletion occurs in already quiescent cells, and analyzed the ability of these cells to re-enter 
the cell cycle after a prolonged serum starvation (Figure 20a). 72 h after serum starvation MEFs 
were efficiently arrested into quiescence, as shown by loss of EdU and Ki67 staining quantified 
by HTM (Figure 20c). However, Mastl(∆/∆) cells showed no defects in the maintenance of 
 
Figure 20. Mastl is not required for maintenance of quiescence in MEFs. a) Schematic 
representation of the protocol used for depletion of Mastl and monitor entry into quiescence in 
iMEFs. Asynchronous iMEFs were infected with LentiCre supernatants and 24 h later cultures were 
serum starved for 72 h. 2 h before recovery cells were incubated with EdU. b) Immunoblot analysis 
from 72 h serum starved iMEFs. c) EdU (Left) and Ki67 (Right) quantification using HTM after 72 h 
of serum starvation. ns, not significant p>0.05 (Student’s t test). 
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quiescence nor differences in the expression of proliferative markers by WB (Figure 20b). These 
data suggests that, in contrast to budding yeast, Mastl is not essential for either entry into or 
maintenance of the quiescence state in mammals. 
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3.2 Mitotic-independent function of MASTL-PP2A/B55 pathway 
3.2.1 Role of MASTL in nutrient-modulated pathways in mammals 
In line with the observations done in yeast where Rim15 is controlled downstream the master 
nutrient regulated pathways of TORC1 and PKA (Pedruzzi et al., 2003), we aimed to analyze 
whether MASTL may also have some relevance downstream nutrient sensing pathways in 
mammals. For this purpose, we studied the effect of MASTL depletion in human cells in the 
signaling through the mTORC1 and PI3K/AKT pathways, which are the main routes involved in 
nutrient and growth factor sensing across organisms (Manning & Toker, 2017; Saxton & Sabatini, 
2017). We chose the breast cancer cell line MDA-MB231 as a cellular model, since it expresses 
high levels of MASTL protein and it responds fast and in a very accurate and consistent manner 
to changes in concentrations of specific nutrients in the media. We knocked down MASTL 
expression by interference RNA using a specific shRNA against MASTL subcloned in the pLKO.1 
lentiviral system (shMASTL). As we have shown in the first part of the results, and in agreement 
with previous work (Burgess et al, 2010), MASTL ablation results in reduced proliferation as 
consequence of defective chromosome condensation and segregation problems in mammalian 
cells. To avoid any interference with mitotic aberrations in our results, experiments were 
performed at early time points after MASTL depletion, before segregation problems occur. Cell 
cycle analysis by flow cytometry 72 h after shRNA lentiviral infection, showed no differences in 
the percentage of cells in the different phases of the cell cycle despite strong reduction in MASTL 
protein levels (Figure 21). All experiments were performed not later than 72 h after induction of 
 
Figure 21. Cell cycle analysis after knockdown of MASTL. Quantification of the different phases 
of the cell cycle in control and MASTL null cells. MDA-MB231 cells were infected with shRNA 
specific for MASTL or Scr as control, and cell cycle was analyzed 72 h later. Mitotic cells were 
scored using Immunodetection of P-S10-H3 (pH3) and total DNA was stained with DAPI followed 
by flow cytometry analysis. Left pictures show representative cell cycle profiles and P-S10-H3 
staining. WB showing the depletion of MASTL 72 h after shMASTL infection (Right). 
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MASTL ablation.  
To study the effect of the MASTL-ENSA/ARPP19-PP2A/B55 pathway in nutrient 
signaling in cells, MDA-MB231 cells were subjected to different nutritional starvations known to 
inhibit the mTORC1 pathway following the protocol depicted in Figure 22a. mTORC1 pathway 
signaling was analyzed by WB using specific antibodies for its upstream regulators and 
downstream targets. In control cells infected with a scramble sequence (shScr), starvation for 
specific nutrients efficiently inhibited mTORC1 activity, as shown by decreased levels of 
phosphorylation of S6K1 and 4E-BP1 on their mTORC1 target sites T389 and S65, respectively 
(Figure 22b). MASTL-depleted cells showed, however, a significant increased in the 
phosphorylation of the mTORC1 targets S6K1, accompanied by increased phosphorylation of its 
substrate S6 (on S235/236), and 4E-BP1, in the absence of glucose, indicating lack of mTORC1 
inhibition under these conditions. These signals were concomitant with a significant increase in 
the inhibitory phosphorylation of TSC2 on T1462, which was also higher in MASTL-depleted cells 
upon amino acid starvation. During glucose starvation, a reduction in cellular energy activates the 
 
Figure 22. Glucose starvation fails to inhibit mTORC1 in the absence of MASTL. a) Schematic 
representation of the protocol followed for depletion of MASTL in human cell lines and different 
nutrient starvations. Asynchronous cells were infected with lentiviral supernatants containing 
shRNAs against MASTL or Scr as control, 72 h later cells were submitted for the different nutrient 
starvations. b,c) Immunoblot analysis of the same extracts using the indicated antibodies. d) 
Quantification of the percentage of cells in the different phases of the cell cycle 24 h after glucose 
starvation. Cell cycle analysis was done by flow cytometry. DNA content was stained with PI. 
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stress responsive metabolic regulator AMPK, which inhibits mTORC1 both indirectly, through 
phosphorylation and activation of TSC2, as well as directly, through the phosphorylation of 
Raptor (Gwinn et al., 2008; Inoki et al., 2003; Shaw et al., 2004). However, no differences were 
found in the activity of AMPK toward its substrates in MASTL-depleted cells using specific 
antibodies against TSC2 P-S1387 and ACC P-S79 (Figure 22c), suggesting that impaired AMPK 
activity is not responsible of the lack of inhibition of mTORC1 upon glucose starvation in MASTL-
depleted cells. AMPK also regulates a cell-cycle checkpoint that monitors glucose availability in 
proliferating MEFs (Jones et al., 2005). This glucose-dependent checkpoint is at the G1/S 
boundary and occurs despite continued amino acid availability and active mTOR. We next 
checked whether depletion of MASTL might alter the glucose-regulated checkpoint in our cells. 
For this purpose we analyzed the cell cycle profile of MASTL-depleted cells by flow cytometry 24 
h after glucose starvation. Glucose starvation induced a mild arrest of control cells in G1, but 
more importantly, there were no differences upon MASTL ablation (Figure 22d). In summary, we 
have found that glucose starvation was able to inhibit mTORC1 only in the presence of MASTL, 
and that MASTL ablation resulted in increased mTORC1 activity that was concomitant with a 
strong inhibition of TSC2 in MASTL-null cells. 
As a complementary approach to analyze the consequences of MASTL ablation, we 
have also developed a strategy for conditionally knockout MASTL gene using a Dox-inducible 
form of the CRISPR-Cas9 technology in the MDA-MB231 cell line (isgMASTL) (see section 
2.1.2). MASTL was efficiently ablated upon Dox treatment, and resulted in increased S6K1 and 
TSC2 phosphorylation in a glucose-sensitive fashion (Figure 23a). A key player in the regulation 
of TSC-mTORC1 axis is the Ser/Thr kinase AKT. AKT is activated downstream of growth factor-
stimulated PI3K activity, full activation of AKT requires its phosphorylation on two sites: the T308 
in the activation loop by PDK1 and the S473 in the hydrophobic motif by mTORC2 (Manning & 
Toker, 2017). AKT was strongly phosphorylated on T308, and also showed increased 
phosphorylation on the S473 in MASTL-null cells (Figure 23a). AKT regulates mTORC1 activity 
by phosphorylation of TSC2 directly on multiple sites (Ser939, Ser981, Ser1130, Ser1132 and 
Thr1462) that relieve the inhibitory effects of the TSC complex on Rheb and mTORC1, and 
thereby activating mTORC1. In consequence, TSC2 was more phosphorylated on S939 and 
especially on T1462, in MASTL-depleted cells. Other AKT substrates, like the mTORC1 inhibitor 
PRAS40, or GSK3 were likewise more phosphorylated on their AKT sites, T246 and S9, 
respectively, upon MASTL ablation, further suggesting enhanced AKT activity in the absence of 
MASTL. Slight differences were observed in the phosphorylation of ERK1/2, another positive 
regulator of the mTORC1 pathway upstream of TSC2, and no differences were observed in the 
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activity of AMPK towards its substrates Raptor S792 and ACC S79. The effect of MASTL ablation 
on the AKT-TSC2-mTORC1/S6K1 axis was specific for MASTL ablation since Dox-mediated 
induction of Cas9 in the presence of scrambled sgRNAs in a different clone of the MDA-MB231 
cells did not modify the phosphorylation status of the components of this pathway (Figure 23b). 
A similar effect of MASTL knockdown in the phosphorylation of AKT in a glucose-
sensitive manner was also reproduced and validated in two other breast cancer cell lines, BT549 
and MCF7, using shRNAs to knockdown MASTL expression (Figure 23c,d). The BT549 cell line 
is null for PTEN, the major phosphatase that counteracts PI3K activity. Ablation of MASTL still 
impaired the effect of glucose on mediating AKT inhibition in this cell line, suggesting that the 
effect of MASTL ablation is independent on PTEN (Figure 23c). In addition, total PTEN levels 
 
Figure 23. Modulation of the AKT-mTORC1 pathway in a glucose-sensitive fashion in MASTL-null 
cells. Immunoblot analysis for the indicated proteins of the AKT-mTORC1, ERK and AMPK pathways. a) 
MASTL expression was ablated by the isgRNA system upon Dox addition in the MDA-MB231 cell line. 72 
h later, cells were starved of glucose in the media in presence of 10% dFBS for 1 h and then re-stimulated 
with 25 mM of glucose for 10 min before recovery. b) Control of the Dox and Cas9 expression in the 
isgRNA system using a control clone of the MDA-MB231 that expresses Scr sgRNAs. Same protocol as in 
a) was followed. c,d) Immunoblot analysis with the indicated antibodies in the BT549 and MCF7 cell lines, 
respectively. MASTL knockdown was done upon infection with shRNAs for MASTL or Scr as control. 
Glucose starvation and re-stimulation experiments were done 72 h after infection with shRNAs following 
the same protocol as in a). β-Actin, or GAPDH when specified, were used as loading controls. 
  Results  
	   87	  
were unaltered in MASTL null cells (Figure 24b). Altogether these results suggested that the up-
regulation of the mTORC1 pathway upon MASTL ablation is consequence of increased AKT 
activity and subsequent inhibition of mTORC1 inhibitors by AKT. 
3.2.2 MASTL regulates AKT through mTORC1/S6K1-dependent feedback 
mechanisms  
The PI3K-AKT-mTORC1 pathway is a highly dynamic network that is balanced and stabilized by 
a number of negative feedback inhibition loops. AKT both regulates and is regulated by the TSC 
complex (Huang & Manning, 2009). Through negative-feedback mechanisms, mTORC1/S6K1 
activity inhibits growth factor stimulation of PI3K/AKT at the level of the RTKs, and this also has 
an important role in the regulation of mTORC1 (Shimobayashi & Hall, 2014). In addition, the 
mTORC1/S6K-dependent feedback loop is as well responsible for inhibiting the activity of the 
ERK/MAPK pathway (Carracedo et al., 2008). To date there is no evidence of glucose regulating 
directly the PI3K/AKT pathway. Instead, glucose has been shown to positively regulate mTORC1 
activity through the Rag GTPases (Efeyan et al., 2013). Interestingly, amino acids have been 
shown to modulate insulin signaling through mTORC1-dependent effects in the insulin receptor 
	  
Figure 24. Glucose modulates PI3K/AKT signaling through an mTORC1/S6K1-dependent 
feedback loop. a) Schematic showing the mTORC1/S6K1-dependent negative feedback loop over 
PI3K signaling and AKT regulation. b) MASTL was depleted using shRNAs against MASTL or Scr 
as control. Cells were starved from glucose for 2 h and re-stimulated with 5 mM glucose in a time 
course for 15 min and 1 h. Total extracts were recovered and tested for the indicated antibodies. 
Quantification of the immunoblots of AKT T308 upon glucose starvation and re-stimulation for 15 
min. N=2 independent experiments. Error bars indicate sem. *p<0.05 (Student’s t-test). 
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substrate protein IRS1, as excess amino acids attenuate and amino acid starvation stimulates 
AKT activation via mTORC1 regulation (Takano et al., 2001; Tremblay & Marette, 2001). Given 
these observations, we hypothesized that glucose availability could control mTORC1-dependent 
feedback loops to regulate the PI3K/AKT pathway, similarly as amino acids do. If this were true, 
glucose starvation would inhibit mTORC1 and relieve the negative feedback loop over PI3K 
pathway, resulting in increased AKT activity. On the other hand, glucose re-addition would induce 
mTORC1 re-activation and trigger the feedback loop-mediated AKT inhibition (Figure 24a). 
Whereas control cells responded to the glucose-mediated feedback loop, MASTL-null cells failed 
to inhibit AKT in response to glucose stimulation, despite having enhanced mTORC1 activity as 
shown by S6K1 T389 (Figure 24b). This data suggested a defective mTORC1/S6K1-dependent 
negative feedback loop and AKT inhibition in the absence of MASTL.  
The primary pathway by which most growth factors activate mTORC1 appears to be the 
PI3K/AKT pathway. As with amino acids, several research groups have found that PI3K/AKT 
mediated activation of mTORC1 also leads to attenuation of insulin signaling in a negative 
feedback loop. Their studies have demonstrated that activation of the PI3K/AKT-mTORC1 
pathway by insulin itself leads to IRS1 serine phosphorylation and downregulation in a 
rapamycin-sensitive manner (Carlson et al., 2004; Greene et al., 2003; Haruta et al., 2000). To 
understand the role of MASTL in the regulation of AKT activity following mTORC1/S6K1 
activation by insulin, we performed a time course of insulin stimulation after 6 h of serum 
starvation. Insulin induces a rapid and gradual activation of the AKT-mTORC1/S6K1 axis with a 
maximal activation 15 min after stimulation in our cells (Figure 25a). Following this peak of 
mTORC1/S6K1 activity and triggering of the feedback loop, there was a strong inhibition of AKT 
at the point of 30 min in control cells. MASTL-null cells despite having comparable levels of AKT-
mTORC1/S6K1 activity at 15 min, by contrast, failed to inhibit AKT at 30 min, resulting in 
sustained TSC2 T1462 and S6K1 T389 phosphorylation (Figure 25a). Loss of TSC2 disengages 
mTORC1 from the upstream inputs, resulting in mTORC1 constitutive activation (Henry, 2003; 
Kwiatkowski et al., 2002). As consequence, TSC2-null cells have potent mTORC1-dependent 
feedback loops and AKT is less responsive to activation by insulin or IGF-I, exposure to 
rapamycin can restore AKT activation in these cells (H. H. Zhang, Lipovsky, Dibble, Sahin, & 
Manning, 2006). Therefore knockdown of TSC2 is a good model for study mTORC1 feedback 
regulation of AKT signaling. Interestingly, knockdown of TSC2 in MDA-MB231 cells using 
shRNAs triggered AKT inhibition, and co-depletion of MASTL in these cells partially restored AKT 
activity, although did not rescue AKT signaling to the same extent as in wild-type cells (Figure 
25b).  In agreement with that, rapamycin treatment boosted AKT phosphorylation in control cells 
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to the same extent as MASTL depletion did, reinforcing the idea of MASTL having a role in the 
mTORC1-mediated feedback loop (Figure 25c). The effect of MASTL knockdown was further 
increased upon rapamycin treatment, suggesting that MASTL is important for the feedback loop, 
but that other MASTL-independent mechanisms are also at play.  
3.2.3 MASTL activity is modulated in conditions of feedback regulation 
To address the question of how MASTL is regulated in a mitotic-independent context, we have 
analyzed MASTL activity in the experimental conditions of glucose starvation and re-stimulation 
 
Figure 25. MASTL promotes AKT inhibition by mTORC1/S6K1-dependent feedback 
mechanisms. a) Time course experiment at the indicated time points after 100 nM insulin 
stimulation in 6 h serum-starved control and MASTL knockout cells. MASTL depletion was induced 
upon addition of Dox and cells were recovered 72 h later. immunoblot for the indicated antibodies 
is shown in each case. Quantification of AKT T308 at 30 min after insulin stimulation. N=5 
independent experiments (Bottom). b) TSC2 expression was knocked down in control or MASTL-
null cells using specific shRNAs for TSC2 or Scr as control. Cells were starved and re-stimulated 
with insulin for 30 min. WB for the indicated antibodies. Quantification of AKT T308. N=3 
independent experiments. c) Control or MASTL null cells were treated with 100 nM rapamycin or 
vehicle as control. Cells were starved for glucose for 1 h and re-stimulated with glucose for 15 min; 
rapamycin was added 15 min before glucose stimulation. Immunoblot of the indicated antibodies. 
Quantification of AKT T308 (Bottom). N=3 independent experiments. Error bars indicate sem. ns, 
not significant. *p<0.05 (2-way ANOVA; Student’s t-test). 
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reported above for modulation of feedback activity. As readouts of MASTL activity we have used 
phosphospecific antibodies generated against the T194 of MASTL, an essential site for MASTL 
kinase activity (Blake-Hodek et al., 2012), and for its substrates ENSA/ARPP19 S67/S62. 
Glucose re-addition following glucose starvation triggers mTORC1-dependent AKT inhibition at 
the same time it increases phosphorylation of MASTL at T194 and of its substrates ENSA and 
ARPP19 (Figure 26a), suggesting that MASTL activity might be positively regulated in response 
to glucose stimulation. 
As shown above, hyperactivation of mTORC1 by means of TSC2 ablation attenuates 
AKT activity in a rapamycin-sensitive manner. In our model MASTL activity favors the mTORC1-
dependent feedback loop and this raises the possibility of MASTL being positively regulated in 
conditions of feedback activity. Phosphorylation of MASTL at T194 was increased upon TSC2 
knockout in a rapamycin- and torin1-sensitive manner (Figure 27a). MASTL activity was also 
modulated in these conditions as shown in an in vitro kinase assay over GST-ARPP19 using 
GFP-MASTL immunocomplexes. In this assay MASTL activity increased upon TSC2 knockout 
and was partially prevented upon rapamycin and more efficiently upon torin1 treatment (Figure 
27b). MASTL activity was similarly partially sensitive to mTORC1 inhibitors in cells using as a 
readout phosphorylation of ENSA and ARPP19 at their MASTL sites by WB (Figure 27c). These 
data further suggest that MASTL activity may correlate with feedback activity and open the 
question of MASTL as being regulated downstream the mTORC1/S6K1 axis.  
 
 
Figure 26. MASTL activity is regulated in a 
glucose-sensitive manner. a) WB for the 
indicated antibodies. MDA-MB231 WT cells 
were starved for 1 h and re-stimulated with 
glucose for 15 min. Immunoblot quantification 
of phosphorylated MASTL T194 and 
ENSA/ARPP19 S67/S62 (Right). N=2 
independent experiments. Error bars indicate 
sem. *p<0.05 (Student’s t-test). 
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Figure 27. MASTL activity is modulated by mTOR under conditions of feedback 
regulation. a) MDA-MB231 cells stables for the knock out of TSC2 protein or control cells 
expressing only Cas9 were treated with rapamycin (Rap), Torin1 (Tor), or vehicle as control 
(V). sgTSC2 cells were depleted for MASTL using shRNA as control of the specificity of the 
antibody. Inhibitors were added 15 min before glucose re-stimulation for 15 min and total cell 
lysates were harvested for immunoblot. Bottom plots represent the quantification of MASTL 
T194. b) In vitro kinase assay using GFP-hMASTL WT immunocomplexes from asynchronous 
sgTSC2 or control cells treated with the indicated inhibitors for 1 h. IP of GFP alone was used 
as control. Phosphorylation over its substrate GST-ARPP19 and autophosphorylation of 
MASTL were used as readouts of MASTL activity. Left panel shows the radiographs of 
MASTL activity in the different conditions accompanied by the immunoblots of the whole cell 
extracts. Quantification of MASTL activity is shown in the plots on the right. c) Immunoblot 
showing MASTL activity over its substrates ENSA/ARPP19 in cells using a specific S67/S62 
phosphoantibody. Cells stably overexpressing FLAG- and HA-tagged versions of ENSA and 
ARPP19, respectively were treated with the indicated inhibitors as in a). Right plot represents 
the quantification of phosphorylated S67/S62 signal. N=2 independent experiments. Error 
bars indicate sem. *p<0.05; **p<0.005 (one-way ANOVA). 
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3.2.4 MASTL controls AKT activity in a ENSA/ARPP19-PP2A/B55 dependent-manner 
The role of MASTL in PP2A/B55 inactivation is indirectly mediated through phosphorylation of the 
endosulfine proteins ENSA and ARPP19, which are the two only known MASTL substrates to 
date (Vigneron et al., 2009; Gharbi-Ayachi et al., 2010; Mochida et al., 2010). As shown above, 
treatment with mTORC1 inhibitors partially reduced the activity of MASTL over ENSA/ARPP19 
(Figure 27b,c), reinforcing the possibility that the participation of MASTL in the mTORC1/S6K1-
dependent feedback loop is mediated by the ENSA/ARPP19-PP2A/B55 axis.  
To further understand if the effect of MASTL on AKT was mediated through the conserved 
ENSA/ARPP19-PP2A/B55 pathway, we evaluated whether knockdown of ENSA and ARRPP19 
 
Figure 28. MASTL controls AKT activity through the ENSA/ARPP19-PP2A/B55 pathway. a) 
Co-depletion of ENSA and ARPP19 proteins in the MDA-MB231 cell line using specific siRNAs or 
against luciferase (Luci) as control. 72 h after transfection cells were starved for glucose for 1 h 
and re-stimulated with glucose for 15 min. Total cell extracts were recovered and analyzed for the 
indicated antibodies. b) MDA-MB231 cells stably co-expressed FLAG- and HA-tagged versions of 
ENSA and ARPP19 phosphomimetic mutants (S67D and S62D). Cells were treated with Dox to 
induce MASTL knockdown, and 72 h later cells were treated as specified in a). c) Control and 
MASTL knockout cells were treated with 5 µM fostriecin, 50 nM OA or vehicle (Veh) 10 min 
before insulin stimulation for 30 min. Total lysates were analyzed for the indicated antibodies. Plot 
representing the quantification of AKT T308 (Bottom). N=2 independent experiments. Error bars 
indicate sem. 
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expression in MDA-MB231 cells using siRNAs could mimic MASTL ablation. Similar to MASTL 
depletion, knockdown of ENSA and ARPP19 proteins resulted in increased AKT phosphorylation 
and prevented the effect of glucose re-addition in the mTORC1-mediated feedback inhibition of 
AKT (Figure 28a). Enhanced AKT phosphorylation led to increased TSC2 T1462 and S6 
S235/236 phosphorylations upon glucose re-addition as readout of S6K1/mTORC1 activity. In 
addition, expression of phosphomimetic mutant cDNAs of ENSA and ARPP19, which mimic 
MASTL-dependent phosphorylation (S67D and S62D for ENSA and ARPP19, respectively) 
restored the levels of phosphorylated AKT in MASTL depleted cells upon glucose re-addition, 
suggesting that MASTL activity is dispensable in the presence of these phosphomimetic mutants 
(Figure 28b). To test the involvement of the PP2A/B55 phosphatase, similar assays were done 
using chemical PP2A phosphatase inhibitors. Treatment of cells, at low doses, with specific PP2A 
inhibitors, fostriecin, or okadaic acid (OA), led to decreased levels of phosphorylated AKT on 
T308 and partially rescued AKT phosphorylation in MASTL-depleted cells (Figure 28c). 
Altogether, these results further suggested that the role of MASTL in the feedback is through the 
conserved pathway of MASTL function, and involves inhibition of the phosphatase PP2A/B55 
through phosphorylation of the endosulfine proteins, ENSA and ARPP19. 
3.2.5 The MASTL-PP2A/B55 axis modulates the phosphorylation status of the 
mTORC1/S6K1-dependent feedback targets, IRS1 and GRB10 
Feedback inhibition of the PI3K/AKT pathway by mTORC1 is an important signaling event that 
plays a critical role in maintaining the stability of the entire PI3K/AKT-mTORC1 network, but the 
molecular connections are poorly understood (Hsu et al., 2011a). It involves mTORC1/S6K1-
depedent phosphorylation and destabilization of the insulin receptor substrates, IRS1 and IRS2 
(Shah et al., 2004; Harrington et al., 2004; Shah & Hunter, 2006), and simultaneous 
phosphorylation and stabilization of GRB10 (Hsu et al., 2011a). IRS and GRB10 are adaptor 
proteins of the insulin and IGF-I receptors that couple transduction to the PI3K pathway in a 
positive and negative manner, respectively. Turnover of the IRS proteins is a physiological 
mechanism to attenuate insulin signaling during prolonged exposure to insulin and this process is 
mTORC1/S6K1-dependent, as rapamycin prevents IRS turnover in multiple cell lines chronically 
exposed to insulin (Shah et al., 2004). IRS proteins are phosphorylated at multiples Ser/Thr sites, 
which controls protein stability by targeting it to the ubiquitin proteosomal pathway (Rui et al., 
2001; Sun et al., 1999). GRB10 is also phosphorylated by mTORC1 at multiple sites (S104, 
S150, S428 and S476), but in contrast to IRS proteins, GRB10 phosphorylation stabilizes it and 
prevents it from proteasomal degradation mediated by NEDD4 (Hsu et al., 2011a). Whereas 
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much is known about the target kinases, little is known about the phosphatases involved. IRS1 
protein stability has been shown to be regulated by the proline-directed S/T phosphatase PP2A 
(Hartley & Cooper, 2002), although the precise mechanism and the regulatory subunits of PP2A 
involved remain unknown.  
We have tested whether the PP2A/B55 phosphatase complexes could control the 
phosphorylation of the feedback targets IRS1 and GRB10. For this purpose, we knocked down 
the B55 alpha and delta subunits in cells using siRNAs and analyzed by WB the phosphorylation 
status of the adaptor proteins using commercial available specific phospho-antibodies against 
proline-directed S/T sites. Depletion of B55 alpha and delta caused hyperphosphorylation of both 
IRS1 and GRB10 as shown by lower mobility of the total proteins in WB, and specifically altered 
the phosphorylation status of IRS1 on S616 and GRB10 on S476. Hyperphosphorylation of IRS1 
led to reduced IRS1 total protein levels. No differences were observed in the phosphorylation 
S312 of IRS1 upon B55 depletion (Figure 29a). As expected, growth factor pathways dependent 
 
Figure 29. The MASTL-PP2A/B55 axis modulates the phosphorylation status of IRS1 and GRB10. a) 
B55 alpha and delta proteins were co-depleted using specific siRNAs. Asynchronous cells were recovered 
and blotted for the indicated antibodies. Plots represent the quantifications of the specified phospho-
residues (Right). N=3 independent experiments. b) Control and MASTL knockout cells were starved from 
glucose and re-stimulated with glucose for 15 min. Phosphorylation status of the adaptor proteins with the 
indicated antibodies in conditions of active mTORC1/S6K1-dependent feedback loop. c) Genetic depletion 
of B55 alpha and delta subunits using siRNAs in control and MASTL null cells. The phosphorylation status 
of the different proteins was scored in conditions of glucose re-addition. Error bars indicate sem. *p<0.05 
(Student’s t-test). 
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on IRS1 and GRB10, like AKT, displayed attenuated phosphorylation in B55 depleted cells. To 
test the involvement of MASTL in the control of PP2A/B55 complexes in this context, we 
analyzed the phosphorylation status of the adaptor proteins IRS1 and GRB10 in MASTL depleted 
cells in response to glucose. Ablation of MASTL reduced the phosphorylation of both IRS1 and 
GRB10 on S616 and S476, respectively, and resulted in increased IRS1 and decreased GRB10 
total protein levels (Figure 29b). This is in agreement with enhanced transduction to the 
PI3K/AKT pathway in MASTL-depleted cells as reflected by increased phosphorylation of AKT on 
T308. Concomitant depletion of B55 alpha and delta with siRNAs in MASTL-null cells partially 
rescued the phosphorylation status of IRS1 and GRB10 proteins (Figure 29c). These results 
suggested that B55 alpha and delta proteins might be the regulatory subunits of the PP2A 
phosphatase responsible to control the phosphorylation status of the feedback target proteins, 
IRS1 and GRB10, and promote growth factor signaling. In addition, MASTL-ENSA/ARPP19 axis 
would participate in the feedback by inhibiting PP2A/B55 complexes to prevent the 
dephosphorylation of the adaptor proteins, and attenuate growth factor signaling to PI3K/AKT.  
If IRS and GRB10 are the main targets that mediate the role of MASTL-PP2A/B55 in the 
mTORC1/S6K1-dependent feedback, and underlie the increased AKT activation in MASTL-
depleted cells, then growth factor pathways dependent on both adaptor proteins should be 
sensitive to MASTL depletion and display enhanced AKT activation, whereas IRS- and GRB10-
independent pathways should remain relatively unaffected. Indeed, AKT activation in response to 
insulin stimulation, a pathway where IRS and GRB10 are obligatory, is significantly enhanced in 
MASTL-null cells (Figure 30a). In contrast, FBS treatment, which mainly contains mitogens that 
activate GPCR independently of IRS1 and GRB10, did not show enhanced AKT activation in 
MASTL-null cells. GRB10, but no IRS1, can also interact with the epidermal growth factor 
receptor (EGFR), although with less avidity than IR/IGFR-I (He et al., 1998). In agreement with 
that, MASTL-null cells present increased tyrosine phosphorylation of the EGFR and mild 
enhanced sensitivity to hEGF (Figure 30b). MASTL depletion had no effect on insulin receptor 
tyrosine autophosphorylation on Y1135/1136, suggesting that MASTL elicits a selective inhibitory 
effect on AKT activation at a point downstream of the insulin receptor. Importantly, treatment with 
specific inhibitors of IR/IGFR-I or EGFR, completely or partially rescued, respectively, the 
increase in AKT T308 in MASTL null cells (Figure 30b). All this data reinforce the idea that 
MASTL attenuates insulin-induced AKT phosphorylation through the participation in the feedback 
at the level of the IRS1- and GRB10-coupled receptors, and modulates insulin and IGF-1 
pathways, and, to a lesser extent to EGFR. 
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3.2.6 Characterization of mTORC1/S6K1-dependent regulation of MASTL 
Our previous data suggested that MASTL may be activated downstream of the mTORC1/S6K1 
axis (Figure 27). The increased activity of MASTL shown in the absence of TSC2, together with 
its sensitivity to the specific mTORC1 inhibitor rapamycin, pointed to mTORC1, but not mTORC2 
(Huang et al., 2008), as the main regulator of MASTL. 
As the mTOR-regulated sites may be phosphorylated by mTOR or by downstream kinases, 
we sought to distinguish if MASTL may be directly phosphorylated by mTORC1 or by any direct 
effector of the mTORC1 pathway like S6K1. mTOR phosphorylates hydrophobic motifs (HMs) of 
the AGC kinases as well as distinct proline-directed sites of proteins such as 4E-BP1 and has 
unique preference for proline, hydrophobic and aromatic residues at the +1 position (Hsu et al., 
 
Figure 30. MASTL-null cells show increased sensitivity to insulin-regulated pathways.  a) 
Control and MASTL-null cells were serum starved from serum for 4 h before perform stimulations 
with the indicated mitogens for 30 min. Immunoblot for the indicated proteins. Quantification of AKT 
T308 signal from immunoblots (Bottom). b) Control and MASTL-null cells were treated for 30 min 
before recovery with 5 µM linsitinib and 5 µM erlotinib, inhibitors of IR/IGFR-I and EGFR, 
respectively. Cell lysates were analyzed for the indicated antibodies. Error bars indicate sem. N=3 
independent experiments for Ins and hEGF. *p<0.05 (Student’s t-test). 
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2011). Interestingly, MASTL sequence contains several candidate mTOR sites. Moreover, a 
S6K1 consensus phospho-acceptor site (R/K)X(R/K)XX(S*/T*) is also present within MASTL 
sequence. We performed in vitro kinase assays using commercial purified mTOR/Raptor/mLST8 
(mTORC1 complex) and S6K1 kinases and GST-hMASTL as a substrate. To reduce any 
interference with the autophosphorylation activity of MASTL on its own, we first incubated MASTL 
alone with non-radioactive ATP and, then, we added the exogenous kinases mTORC1 and S6K1 
together with radiolabelled ATP. Both kinases, mTORC1 and S6K1, were able to phosphorylate 
MASTL (Figure 31a). We next performed mass-spectrometry analysis to identify candidate 
mTORC1- and/or S6K-regulated phosphorylation sites in MASTL in vitro. To discard those 
phosphorylations present in the purified MASTL or resulting from MASTL autophosphorylation, 
we selected only those phosphopeptides enriched in the presence of the candidate upstream 
kinase. We identified 4 specific phosphorylation sites (T710, T716/717, T722 and S878) from 23 
detected phosphosites. Phosphorylation at T722 was increased 3-fold relative to MASTL alone by 
both mTORC1 and S6K1, and phosphorylation at T710 and T716/718 was enriched 8- and 7-fold, 
respectively, in presence of mTORC1, and around 2.5-fold increase by S6K1. Phosphorylation at 
S878 was dramatically increased by mTORC1 more than 150-fold, suggesting that this 
phosphosite is a bona fide candidate for being a direct mTORC1- site, at least in vitro (Figure 
31b). Interestingly, the four sites were mapped in the C-terminal tail of MASTL and presented 
high conservation among species (Figure 31c). Moreover, sequence analysis revealed that the 4 
residues contained proline or hydrophobic residues at the +1 position, a requirement for mTOR 
phosphorylation motifs, and further suggested that these sites might be mTOR-phosphorylated 
sites. We cannot rule out whether these residues are direct mTORC1- or S6K-sites in vitro, or 
instead these kinases may promote MASTL activity that in turn triggers autophosphorylation at 
these sites.  
Data in human cells and Xenopus, as well as in other independent proteomic screens, 
indicate that S878 is also phosphorylated in vivo in mitosis (Blake-Hodek et al., 2012; Vigneron, 
Gharbi-Ayachi, et al., 2011). To check if this and the other sites identified on MASTL, were 
sensitive to growth factors in cells and further identify other serum-responsive sites of MASTL, we 
also analyzed the phosphorylation of MASTL in vivo in immunoprecipitates of endogenous 
MASTL from MEFs, arrested in quiescence by serum starvation (G0), and re-stimulated for 6 h 
FBS (G1). We identified 3 out the 4 potential mTORC1/S6K1-dependent sites identified in vitro to 
be also phosphorylated in vivo. Interestingly, phosphorylation at S878 was responsive to growth 
factors and it was increased 3-fold in G1 compared to G0 arrested cells (Figure 32a). Previous 
research had shown that mutation of the equivalent site to S878 to alanine in Xenopus MASTL 
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protein results in a partial inactivation of MASTL in mitosis (about 60% kinase activity on its 
substrates), whereas mutation to A of the other sites (T710, T716/T718 and T722) did not affect 
MASTL activity (Blake 2012). Considering all this data together, S878 appears to be the most 
promising site on MASTL for being mTOR-regulated (Figure 32b). Functional analysis of this site 
and its relevance in the role of MASTL regulating the mTORC1/S6K1-AKT feedback is currently 
ongoing. 
  
 
Figure 31. Characterization of mTORC1/S6K1-dependent phosphorylation sites on MASTL 
in vitro. a) In vitro kinase assay using purified GST-hMASTL as a substrate and purified 
mTORC1 and S6K1 kinases. A condition of MASTL without kinase was included as control of 
autophosphorylation. Autoradiograph showing the phosphorylation of MASTL by mTORC1 and 
S6K1. Red arrowheads show a phosphorylated band at the high of MASTL. mTORC1-mediated 
phosphorylation of MASTL induces a band shift of the protein (Right).  Imperial staining shows 
the dried gel and the GST-MASTL protein. b) Mass spectrometry analysis of samples treated as 
a). Plots represent mTORC1- S6K1-regulated sites on human MASTL. Intensities of the 
phosphopeptides were normalized to the total levels of MASTL and plotted as relative values to 
the condition of MASTL alone. c) Schematic representation of human MASTL protein structure 
with the phosphorylation sites from vertebrate orthologous aligned below. Nd, not detected (when 
the peptide containing this phosphosite was not detected on the proteomic analysis). 
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3.2.7 MASTL depletion alters GLUT4 translocation and glucose metabolism in cells 
The PI3K/AKT pathway is a central signaling node within all cells of higher eukaryotes and plays 
critical roles in insulin-mediated glucose uptake and metabolism (Manning & Cantley, 2007; 
Manning & Toker, 2017). In both 3T3-L1 adipocytes and myocytes it has been demonstrated that, 
via mTORC1-dependent feedback loop regulation, amino acid starvation stimulate AKT activation 
and subsequent glucose uptake in response to insulin (Takano et al., 2001; Tremblay & Marette, 
2001). The stimulation of glucose uptake by insulin requires translocation of GLUT4 transporter 
protein from intracellular storage sites to the cell surface (Leto & Saltiel, 2012), and IRS adaptor 
proteins and AKT are necessary for this process (Clarke, Young, Yonezawa, Kasuga, & Holman, 
1994; Quon et al., 1994) (Figure 33a). Given the participation of MASTL in the mTORC1-
mediated feedback control of AKT, we have tested whether MASTL depletion could affect 
glucose homeostasis in cells. We first analyzed whether MASTL depletion and concomitant AKT 
activation in MDA-MB231 cells had an effect in GLUT4 translocation following insulin stimulation. 
We quantified by IF the percentage of cells positive for GLUT4 localization at the plasma 
membrane (PM). As expected, insulin stimulation increased the percentage of cells positive for 
GLUT4 translocation compared to serum-starved cells, and MASTL knockdown further increased 
the percentage of cells positive for GLUT4 at the PM after insulin stimulation (Figure 33b,c). 
Same analysis was done upon glucose starvation and re-stimulation. Similarly, we found 
increased percentage of cells positive for GLUT4 in the PM upon MASTL depletion, further 
supporting a role for MASTL in the regulation of AKT-mediated GLUT4 translocation (Figure 
33d). 
 
Figure 32. Characterization of growth factor-stimulated phosphosites on MASTL in vivo. a) 
Plots represent sites on mouse MASTL regulated upon serum stimulation for 6 h (G1) compared to 
G0 cells that had been serum starved for 24 h. Endogenous MASTL was immunoprecipitated from 
MEFs in the indicated conditions and phosphosites on MASTL were identified by mass 
spectrometry analysis. Intensities of the phosphopeptides were normalized to the total levels of 
MASTL and plotted as relative values to the condition of MASTL alone. Hs indicate the 
corresponding phosphorylation site on human MASTL. b) A summary of Figure 31 b,c) and Figure 
32 a) for each MASTL phosphorylation site. Nd, not detected.  
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Figure 33. Depletion of MASTL alters GLUT4 translocation in cultured cells. a) Scheme of the 
AKT-mediated regulation of glucose uptake and metabolism. b) Immunodetection confirming 
MASTL depletion and activation of the AKT pathway in MASTL null cells in the conditions of the 
assay. MASTL was knocked down using shRNAs for MASTL and Scr as control. c,d) 
Immunofluorescence for GLUT4 in MDA-MB231 cells in conditions of serum starvation and insulin 
stimulation c), and glucose starvation and re-addition d). Representative micrographs of GLUT4 
(green) and nucleus (red) (Upper panels). Arrowheads indicate positive cells for GLUT4 
translocation to the PM. Plots represent quantification of the percentage of cells positive for GLUT4 
translocation to the PM (Bottom right). Around 800 cells were counted per condition. Error bars 
indicate SD. Ns, not significant; **p<0.005; ***p<0.001 (2-way ANOVA). 
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Apart from the regulation of glucose uptake, AKT activation can also affect glucose 
metabolism by stimulating glucose conversion to glycogen through phosphorylation and inhibition 
of GSK3β, thus relieving glycogen synthase activity (Cross et al., 1994) . AKT can also increase 
the rate of glycolysis (Elstrom et al., 2004) due, at least in part, to its ability to promote expression 
of glycolytic enzymes through mTORC1-dependent induction of Hypoxia Inducible Factor 1α 
(HIF1α) transcription factor (Lum et al., 2007; Majumder et al., 2004). The mTORC1-HIF1α axis 
also mediates transcription of GLUT1 gene and cap-dependent translation of GLUT1 mRNA 
(Taha et al., 1999; Zelzer et al., 1998). Therefore the AKT-mTORC1 pathway promotes a switch 
from mitochondrial oxidative metabolism to glycolysis (Figure 33a). We next analyzed whether 
the increased AKT-mTORC1 signaling observed upon MASTL depletion in conditions of feedback 
regulation had any impact on the metabolic status of these cells. We detected increased levels of 
HIF1α upon glucose re-addition in MASTL null cells, which were accompanied by increased 
expression of its target pyruvate dehydrogenase kinase 2 (PDHK2) and increased 
phosphorylation of the pyruvate dehydrogenase E1 (PDHE1) protein at S293 (Figure 34a). 
PDHK2-mediated phosphorylation of PDHE1 inactivates the PDH complex, which is the 
gatekeeping enzyme that converts pyruvate to acetyl-CoA, thus linking glycolysis to TCA cycle. 
Increased PDHE1 S293 phosphorylation in MASTL null cells upon glucose re-addition suggested 
increased glycolytic activity in these cells. Importantly, these signals were prevented in MASTL-
deficient cells treated with AKT inhibitors, further suggesting that ablation of MASTL may lead to 
increased glycolytic flux in an AKT-dependent manner in conditions of feedback regulation 
(Figure 34a). In addition, we also found a modest increase in the transcription of the HIF1α-
target gene GLUT1 in MASTL depleted cells after glucose stimulation (Figure 34b). 
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To further explore this idea we performed Seahorse analysis that allows the quantification 
in real time of the extracellular acidification rate (ECAR) and the consumption of oxygen (OCR) in 
the media, whose values can be correlated to glycolysis and mitochondrial respiration, 
respectively. To analyze the glycolytic flux, cells are incubated in glucose-free media followed by 
sequential addition of glucose and oligomycin A to score the glycolytic flux and capacity of the 
cells, respectively. Ablation of MASTL induced a mild increase in ECAR upon glucose re-addition 
at two different concentrations reflecting higher glycolytic flux in MASTL null cells in these 
conditions (Figure 35a). However, there were no differences in the glycolytic capacity of the cells 
suggesting that MASTL depletion does not induce a general metabolic switch but rather a 
controlled and well-defined upregulation of glycolysis under conditions of feedback-mediated AKT 
regulation. We also analyzed the mitochondrial respiratory capacity in conditions of regular 
complete media, in which cells are challenged with different drugs targeting the machinery of 
OXPHOS. MASTL null cells had a mild reduction in maximal respiration upon treatment with the  
 
 
Figure 34. Depletion of MASTL upregulates the AKT-mTOR-HIF1α  axis. a) Immunoblot for the 
indicated antibodies of the AKT-mTOR-HIF1α. MASTL was knocked down using shRNAs for 
MASTL and Scr as control. Cells were glucose starved followed by glucose stimulation. AKT 
inhibitor was added 15 min before glucose re-addition. b) Quantitative PCR for GLUT1 in control 
and MASTL depleted cells upon glucose re-addition for 30 min. N=2 independent experiments. 
Error bars indicate sem. Ns, not significant; **p<0.005 (Paired Student’s t test). 
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Figure 35. Depletion of MASTL promotes glycolysis under glucose re-stimulating conditions. 
a) Seahorse experiment to assay glycolysis in control and MASTL depleted cells. Indicated 
compounds were added over the time and ECAR values were plotted over the time in control and 
MASTL-null cells (Upper left). Data was expressed as mean ± sem of 3 independent experiments. 
Immunodetection of MASTL confirming MASTL depletion (Right). Plots representing quantifications 
of glycolytic flux, capacity and spare according to manufacturer instructions. Data is represented as 
mpH/min per cell (Bottom). b) Seahorse experiment to determine the mitochondrial respiratory 
capacity in control and MASTL-depleted cells. c) Immunoblot showing phosphorylation of GSK3β on 
S9 in control and MASTL-null cells in glucose starvation and re-addition in a time course of 15 min 
and 1 h. Data was expressed as mean ± sem of 3 independent experiments. Error bars indicate sem. 
Ns, not significant p>0.05; *p<0.05; **p<0.005; ***p<0.001 (Paired Student’s t-test). 
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decoupling agent FCCP that might reflect some mitochondrial alteration (Figure 35b). 
Together, the above observations suggested that depletion of MASTL in conditions of 
feedback-mediated AKT regulation results in increased AKT-mediated GLUT4 translocation and 
likely glucose uptake. Moreover, AKT couples glucose metabolism to glycolysis by increasing the 
expression of glycolytic proteins downstream the mTORC1-HIF1α axis. AKT may as well favor 
glycogen synthesis through phosphorylation and inhibition of GSK3β, as is suggested by the 
increased phosphorylation at S9 in MASTL-null cells (Figure 35c). 
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3.3 Physiological functions of Mastl in vivo in mammals 
3.3.1 Control of tissue proliferation by Mastl in young and adult mice  
To address the physiological relevance of Mastl in vivo, we made use of the ubiquitous and 
conditional loss-of-function mouse model for Mastl previously generated. TAM treatment induces 
Cre-mediated recombination of Mastl gene and generates a mouse KO for Mastl in the whole 
body. We first analyzed the consequences of Mastl depletion in young mice by treating them with 
TAM in the diet starting at 3 weeks of age. Mastl(Δ/Δ) mice died within 3-4 weeks after treatment 
whereas control littermates survived normally and did not presented any abnormality (Figure 
36a). Body weight at the human end point (HEP) was dramatically decreased in Mastl(Δ/Δ) mice, 
which had lost around half of their weight (Figure 36b). According with the above-described 
mitotic function of Mastl in cells, histological analysis of tissues revealed the presence of dramatic 
mitotic defects in highly proliferative tissues, which were severely affected by Mastl loss. Among 
them, the small intestine was one of the most affected tissues. Its architecture was completely 
 
 
Figure 36. Deletion of Mastl in young mice causes severe proliferative defects. a) Survival 
curves of Mastl(lox/lox) and (Δ/Δ) mice. 3-week-old mice were fed with TAM diet to induce Mastl 
deletion. Graph show the proportion of mice that survived, HEP was applied according CNIO 
regulation. Mice were sacrificed for samples at the HEP. b) Body weight of the mice as in a) at the 
HEP. c) HE staining and Ki67 IHC of small intestine sections of control and Mastl KO mice. d) Full 
blood cell counts at the HEP. Plot representing the quantifications of the different lineages. Red 
blood cells (RBC), white blood cells (WBC) including lymphocytes (LYM) and granulocytes (GRA), 
precursor white cells and rare cells (MID), and platelets (PLT). N=8 Mastl(lox/lox); N=10 (Δ/Δ). 
Error bars indicate sem. Ns, not significant. *p<0.05; **p<0.005; ***p<0.001 (Student’s t-test). 
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disrupted as seen by HE staining and suffered a dramatic reduction in cell proliferation, which 
was detected by loss of staining for the proliferative marker Ki67 (Figure 37c). The efficiency of 
Mastl deletion was confirmed by IHC for MASTL in the small intestine of Mastl(Δ/Δ) mice. The 
severe damage to the intestine was very likely the main cause of the severe weight loss and 
consequent death of Mastl(Δ/Δ) mice. Mastl(Δ/Δ) mice also presented atrophy in the skin and 
spleen, with reduction of the red pulp; and hypoplasia in the bone marrow. In agreement, blood 
cell count analysis reflected a dramatic reduction of the whole white blood cell lineage including 
lymphocytes, and granulocytes (Figure 36d).  
We next sought to analyze the effect of Mastl depletion in adult mice. For this purpose, 
and following the protocol for Mastl depletion in young mice, 1-year-old mice were treated with 
TAM in the diet for the whole time the experiment lasted. Surprisingly, Mastl(Δ/Δ) mice survived 
in similar proportions to control mice with no obvious phenotype until 6-months after TAM 
treatment (Figure 37a). At that time we had to apply the HEP since Mastl(Δ/Δ) mice experienced 
some signs reminiscent of aging including kyphosis, difficulties in movement, and in some cases, 
cataracts in one or both eyes. Only elder Mastl(Δ/Δ) females suffered from a mild loss of weight 
compared to their controls, that in contrast to young Mastl(Δ/Δ) mice, did not compromise survival 
in any case (Figure 37b). No differences in body weight were observed in male mice. Histological 
analysis of tissues extracted after 3 and 6 months on TAM diet, revealed no major abnormalities 
in Mastl(Δ/Δ) mice, and much less severe proliferative problems compared to young Mastl(Δ/Δ) 
mice, even in highly proliferative tissues such as the intestine, and despite having a comparable 
deletion of Mastl (Figure 37c). In addition, Mastl(Δ/Δ) mice showed a mild reduction in cell blood 
counts although there were no significant differences, except for red blood cells (Figure 37d). 
This data suggests that elder mice are more tolerant to Mastl depletion than young mice, 
suggesting that, either proliferative tissues become more independent on the mitotic function of 
Mastl as they age, or they become more tolerant to mitotic aberrations given probably due to 
reduced regenerative capacity as organism ages.  
However, a detailed histopathology analysis showed that some proliferative tissues from 
Mastl(Δ/Δ) mice still presented some mitotic aberrations, increased apoptosis and reduced 
regenerative capacity. These alterations were present at 3 months after TAM and were even 
more pronounced at 6 months after TAM. This was specially clear in the intestine, where 
quantification of positive cells for Ki67, revealed a strong reduction of Ki67 in the transit 
amplifying compartment of the villi, together with some signs of atrophy and irregular villi 
morphology (Figure 38a). Even though Ki67 was not significantly decreased in the crypts, there 
were reduced mitotic figures and increased apoptosis, based on cleaved caspase-3 (CA3) 
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staining, probably reflecting the loss of regenerative capacity in this tissue (Figure 38a). The 
colon also had a reduction in Ki67 positive cells concomitant with an increase in apoptotic cells 
(Figure 38a). 
At the time of 6 months after TAM it was also prominent the presence of rare cells with 
big, vacuolated nuclei, and less condensed chromatin in liver, kidney, skin and eye from 
Mastl(Δ/Δ) mice. This was accompanied by disorganized tissue structures that had lost tissue 
homeostasis and that were absent in Mastl(+/lox) control mice. Liver was among the most 
affected tissues with high levels of nuclear pleomorphic nuclei and fragmented chromatin in 
 
Figure 37. Effect of Mastl deletion in adult mice. a) Survival curves of Mastl(lox/lox) and (Δ/Δ) 
mice. 52-week-old mice were fed with TAM diet to induce Mastl deletion. Graph show the proportion 
of mice that survived along the time, humane end point (HEP) was applied according to CNIO care 
program. Mice were sacrificed for samples at the HEP. Representative pictures of Mastl KO mice at 
the HEP are shown (Left). b) Relative loss of body weight at HEP compared to their initial weight 
before TAM. c) HE staining and Mastl immunohistochemistry of small intestine sections of control 
and Mastl KO mice at 3 months after TAM. d) Full blood cell count at 3 months after TAM diet. Plot 
representing the quantifications of the different lineages. N=14 Mastl(+/Δ); N=12 (Δ/Δ). Error bars 
indicate sem. Ns, not significant. *p<0.05; ***p<0.001 (Student’s t test). 
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hepatocytes, resembling dead and damaged cells. This was accompanied by an increased 
percentage of Ki67 positive hepatocytes, probably reflecting the attempt to regenerate those 
damaged hepatocytes (Figure 38b). 
As a summary of this part, we conclude that deletion of Mastl in young mice causes 
severe proliferative defects, and mice die early after Mastl ablation. In contrast, knockout of Mastl 
in adult mice results in less severe proliferative defects and improved survival compared to young 
 
Figure 38. Histological analysis of Mastl deletion in adult tissues. a) Plots showing 
quantifications of immunohistochemical staining for Ki67 and CA3 in small intestine and colon 
tissue sections of Mastl(+/Δ) control and Mastl(Δ/Δ) mice after 3 months of TAM diet. 
Representative images of IHC for Ki67 and CA3 in the crypts of small intestine sections (Right).  
Asterisks indicate apoptotic cells. b) Quantification for Ki67 positive hepatocytes by IHC. 
Representative images of HE staining in liver sections of 64-week-old Mastl(+/Δ) control and 
Mastl(Δ/Δ) mice 6 months after TAM diet (Bottom). Asterisks indicate representative images of 
irregular vacuoles, protein aggregates and damaged hepatocytes. N=2 Mastl(+/Δ); N=2 (Δ/Δ). 
Error bars indicate sem. Ns, not significant. ***p<0.001 (Student’s t-test). 
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Mastl(Δ/Δ) mice. Accumulation of mitotic defects may eventually lead to impaired regenerative 
capacity of the tissues and inability to maintain tissue homeostasis, which, in the long term, may 
contribute to the systemic organ failure and premature death of Mastl(Δ/Δ) mice. 
3.3.2 Mastl depletion improves glucose tolerance in vivo 
 As discussed above, our results in cells suggested the participation of the MASTL-PP2A/B55 
axis in the modulation of the mTORC1/S6K1-feedback inhibition of PI3K/AKT pathway. Through 
this feedback loop mTORC1 hyperactivation is a critical event in rendering cells unresponsive to 
insulin/IGF-I, and has physiological relevance in controlling insulin sensitivity of peripheral 
tissues, such as fat and skeletal muscle, and profound effects in metabolic disorders 
characterized by insulin resistance, such as obesity or type-2 diabetes (Saxton & Sabatini, 2017). 
S6K1-deficient mice remain sensitive to insulin despite HFD and constitutive mTORC1 activation 
(Um et al., 2004). This has led to speculate that mTORC1 or S6K1 inhibitors that relieve AKT-
mediated feedback inhibition could improve glucose tolerance and protect against type 2 
diabetes. Taking into account the potential role of MASTL in metabolism, beyond its function in 
proliferation, we analyzed the expression of Mastl by RT-qPCR in several different metabolic 
tissues, such as the pancreas and the insulin-sensitive tissues including skeletal muscle, white 
adipose tissue (WAT) and liver. We found expression of Mastl in all analyzed tissues at 
comparable levels to the expression of Mastl in spleen, as a reference of proliferative tissue, 
indicating that expression of MASTL is not restricted to proliferative tissues (Figure 39a). We also 
observed that Mastl expression at mRNA level was modulated in vivo in response to food intake 
in muscle and epididimal WAT (eWAT). Mastl expression was increased in ad libitum fed mice 
compared to overnight fasted mice in both tissues (Figure 39b), further suggesting a non-mitotic 
role for Mastl in these tissues. 
 
Figure 39. Expression levels of Mastl in metabolic tissues. a) RT-qPCR analysis for Mastl in 
different tissues from ad libitum mice. N=3 mice. b) RT-qPCR for Mastl in muscle (Left) and eWAT 
(Right) in fasting and ad libitum fed mice. N=3. Error bars indicate sem. *p<0.05 (Student’s t test). 
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 To address the question of whether MASTL-mediated modulation of mTORC1/S6K1-
feedback activity could affect glucose homeostasis in vivo we performed a GTT in young mice 
that had been fed with HFD for 9 weeks. To avoid interference of the mitotic phonotype in Mastl 
KO upon continuous TAM treatment, Mastl was acutely ablated by intraperitoneal injection of 
TAM one week before the GTT (Figure 40a). TAM injection and concomitant loss of Mastl did not 
affect the body weight of Mastl(Δ/Δ) compared to control Mastl(+/+) mice, and there were no 
differences neither in body weight gain after the HFD or after fasting among groups (Figure 40b). 
 
 
Figure 40. Improved glucose tolerance in Mastl(Δ/Δ) mice. a) Schematic of the protocol 
followed. 8- to 12-week-old mice were fed with HFD 60% for 9 weeks to induce glucose 
intolerance and insulin resistance. 1 week before every experiment mice were injected twice with 
TAM every other day to induce Mastl deletion; control mice Mastl(+/+) were also injected with 
TAM. Mice were left to rest for 2 weeks in between experiments and fed always with HFD. b) 
Plots representing the relative body weight at the indicated times. Body weight gain after 9 weeks 
of HFD (Left); Weight loss 1 week after TAM injection (Middle); Weight loss after 16 h fasting 
(Right). N=6 Mastl(+/+) and N=11 Mastl(Δ/Δ). c) GTT experiment in Mastl(+/+) and Mastl(Δ/Δ) 
mice from b). Dashed lines indicate GTT experiment in the same mice a different day upon 
treatment with the CNIO-PI3Ki (ETP46992). Inhibitor was administered by oral gavage to 16 h 
fasted mice at a single dose of 20 mg/kg body 1 h before the GTT. d) Immunoblot for the 
indicated antibodies in muscle extracts. Mice were fasted overnight for 16 h and injected 
intraperitoneally with glucose (2 g/kg body) and mice were sacrificed 30 min later for samples. 
Quantification of the signal of AKT P-T308 represented as fold change relative to total AKT. 3 
mice were analyzed per genotype. Same mice as in c) were used. Error bars indicate sem. Ns, 
not significant p>0.05; *p<0.05 (Student’s t test); **p<0.005; ***p<0.001 (2-way ANOVA). 
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Mastl(Δ/Δ) mice were more glucose tolerant in a GTT experiment, having significantly reduced 
blood glucose levels 30 and 45 min after glucose injection (Figure 40c). This result was 
indicative of better glucose clearance by peripheral tissues in Mastl(Δ/Δ) mice. As a direct 
mediator of glucose uptake in cells and tissues, we next evaluated PI3K/AKT activation upon a 
boost of glucose in control and Mastl(Δ/Δ) mice. Mastl(Δ/Δ) mice exhibited increased glucose-
stimulated AKT activation in muscle (Figure 40d). No significant differences were found in eWAT 
or liver (data not shown). In agreement with and increased AKT activation in Mastl(Δ/Δ) mice, 
treatment with a single dose of an orally bioavailable and specific PI3K inhibitor (CNIO992-PI3Ki) 
(Martínez González et al., 2012) 1 h before the GTT assay completely rescued the differences 
among groups. As expected, the inhibitor increased the fasted glycaemia and both group of mice 
become glucose intolerant in the assay (Figure 40c). Of note, the effect of the inhibitor was even 
more pronounced in Mastl(Δ/Δ) mice, who reached the highest and most sustained levels of 
hyperglycemia. Noteworthy, 3 out of the 10 Mastl(Δ/Δ) mice died 2 days after the assay due to 
extreme hyperglycemia, suggesting that Mastl(Δ/Δ) mice might be more sensitive to the inhibitor, 
probably reflecting a higher dependence of Mastl(Δ/Δ) mice on the PI3K/AKT pathway. These 
data also suggest that the enhanced glucose tolerance upon MASTL ablation might be a 
consequence of increased PI3K/AKT activity in Mastl(Δ/Δ) tissues responsible of glucose uptake, 
such as muscle, even though we cannot discard contribution of other tissues like the WAT or 
liver. 
Better glucose tolerance is consequence of increased glucose uptake by peripheral 
 
Figure 41. Mastl deletion does not affect glucose-stimulated insulin secretion. a) Insulin 
plasma concentration determination in a time course in 16 h fasted mice and 30 min after glucose 
injection. Same mice as in Figure 41 b) were used. N=6 Mastl(+/+) and N=7 Mastl(Δ/Δ). b) IHC 
for insulin in pancreas tissue sections of Mastl(+/+) and Mastl(Δ/Δ) mice. c) IHC for Mastl in 
pancreas tissue sections of Mastl(+/+) and Mastl(Δ/Δ) mice. Arrows indicate representative 
positive cells for Mastl. Error bars indicate sem. Ns, not significant p>0.05 (2-way ANOVA). 
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tissues, which can be modulated by either increased glucose-induced insulin secretion (GSIS) by 
the pancreas and concomitant enhanced AKT signaling in insulin-responsive tissues, or by the 
mTORC1-dependent feedback loop, whereby impaired feedback-mediated AKT inhibition 
improves glucose uptake. GSIS is also affected by the PI3K/AKT (Bernal-Mizrachi et al., 2004), 
and mTORC1 pathways (Rachdi et al., 2008). To rule out the possibility of Mastl(Δ/Δ) mice 
having increased GSIS, we measured levels of insulin in plasma 30 min after glucose injection. 
We found no differences in the levels of GSIS in Mastl(Δ/Δ) mice compared to controls (Figure 
41a). There were no differences in plasma insulin concentration in fasting either. Histological 
examination of pancreas sections showed no gross abnormalities or differences in the number or 
size of the Langerhans islets (Figure 41b). Positive nuclear staining for Mastl by IHC in tissue 
sections was found in some cells of the exocrine an endocrine pancreas as well, and Mastl was 
efficiently ablated in Mastl(Δ/Δ) mice (Figure 41c). This data suggests that the increased glucose 
tolerance of Mastl(Δ/Δ) mice is likely not consequence of increased GSIS.  
 In order to determine the potential involvement of the liver in the better glucose tolerance 
of Mastl(Δ/Δ) mice, we generated a hepatocyte-specific conditional mouse model for Mastl. For 
this, we crossed our Mastl(lox) model with a strain expressing a TAM-inducible Cre-recombinase 
under the control of the albumin gene promoter, Mastl_L(lox/lox). Mice were also feed with HFD 
for 9 weeks and injected with TAM (Figure 42a). Ablation of Mastl specifically in hepatocytes 
does not recapitulate the glucose tolerance phenotype observed upon ubiquitous ablation of 
Mastl in the whole body (Figure 42b). However, the kinetics of the response of Mastl_L(Δ/Δ) 
mice is delayed compared to controls. At 15 min after glucose injection Mastl_L(Δ/Δ) mice 
 
Figure 42. No differences in glucose tolerance upon Mastl specific knock out in the liver. a) 
Schematic of the protocol followed. 8- to 12-week-old mice were fed with HFD 60% for 9 weeks to 
induce glucose intolerance and insulin resistance. 1 week before every experiment mice were 
injected twice with TAM every other day to induce Mastl deletion. b) GTT experiment in mice in 
Mastl_L(lox/lox) mice. Mice were fed with HFD and intraperitoneally injected with TAM to deplete 
Mastl following the protocol as in a). N=6 Mastl_L(+/+); N=8 Mastl_L(lox/lox). Error bars indicate 
sem. Ns, not significant p>0.05 (2-way ANOVA). 
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reached significantly lower glucose levels, although we do not have an explanation for this 
observation, one hypothesis is that glucose-induced inhibition of gluconeogenesis, which 
depends on AKT activation, is enhanced in Mastl_L(Δ/Δ) mice. Even though we can cannot rule 
out a contribution of the liver to Mastl KO phenotype, this results suggests that other tissues 
rather from the liver are responsible for the better glucose clearance of Mastl(Δ/Δ) mice.  
In agreement with a better glucose tolerance of young Mastl(Δ/Δ) mice fed with HFD, we 
found that 1-year-old whole-body Mastl(Δ/Δ) mice fed with chow diet ad libitum had a significantly 
reduced glycaemia compared to control littermates Mastl(+/Δ) mice (Figure 43a). Again, there 
were no differences in insulin plasma concentration evaluated in the same feeding conditions 
(Figure 43b). Despite the lower glucose levels, Mastl(Δ/Δ) mice fed with chow TAM diet failed to 
show better glucose tolerance in a GTT assay (Figure 43c). This result suggests that Mastl 
ablation likely improves glucose tolerance upon a stressful and challenging condition such as 
HFD and also lowers basal glycaemia in old mice. Altogether, this data place Mastl as a new 
 
Figure 43. 1-year-old Mastl(Δ/Δ) mice present reduced glycaemia. a) Blood glucose levels in 
Mastl(Δ/Δ) and Mastl(+/Δ) mice. Mice were treated with TAM chow diet to induce Mastl depletion in the 
whole body. 1-month later blood glucose concentration was determined in the morning in ad libitum fed 
mice. N=11 Mastl(+/Δ) and N=12 Mastl(Δ/Δ). b) Insulin plasma concentration determined in same feeding 
conditions as in a). N=9 Mastl(+/Δ) and N=12 Mastl(Δ/Δ).  c) GTT in Mastl (+/Δ) and Mastl(Δ/Δ) treated 
as in a). N=9 Mastl(+/Δ) and N=12 Mastl(Δ/Δ).  d) Plots representing the relative body weight at the 
indicated times of the mice in c). Body weight loss upon 1 month in TAM diet (Left); Weight loss after 16 
h fasting (Right). N=9 Mastl(+/Δ) and N=12 Mastl(Δ/Δ). Error bars indicate sem. Ns, not significant; 
**p<0.005 (Student’s t test). 
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potential target of intervention for metabolic diseases, such as obesity-induced diabetes.  
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4.1 Cell cycle-dependent functions of MASTL 
4.1.1 Different requirements of MASTL for mitotic entry  
Different studies, including ours, have shown that Mastl/Greatwall is an essential mitotic kinase in 
different organisms. Depletion of Mast/Gwl in Xenopus oocytes (Mochida et al., 2010) as well as 
in HeLa cells using siRNAs impaired mitotic (M) entry (Burgess et al., 2010; Voets & Wolthuis, 
2010). These results are in contrast to our findings in mouse embryonic fibroblasts (MEFs) from 
the conditional knockout (cKO) mouse model of Mastl, in which genetic ablation of Mastl does not 
impair M entry but, instead, affect mitotic progression upon NEB. Mastl depleted cells enter into 
M with the same kinetics as control cells, although due to the presence of mitotic defects, such as 
chromosome condensation, they remain arrested in prometaphase; eventually they abnormally 
exit mitosis presenting segregation defects. One reasonable explanation for this difference is that, 
in our experiments, MEFs are synchronized by serum starvation and Mastl is ablated in non-
dividing cells, thus allowing us to monitor the first division after Mastl loss. However, experiments 
in HeLa cells are performed in asynchronous cultures where a first division in the absence of 
MASTL might have already occurred before M entry analysis. From out data, we known that cell 
dividing in the absence of MASTL frequently fail to segregate and exit mitosis as tetraploid (4n) 
cells, a phenotype that interferes with a successful progression through the next cell cycle and 
timely mitotic entry. In addition, HeLa cells were synchronized at the G1/S transition with an 
overnight thymidine block before scoring M entry. This treatment may cause a certain level of 
DNA damage and force cells to recover from the DNA-damage associated checkpoint before 
resuming the cell cycle. In line with a role for MASTL in the checkpoint recovery (Wong et al., 
2016), it is not surprising that MASTL deficient cells experienced defects in the G2/M transition as 
scored in their experiments. Altogether, the data from our cKO MEFs, along with the 
accumulation of M figures in Mastl null embryos (Figure 13c), suggest that Mastl is largely 
dispensable for M entry in unperturbed cell cycles in mammals, but essential for a proper 
progression through M phase.  
An intriguing conclusion from our results is that MASTL-mediated inhibition of PP2A/B55 may 
be dispensable for full activation of Cdk1-cycB during M entry in MEFs, a requirement thought to 
essential for M entry. A similar observation has been done in starfish oocytes, where depletion of 
the Mastl orthologous, Gwl, does not impair M entry, but, instead, causes segregation defects 
upon NEB (Okumura et al., 2014). In this system the absence of Gwl is compensated by Cdk1-
mediated phosphorylation of Arpp19, which promotes binding to and inhibition of PP2A/B55 and 
allow full Cdk1 activation, via its autoregulatory loop, and M entry. However, further reduction of 
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PP2A/B55 activity by Gwl-mediated phosphorylation of Arpp19 in mitosis is required to ensure 
proper chromosome segregation. According to these results, Gwl is dispensable, in starfish and 
MEFs, for the initial PP2A/B55 inhibition and activation of Cdk1-cycB at the cytoplasm, but 
instead, Gwl-mediated inhibition of PP2A/B55 is essential after NEB to prevent premature 
dephosphorylation of Cdk1-cycB phosphosubstrates, and allow normal progression through 
mitosis and proper chromosome segregation. This hypothesis is in agreement with a model in 
which Mastl/Gwl is almost exclusively nuclear before Cdk1-cycB complexes get activated and 
enter into the nucleus. Mastl is subsequently phosphorylated by nuclear Cdk1-cycB complexes 
and shuttles to the cytoplasm just before nuclear envelope breakdown to inhibit PP2A/B55 and 
prevent the massive dephosphorylation of mitotic proteins (Álvarez-Fernández et al., 2013; Wang 
et al., 2013). 
The above-mentioned different roles of Arpp19 upon either Cdk1 or Mastl phosphorylation 
suggest different affinity towards PP2A/B55 and different levels of phosphatase activity inhibition. 
In the same line, PP2A/B55 substrates might also have different sensitivity to the levels of PP2A-
B55 phosphatase activity. Interestingly, the homologous site of Cdk1-cycB phosphorylation in 
starfish Arpp19 is also present in Xenopus Ensa and Arpp19 proteins, in human and murine 
Arpp19, and in C. elegans Ensa; but it is absent in Ensa from human or Drosophila. In 
Drosophila, the equivalent position to the Cdk1 site is a phosphomimetic aspartic acid, and 
genetic studies have shown that lack of Mastl does not impair M entry, and mostly leads to delays 
in M entry accompanied by defective chromosome condensation (Yu et al., 2004).  In C. elegans, 
which appears not to have a Mastl homologue, Cdk1 phosphorylation of Ensa appears to 
compensate for the lack of Mastl. Therefore, it is plausible that Cdk1-dependent phosphorylation,	  
or a phosphomimetic mutation in the equivalent site, of at least one endosulfine family member is 
sufficient for mitotic progression in almost all metazoans.  
The only exception to the above-mentioned hypothesis is Xenopus, where depletion of Gwl 
from cycling extracts in Xenopus prevents Cdk1-cycB activation and mitotic entry (Yu et al., 
2006), and the concomitant inhibition or depletion of PP2A-B55 rescues defective mitotic entry 
(Castilho et al., 2009). One plausible explanation is that in Xenopus, Cdk1-mediated ENSA 
phosphorylation only moderately increases its affinity for binding to and inhibiting PP2A-B55 
(Mochida, 2014), and in the absence of Mastl this is not sufficient to counteract the phosphatase 
activity and reach the Cdk1-cycB threshold required for M entry in Xenopus. Another possibility is 
that the threshold of Cdk1-cycB activity for M entry might be higher in Xenopus, making Gwl 
mediated inhibition of PP2A/B55 essential to reduce the amount of Cdk1-cycB required for M 
entry (Hara et al., 2012), similarly to what happen under stressful conditions such as recovery 
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from DNA damage (Peng et al., 2010). It is also plausible that Xenopus has higher levels of 
phosphatase activity compared to other species, which need to be reduced for M entry, thus 
making essential Gwl-mediated phosphorylation of endosulfines. This is just speculation since a 
comparison of phosphatase activity among species has not been addressed. In summary, these 
data highlight the different requirements of Cdk1-cycB and PP2A/B55 activity, and, as 
consequence, of Mastl/Gwl for M entry among species.  
Interestingly, in fission yeast, as in Xenopus, cells depleted of the Mastl orthologous, Ppk18, 
are unable to enter into mitosis due to high PP2A/B55 activity (Chica et al., 2016). It is not known, 
however, whether in S. pombe, similar to multicellular organisms, Cdk1-cycB phosphorylates 
endosulfine, and if this promotes binding to PP2A/B55. In any case, this putative Cdk-mediated 
phosphorylation of endosulfine, would not be sufficient to reach the threshold of Cdk1 activity 
required for M entry in S. pombe, thus making essential Mastl activity. In budding yeast, the 
pathway is still conserved but with some conceptual differences. PP2A/B55 activity promotes, 
rather than prevents, entry into mitosis, and yeast Mastl and endosulfines orthologous, activate 
rather than inhibit PP2A/B55 at mitotic entry (Juanes et al., 2013). In S. cerevisiae, this pathway 
is dispensable for mitotic entry in unperturbed cell cycles, and, only under stress conditions lack 
of either Rim15 or endosulfines delay mitotic entry, and mitotic defects become apparent. 
4.1.2 Mitotic-independent roles in cell cycle regulation  
PP2A is a master phosphatase involved in cell cycle regulation and as such, has mitotic 
independent roles (Kurimchak & Graña, 2012). PP2A/B55 complexes restrain the G1/S transition 
in human cell lines by counteracting CDK-mediated phosphorylation and inhibition of the 
retinoblastoma protein (pRb).	  PP2A/B55 complexes also dephosphorylate the other pocket family 
proteins, p107 and p130, which are important for entry into quiescence (Kurimchak & Graña, 
2012). Nevertheless, it was not known if these PP2A/B55-dependent roles could be mediated by 
MASTL. We analyzed S-phase and quiescence entry in our MEFs cKO for Mastl and found no 
differences (Figure 18,19), indicating that Mastl does not control PP2A/B55 function at the G0-
G1/S transition in mammals.  
In yeast, the Rim15-Igo1/2-PP2A/Cdc55 module regulates entry into quiescence and survival 
in the stationary phase, also known as chronological life span (CLS). Given the universal role of 
TORC1 in nutrient sensing and regulation of CLS across species, as well as the remarkable 
conservation of the Rim15-Igo1/2-PP2A/Cdc55 module, it was interesting to examine whether the 
MASTL-ENSA/ARPP19-PP2A/B55 pathway also regulates quiescence and CLS in higher 
eukaryotes via similar mechanisms as described in budding yeast (Bontron et al., 2013). 
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However, ablation of Mastl in MEFs did not impair either entry into or maintenance of quiescence 
(Figure 19,20), suggesting that the central role of Rim15 in the control of quiescence in yeast is 
not conserved in mammals. It would be as well interesting to know whether in fission yeast Ppk18 
controls entry into quiescence and CLS upon nutrient deprivation. 
As a summary, the only essential role of Mastl in the control of the mammalian cell cycle is 
regulation of mitosis, a function mediated by Ensa/Arpp19 phosphorylation and inhibition of 
PP2A/B55 phosphatase.  
4.1.3 Different requirements of Mastl for cell proliferation in vivo 
The essential function of Mastl in mitosis has also physiological consequences in vivo. TAM-
inducible Mastl deletion in young mice caused severe proliferative defects, especially in highly 
proliferative tissues, such as intestine or bone marrow, which led to dramatic loss of weight and 
rapid death after ablation of Mastl. In contrast, depletion of Mastl in adult mice resulted in 
improved survival compared to young Mastl(Δ/Δ) mice and less severe proliferative defects, even 
in highly proliferative tissues like the intestine, whose renewal occurs at approximately the same 
rate in adult and young organisms. It was very surprising the difference observed in survival 
among young and adult mice upon Mastl ablation in the cKO mouse model, since both groups 
were continuously treated with TAM in the diet and reached similar efficiencies of Mastl depletion. 
This is in striking difference to the phenotype observed upon deletion of other essential mitotic 
regulator, such as the kinase Plk1, in adult mice. Plk1 null mice experience severe loss of body 
weight, disruption of the architecture of proliferative tissues and rapid death after treatment, a 
phenotype that was observed in both young and adult mice null for Plk1, and resembled 
Mastl(Δ/Δ) young mice (de Ca ́rcer et al., 2017). Data from Plk1 and Mastl cKO mouse models are 
comparable, since both express Cre-ERT2 under the ubiquitous promoter of Polr2a, and deletion 
is induced by TAM treatment in the diet in both models. These results led us to speculate that 
either highly proliferative tissues become more independent on the mitotic function of Mastl as 
the organism ages, or other pathways might compensate for the loss of Mastl in adult organisms. 
According to the mitotic role of Plk1, Plk1 promotes adaptive pancreatic β-cell proliferation in 
response to insulin, and ablation of an essential mediator of Plk1 function impairs adaptive β-cell 
growth and chronic glucose intolerance (Shirakawa et al., 2017). Mastl, by contrast, does not 
seem to be an essential mediator of β-cell proliferation as Mastl(Δ/Δ) mice do not present 
alterations either in the number of β-cells or the morphology of the Langerhans islets in the 
pancreas, and more importantly, Mastl(Δ/Δ) mice have increased glucose tolerance.  
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4.2 MASTL as a new modulator of the mTORC1/S6K1-dependent feedback loop 
4.2.1 Metabolic roles of cell cycle regulators 
Additional roles for well-established cell cycle regulators have recently emerged in non-
proliferative tissues to control metabolism independently of cell cycle progression. Different works 
have demonstrated that CDK4-cycD complexes control glucose homeostasis through different 
mechanisms. In pancreas, the CDK4-pRb-E2F axis activates the expression of Kir6.2, a key 
component of KATP channels, promotes insulin secretion, and improves glucose tolerance in mice 
(Annicotte et al., 2009). CDK4 is also important in adipose tissue where it phosphorylates IRS2 
and enhances AKT signaling and insulin sensitivity in vivo (Lagarrigue et al., 2016). In liver, 
CDK4 suppresses hepatic glucose production through activation of GCN5, and subsequent 
inhibition of PGC-1α (Lee et al., 2014). Nevertheless, CDK4-cycD activity is chronically elevated 
and deregulated in diabetes patients, probably reflecting the relevance in vivo of the ability of 
CDK4 to activate mTORC1 through the phosphorylation of TSC2 and inhibit the PI3K/AKT 
pathway (Zacharek, Xiong, & Shumway, 2005). CDK4 also affects cell metabolism through the 
pRb pathway, as CDK4 inhibition increases oxidative metabolism (Franco et al., 2016). Another 
example of control of metabolism by cell cycle regulators is given by mitotic checkpoint p31-
MAD2-BUBR1 module, which has recently emerged as a regulator of insulin receptor 
internalization and controls insulin signaling and glucose homeostasis in mice (Choi et al., 2016).  
In this work we describe a new mitotic-independent role of MASTL-ENSA/ARPP19-
PP2A/B55 (Figure 31), another cell cycle module with a metabolic function that appears to be 
relevant in non-proliferative cells as well as in insulin-responsive tissues to maintain glucose 
homeostasis in vivo. 
4.1.1 mTORC1/S6K1-dependent feedback modulation in a glucose-dependent manner 
mTORC1 activation is a critical event in the mTORC1/S6K1-dependent negative feedback loop 
that leads to AKT inhibition and renders cells irresponsive to insulin. Full mTORC1 activity 
requires growth factors and nutrients, and both amino acids and growth factors have been shown 
to modulate insulin signaling through mTOR-dependent effects (Haruta et al., 2000; Tremblay & 
Marette, 2001). However, whether glucose levels have the ability to modulate mTORC1-
dependent feedback loop has not been directly explored. Chronic activation of mTOR by glucose 
and IGF-I in pancreatic β-­‐cells decreased AKT phosphorylation in a rapamycin-dependent 
manner (Briaud et al., 2005), and now it is also known that mTORC1 has the ability to sense 
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glucose (Efeyan et al., 2013). The increased AKT-TSC2 and S6K1 phosphorylation in a glucose-
sensitive manner in MASTL null cells, together with the lack of evidence for glucose regulating 
directly the PI3K/AKT pathway, led us to speculate that glucose may regulate AKT activity 
through the mTORC1-dependent feedback loop, and that MASTL might participate in this loop to 
potentiate AKT inhibition. We have explored this idea in our experiments by doing starvations and 
short re-stimulations with glucose. We have observed that glucose starvation increases and 
glucose re-stimulation decreases AKT phosphorylation, and this inversely correlates with 
mTORC1 activity, suggesting that glucose is able to modulate AKT activity downstream of 
mTORC1 signaling (Figure 24). Given that glucose activates mTORC1 through a similar 
mechanism as amino acids, which involves the Rag GTPases and mTORC1 recruitment to the 
lysosome (Efeyan et al., 2013), it is not surprising that glucose also modulates insulin signaling 
through mTORC1.  
4.2.2 Downstream targets of MASTL-PP2A/B55 
The fact that ENSA/ARPP19 depletion mimicked the absence of MASTL in the feedback-
mediated regulation of AKT, together with the rescue of MASTL-depletion phenotype using PP2A 
inhibitors, suggested that MASTL function in the feedback is mediated by PP2A/B55. From the 
use of chemical inhibitors of PP2A it is known that PP2A can positively regulate AKT and mTOR 
signaling through the insulin pathway, as PP2A dephosphorylates and stabilizes the adaptor 
protein IRS1 (Hartley & Cooper, 2002). A recent work has shown that PP2A/B55α sustains 
hyperactive signaling of the AKT, ERK and Wnt pathways in pancreatic cancer cells through an 
unknown mechanism (Hein et al., 2016). Therefore, increased PP2A/B55 phosphatase activity 
might explain the increased AKT and mTOR activity and sustained insulin signaling observed in 
absence of MASTL.  
mTORC1 and S6K1 activity down-regulates insulin/IGF-I signaling through effects on IRS 
serine phosphorylation and protein stability, which are the result of a balance between specific 
kinases and phosphatases. IRS phosphorylation by S6K1 and mTORC1 induce their 
delocalization and degradation (Haruta et al., 2000). Conversely protein dephosphorylation by 
PP2A protects IRS1 against excessive serine phosphorylation and degradation (Hartley & 
Cooper, 2002), and PP2A counterbalances mTOR/S6K1-mediated phosphorylation of IRS by 
directly dephosphorylating S312 (of human IRS1) (Carlson et al., 2004). Importantly the 
regulatory subunit that mediates PP2A function, and the effect of PP2A on specific 
phosphorylated residues of IRS remains elusive. In our work we have characterized the proline-
directed S616 on IRS1 as a new phosphosite targeted by the proline-directed S/T PP2A/B55 
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phosphatase (Figure 18a), whose phosphorylation is decreased upon S6K1 inhibition, and 
contributes to the degradation of IRS1. S312 on IRS1 was not affected by B55 depletion, 
suggesting that additional B regulatory subunits of PP2A might target this site. Additional 
residues on IRS1 are phosphorylated by S6K1, such as S307 (of human IRS1) (Harrington et al., 
2004), and S527, as both sites matched the S6K1 consensus site (RXRXXS/T) (Shah & Hunter, 
2006). The proline-directed S/T sites on IRS1, S312, S616, and S636 (all of human IRS1), were 
more phosphorylated in TSC2 −/− MEFs and were sensitive to rapamycin. Although they were 
not phosphorylated in vitro by S6K1, expression of a rapamycin-resistant gain-of-function S6K1 
mutant partially rescued phosphorylation at these S/P sites after rapamycin treatment, suggesting 
that phosphorylation of these sites in vivo requires S6K1 activity (Shah & Hunter, 2006). 
Additional kinases can phosphorylate IRS proteins in response to different stimuli, such is the 
case of S312 on IRS1 that is targeted by JNK1 upon TNFα stimulation (Rui et al., 2001).  
In the last years new targets of the feedback have also emerged. GRB10 is phosphorylated 
by mTORC1 at multiple serine sites and cooperates with IRS to control insulin signaling (Hsu et 
al., 2011a). Whether PP2A counteracts mTORC1 activity towards GRB10 is not known. Here we 
have shown that the proline-directed S476 on GRB10 is dephosphorylated by PP2A/B55 
phosphatase, and phosphorylation of this site influence insulin signaling. 
As a summary we propose a new function for the MASTL-PP2A/B55 pathway in the 
regulation of the mTORC1/S6K1-mediated feedback loop. Through inhibition of PP2A/B55, 
MASTL prevents the dephosphorylation of the feedback-target proteins, IRS1 and GRB10, which 
are adaptors of the RTKs and mediate signal transduction to the PI3K/AKT pathway. MASTL 
functions to negatively regulate AKT signaling by promoting feedback activity (Figure 44). 
 
Figure 44. Model for the function of the 
MASTL-PP2A/B55 pathway in the regulation of 
the negative feedback loop mediated by 
mTORC1/S6K1. Schematic of the PI3K-mTOR 
signaling pathway, depicting feedback regulation 
and the proposed MASTL-PP2A/B55 participation. 
Green and red boxes indicate active and inactive 
protein, respectively. Red arrow over MASTL 
indicates that MASTL is activated in feedback 
conditions although its upstream regulators are 
not known. 
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PP2A has a dual role, as PP2A not only activates insulin signaling but also inhibits AKT and 
mTORC1 (Wlodarchak & Xing, 2016). PP2A/B55α dephosphorylates AKT on T308, leading to 
kinase inactivation in a murine prolymphocytic cell line and NIH3T3 murine fibroblasts (Kuo et al., 
2008). PP2A can also revert phosphorylation of S6K1 at T389, although the regulatory subunit 
involved is not known. In our experiments, we did not found decreased levels of AKT T308 or 
S6K1 T389 in the absence of MASTL suggesting that either this pathway does not operate in this 
context or it is not regulated by MASTL. Further, PP2A/B56 counteracts mTORC1 activation by 
amino acids by targeting through MAP4K3 (Yan et al., 2010), and PP2A/B55α targets mTORC1-
dependent phosphorylation in ULK1 on S637 to promote autophagy in pancreatic cell lines 
(Wong et al., 2015). As MASTL null cells did not presented increased autophagy, it is likely that 
MASTL is not controlling PP2A/B55α to regulate autophagy in our cellular context. The only 
evidende of MASTL positively regulating AKT published so far, comes from experiments of 
MASTL overexpression in cancer cell lines. MASTL induced hyperphosphorylation of AKT on 
S473, through an ENSA/ARPP19-PP2A/B55-independent mechanism, which seems that involve 
activation of GSK3 and degradation of the S473-target phosphatase PHLPP (Vera et al., 2015).  
This dual role of PP2A may therefore serve to counterbalance the actions of mTOR/S6K1 
signaling to promote coordinated signaling output, and demonstrates that protein phosphatase 
activity must be also regulated to modulate signaling.	  Analogous to its kinase courterparts, which 
are subjected to nutrient regulated pathways and multiple layers of regulation, PP2A may also 
sense nutrient and growth signaling. Multiple reports have shown that mTOR can negatively 
regulate PP2A activity. Treatment with rapamycin increases PP2A activity (Hartley & Cooper, 
2002; Peterson et al., 1999) and most of this negative regulation supports mTOR activation 
through insulin signaling and PI3K. More recent data has demonstrated that mTORC1 
inactivation relieves PP2A/B55 phosphatase activity (Di Conza et al., 2017), although nothing is 
known about the precise mechanisms involved in mTORC1-dependent regulation of PP2A. In 
yeast, the PP2A regulatory subunit Tap42 is target of TOR signaling and is another mechanism 
of TOR-mediated PP2A inhibition (de Virgilio, 2012). However, this function is not conserved in 
mammals, where the association between PP2Ac and α4, the mammalian homolog of TAP42, is 
not dependent on mTOR (Wong et al., 2015; Yoo et al., 2008). Interestingly, if the PP2A/B55-
inhibitory kinase MASTL is regulated downstream mTORC1 to coordinate the effect of the 
feedback on insulin signaling, MASTL could emerge as the missing  link between mTORC1 and 
PP2A/B55.  
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4.2.3 Upstream regulation of MASTL  
The mechanism by which MASTL is activated during M phase involves phosphorylation of the T-
activation loop by CDK1/cycB at T194 and T207 sites and subsequent MASTL 
autophosphorylation at the C-terminal tail on S875 (Blake-Hodek et al., 2012). These two 
sequential phosphorylations are thought to be essential for MASTL activity as mutation to alanine 
of any of them prevents MASTL activity over its substrate in vitro. In the current model 
phosphorylation of MASTL at the C-tail allows the C-tail to interact with the N-lobe to help 
stabilizing the active kinase conformation. Whether MASTL is also active in a mitotic-independent 
context, or whether other kinases can contribute to MASTL regulation by phosphorylating MASTL 
at different sites, is not known.  
Additional CDKs, apart from CDK1/cycB complex might target MASTL’s T-loop in other 
phases of the cell cycle where CDK1 activity is low. As such we have observed that this 
phosphosite is sensitive to the CDK1/2 inhibitor RO-3306 (data not shown). Phosphorylation of 
MASTL on T194 was enhanced upon TSC2 knockdown and was prevented by treatment with the 
CDKs inhibitor, suggesting that mTORC1 hyperactivation indirectly favors MASTL 
phosphorylation at T194 by CDKs. Interestingly, treatment with the mTORC1 allosteric inhibitor 
rapamycin, or with the mTOR kinase inhibitor Torin1, also prevented phosphorylation of MASTL 
on T194, indicating that either mTORC1 can directly phosphorylate MASTL on T194 or that 
mTORC1 inhibits the phosphatase that targets this residue (Figure 27a). Similar observations 
were done in HeLa cells by phosphoproteomics, where phosphorylation on T194 of MASTL 
decreases up to 2-fold upon rapamycin treatment (Chen et al., 2009). T194 is a proline-directed 
site and PP2A/B55α has been proposed to dephosphorylate it, contributing to MASTL 
inactivation at mitotic exit (Hegarat et al., 2014). One possibility is therefore, that mTORC1 
inhibition contributes to MASTL inactivation by relieving MASTL inhibition over PP2A/B55α, but 
still the direct mechanism of mTORC1-mediated regulation of MASTL activity remains elusive. 
Based on our preliminary results, mTORC1 can directly phosphorylate MASTL in vitro, and the 
S878 emerge as a clear candidate phosphosite, given that mTORC1 increased its 
phosphorylation over 150-fold in a kinase assay in vitro (Figure 31b). Of note, this site is 
phosphorylated in vivo and contributes to MASTL kinase activity in mitotic extracts of Xenopus 
(Blake-Hodek et al., 2012). Further characterization of phosphorylation on MASTL in vivo, in 
interphase and mitotic cells indicated that this site was targeted by a non-mitotic kinase and was 
not an autophosphorylation site MASTL (unpublished data from our collaborators). S878 is 
located at the end of the C-tail, just 3 amino acids after S875 and 1 amino acid before the last 
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one of MASTL sequence, and is highly conserved among species. According to the last 
refinement of mTORC1 phosphorylation motif, which revealed preferences for non-charged 
residues surrounding the phosphoacceptor site, in addition to a preference for either proline or a 
non-proline hydrophobic residue in the +1 position (Kang et al., 2013), S878 on MASTL is a good 
potential mTORC1 site. Further experiments are required to confirm if phosphorylation of MASTL 
at S878 is necessary in vivo and contributes to MASTL activity in conditions of feedback activity 
(Figure 45).  
Interestingly, a TOR signaling motif (TOS) is found in some of the mTORC1 substrates and is 
essential for substrate recognition mediated by RAPTOR and subsequent phosphorylation 
(Schalm & Blenis, 2002; Schalm et al., 2003). MASTL sequence might have a putative TOS motif 
within its N-domain (FDEEMA, 128-133 aa of human MASTL) as the amino acidic sequence 
resembles the TOS motif of well-known mTORC1 substrates, reinforcing the idea of MASTL 
being directly regulated by mTORC1. Of note, this putative TOS motif is well conserved across 
species, suggesting that might play an important role in MASTL regulation.  
mTORC1-mediated phosphorylation of MASTL implies that they should co-localize in the 
same cellular compartment, whereas have not directly addressed this question in our 
experimental conditions, there are some evidences indicating that this may happen. mTOR and 
Raptor have been found in abundant levels in the cytoplasm and the nucleus (X. Zhang et al., 
2002), and mTORC1 assembly predominantly occurs in the cytoplasm although it also exists in 
the nucleus in non-transformed human fibroblasts (Rosner & Hengstschläger, 2008). Indeed, 
mTORC1 phosphorylates some transcription factors and associate with rDNA suggesting that it 
might have a role in transcription regulation (Betz & Hall, 2013). Data obtained by 
 
Figure 45. Proposed model of MASTL activation in mitosis and under nutrient-regulated 
conditions. Phosphorylation of MASTL on the C-tail is a requisite for MASTL activity. In mitosis 
priming phosphorylation by CDK1 on the T-loop is required for MASTL autophosphorylation and 
full kinase activity. Under nutrient regulated conditions mTORC1 might phosphorylate MASTL on 
S878 at the C-tail to fine tune modulate MASTL activity. 
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videomicroscopy using a GFP-tagged version of MASTL showed that MASTL is a nuclear protein 
that shuttles to the cytoplasm just before NEB in mitosis (Álvarez-Fernández et al., 2013; Wang 
et al., 2013). Moreover, in a subfractionation analysis endogenous MASTL is found both in the 
nucleus and in the cytoplasm (data not shown). Accordingly, MASTL sequence has two nuclear 
localization signal (NLS) and one nuclear export signal (NES) consensus sequence, which are 
responsible for the nuclear and cytoplasmic localization of MASTL, respectively. It would be 
interesting to know where MASTL localizes in response to nutrient stimuli, and where the putative 
mTORC1-dependent regulation of MASTL might occur. PP2A/B55 complexes are mostly 
cytoplasmic, and endosulfines are nucleocytoplasmatic proteins providing enough flexibility for 
MASTL-mediated inhibition of PP2A/B55 in any cellular compartment.  
4.2.4 Metabolic implications of MASTL function in the regulation of AKT 
Depletion of MASTL renders cells more sensitive to insulin stimulation and AKT activation in 
conditions of feedback activity. Markedly, AKT targets involved in glucose metabolism are 
upregulated in MASTL null cells, including GLUT4 translocation to the plasma membrane and the 
expression of glycolytic enzymes through the mTORC1-HIF1α axis, which mediates glucose 
uptake and allocates intracellular glucose towards the glycolytic pathway, respectively (Figure 
34,35). Eventually AKT can also potentiate the conversion of glucose to glycogen through the 
inhibition of GSK3 and subsequent activation of glycogen synthase. Even though glycogen 
determination has not been directly addressed, increased GSK3 phosphorylation is observed in 
MASTL depleted cells (Figure 36c). HIF1α protein levels are increased upon MASTL depletion 
in an AKT-dependent manner, as they are restored by treatment with AKT inhibitors. It has been 
recently published that PP2A/B55α prevents HIF1α from degradation through a different 
mechanism and favor survival under hipoxia and glucose deprivation in breast cancer cell lines. 
In this scenario PP2A/B55α counteracts S6K1-mediated PHD2 phosphorylation, suggesting 
additional mechanisms of B55-mediated control of metabolism (Di Conza et al., 2017).  
Chronic mTORC1 activation as consequence of over nutrition and excess of nutrients in the 
blood renders cells insensitive to insulin and impairs GLUT4-mediated glucose uptake. Therefore 
mTORC1/S6K1-dependent feedback modulation of AKT activity has implications in vivo in 
obesity and metabolic disorders involving insulin resistance, such as type 2 diabetes. 
Interestingly, ablation of Mastl in vivo improves glucose tolerance in a model of high fat diet 
(HFD)-induced obesity without affecting glucose-stimulated insulin secretion. Ablation of Mastl did 
not improved insulin sensitivity, although HFD-fed control mice did not develop insulin resistance 
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either. Nevertheless, the fact that Mastl null mice are not hyperinsulinemic might suggest that the 
improved glucose tolerance is consequence of better glucose uptake in Mastl depleted tissues. 
The effect of Mastl ablation is likely mediated by increased PI3K/AKT signaling in the muscle and 
concomitant glucose uptake, as the effect is rescued upon treatment with a PI3K inhibitor (PI3Ki). 
Muscle is likely the tissue of Mastl function, although we cannot rule out a contribution of WAT or 
liver. Deletion of Mastl in old mice lowers basal glycaemia in ad libitum conditions, suggesting 
that Mastl might improve glucose tolerance upon challenging conditions of either HFD or aging.  It 
has just been published a new glucose sensing mechanism in the skeletal muscle that is 
essential to maintain postprandial glucose homeostasis independently on insulin signaling (Meng 
et al., 2017). This mechanism involves glucose sensing by KATP channels and insulin-
independent activation of AKT through Baf60c-dependent transcription of DEPTOR. This 
highlights the necessity of inhibition of the mTORC1-dependent feedback loop to relieve inhibition 
of AKT signaling and maintain whole body glucose homeostasis, suggesting that Mastl could play 
a role in skeletal muscle independently on insulin signaling.  
Of note, Ensa knockout mice have improved glucose tolerance, despite having defective 
insulin secretion, and are more insulin sensitive (Wiles et al., 2002), suggesting that lack of Ensa 
increases glucose uptake. Whether Ensa depletion affects insulin signaling in vivo has not been 
explored, but fit in a model where Mastl phosphorylates Ensa to inhibit PP2A/B55 and AKT 
signaling. In the same direction, haploinsuficiency of the B55α	   subunit of PP2A causes insulin 
resistance likely due to the defective insulin-induced AKT stimulation in insulin-responsive tissues 
(Goldsworthy et al., 2016).  
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4.3 Uncoupling the MASTL-ENSA/ARPP19-PP2A/B55 pathway 
The only molecular pathway attributed so far to the kinase MASTL is the inhibition of PP2A/B55 
phosphatase complexes through the phosphorylation of ENSA and ARPP19 proteins. With the 
exception of a recent work in which it was proposed that MASTL induced GSK3 
dephosphorylation independent of endosulfines, through an unknown mechanism (Vera et al., 
2015), all functions ascribed for MASTL operate through the same molecular pathway. That is the 
case of its well-studied function in mitosis, as well as its new function in metabolism. PP2A/B55 
phosphatase complexes and endosulfines function in many different pathways in the cell and, as 
such, control other cellular and physiological functions in addition to mitosis and the 
mTORC1/S6K1-dependent feedback loop. Nevertheless, it is not known to what extent all of 
these endosulfine- and PP2A/B55-dependent functions are also mediated by MASTL. 
As stated above, ENSA and ARPP19 are able to regulate PP2A/B55 complexes at M entry 
even when MASTL is inactive, and this is achieved through ENSA/ARPP19 phosphorylation by 
CDK1. This raises the possibility that there might exist some cellular contexts, such as those 
where MASTL activity is irrelevant, where ENSA/ARPP19-mediated inhibition of PP2A is 
independent of MASTL. ENSA/ARPP19 proteins are known to be involved in several biological 
processes in addition to the cell cycle. In the murine brain, suppression of ARPP19 expression 
increases neurite length (White & Giffard, 2013), and this is consistent with previous reports that 
showed that PP2A/B55γ activity induces neurite outgrowth (Strack, 2002), although whether 
ARPP19 modulates PP2A/B55γ activity in this context has not been addressed. Interestingly, 
ARPP19 is a major substrate for cAMP activated protein kinase (PKA) in postsynaptic neurons, 
whether PKA-mediated ARPP19 phosphorylation contributes to PP2A/B55 inhibition in this 
context is unknown. Interestingly, in some cellular scenarios such as meiosis, PKA-mediated 
phosphorylation of ENSA/ARPP19 antagonizes the effect of MASTL phosphorylation (Dupré et 
al., 2013). 
ENSA was identified as an endogenous ligand and regulator of the sulfonylurea-binding site 
of KATP channels in pancreatic β-cells and ovine brain (Virsolvy-Vergine et al., 1992). ENSA 
binding mediates the closure of the KATP channels, and stimulates insulin secretion in β-cells, 
although the precise mechanism and ENSA regulation is unknown. The involvement of 
PP2A/B55, as target of ENSA, in insulin secretion has not been directly addressed either. A 
recently published work showed that haploinsuficiency of B55α in mice causes insulin resistance 
and highly compensatory increase in β-cell mass and hyperinsulemia (Goldsworthy et al., 2016). 
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Although diminished PP2A/B55α activity would fit in a model of ENSA promoting insulin secretion 
through inhibition of phosphatase complexes, the hyperinsulemia phenotype and increased β-cell 
mass in B55α heterozygous mice were most likely adaptive responses to insulin resistance 
caused by defective insulin-induced AKT stimulation in metabolic tissues. As mentioned above, 
ENSA acts as an endogenous counterpart to sulfonylureas; drugs that are used in type 2 diabetic 
patients for triggering insulin secretion. PKA is also known to be involved in the process of insulin 
secretion, since treatment of cells with the PKA activator, forskolin, enhances insulin secretion (F. 
Wei et al., 2005). However, the potential contribution of PKA to the regulation of ENSA has not 
been addressed. According to our data, ablation of MASTL in mice does not impair insulin 
secretion either in fasting or after glucose-stimulation (Figure 32). Since ENSA ablation blunts 
insulin secretion it is unlikely that MASTL positively regulates ENSA in β-cells to trigger insulin 
secretion, pointing to a MASTL-independent function of ENSA in cellular metabolism. 
PP2A/B55 complexes target many different signaling pathways and have also been linked to 
several cell cycle and metabolic functions but little is known about their regulation in specific 
cellular contexts. Here we present a mechanism of PP2A/B55 regulation mediated by MASTL 
that is relevant for mitosis and the control mTORC1/S6K1-mediated feedback loop. Further there 
exist another mechanism driven by the inhibitory protein α4, which binds PP2A catalytic subunit 
and impairs assembly with the B regulatory subunits and that might regulate PP2A/B55 activity 
independently on MASTL. Such is the case of PP2A/B55α	   driving a p53-dependent metabolic 
adaptation to glutamine deprivation, where PP2A/B55α activity is controlled by α4 protein, as 
glutamine deprivation induces dissociation of PP2A from its inhibitor α4 (Reid et al., 2013). 
Similarly, PP2A/B55α is activated upon amino acid and serum starvation, but not rapamycin 
treatment, through a similar mechanism to activate autophagy (Wong et al., 2015). As mentioned 
above, PP2A/B55 complexes also regulate G0-G1 and G1/S transitions through phosphorylation 
of Rb family of pocket proteins (Kurimchak & Graña, 2012), and this function was regulated in a 
MASTL-independent manner, suggesting additional levels of regulation of PP2A/B55. 
In summary, even though the MASTL-ENSA/ARPP19-PP2A/B55 module is evolutionary 
conserved from yeast to mammals, and MASTL has emerged as a PP2A/B55-inhibitory kinase, 
not all the functions attributed to the different components of the pathway seem to be controlled 
by MASTL. Thus, there must be additional mechanism of regulation of endosulfines and 
PP2A/B55 complexes to meet specific necessities in a cell context and cell type specific manner.  
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4.4 Therapeutic implications of MASTL regulation 
Based on its mitotic function and the antiproliferative response of MASTL depletion, MASTL has 
been proposed as a potential new target for cancer therapy. As such MASTL is overexpressed is 
breast tumors and its expression correlates with poor prognosis, and MASTL depletion impairs 
proliferation of breast tumor cells in vitro and in vivo (Álvarez-Fernández et al., submitted). 
Current efforts are based in the identification of those tumors that might benefit of MASTL-based 
therapies. 
With the newly identified role of MASTL in the mTORC1-dependent feedback loop, MASTL 
also emerges as a new potential therapeutic target for metabolic diseases. That mTORC1 
hyperactivation from genetic or dietary manipulation results in insulin resistance, and mice lacking 
S6K1 are protected from obesity-induced insulin resistance, has led to speculate that mTORC1 
or S6K1 inhibitors could improve glucose tolerance and protect against type 2 diabetes (Um et 
al., 2004). Pharmacological inhibition of mTORC1 using rapamycin has the opposite effect, 
causing insulin resistance and impaired glucose homeostasis (Fang et al., 2013). This result is 
explained at least in part by the fact that prolonged rapamycin treatment also inhibits mTORC2 
signaling in vivo. As mTORC2 directly activates AKT downstream of insulin/PI3K signaling, it is 
not surprising that mTORC2 inhibition disrupts the physiological response to insulin. A selective 
S6K1 inhibitor improves glucose tolerance in HFD-fed mice and enhance insulin signaling in 
metabolic tissues, overcoming the limitations of rapamycin (Shum et al., 2016). Targeting 
regulators of the feedback loop downstream of mTORC1 might be bona fide targets to improve 
glucose disposal in obese diabetic individuals while avoiding toxicity associated with inhibition of 
mTOR. In this line, MASTL appears as a new potential target given the low toxicity associated 
with Mastl inhibition in adult mice, whereas improves glucose tolerance and insulin signaling in 
mice.  
The mTORC1/S6K1-dependent feedback loop also influences therapeutic responses to 
mTOR inhibitors in cancer therapy, as PI3K/AKT and ERK/MAPK activation attenuates antitumor 
effect of mTORC1 inhibition (Carracedo et al., 2008; O’Reilly et al., 2006). In addition to insulin 
and IGF-I signaling, mTOR inhibitors also enhance the activation of other receptor tyrosine 
kinases (RTKs) upstream of PI3K and AKT. This includes members of the EGF Receptor family 
(EGFR, ErbB2 [also known as Her2], ErbB3 [Her3], and ErbB4 [Her4]), which are acutely 
activated upon mTOR inhibition, without having immediate effects on receptor levels (O’Reilly et 
al., 2006; Rodrik-Outmezguine et al., 2011). While the post-translational mechanisms underlying 
this regulation are not currently known, the effects are most prominently seen with mTOR kinase 
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inhibitors, rather than the allosteric inhibitor rapamycin. As this class of compounds inhibits 
mTORC1 and mTORC2 equally, some of this feedback regulation could be mediated by 
mTORC2 signaling. Microarray analyses showed that MASTL depleted cells have strong 
upregulation of the ERBB pathway and its downstream effectors, including the MAPK pathway, 
suggesting that the effect of MASTL in the feedback is not restricted to the insulin pathway (data 
not shown). MASTL inhibition might affect the status of other adaptor proteins of the ERBB 
receptors although this has not been addressed, or there might be crosstalk among insulin 
receptor and other RTKs. Furthermore, MASTL nulls cells are more sensitive to human epidermal 
growth factor (hEGF) stimulation, as shown by increased autophosphorylation of EGFR, and 
although signal transduction to AKT is not largely enhanced, treatment with and EGFR inhibitor 
partially rescued AKT T308 phosphorylation in MASTL null cells (Figure 20). Whereas GRB10 
has been found bound to EGFR (He et al., 1998), GRB10 depletion does not restore sensitivity to 
hEGF in TSC2-/- MEFs (Hsu et al., 2011a). These results are still controversial, so we cannot 
rule out whether MASTL might regulate EGFR activity by another mechanism independent on 
GRB10. MASTL depleted cells also present higher EGFR total levels (Figure 20b), and it has 
been proposed that mTORC1 activity protects EGFR from lysosomal degradation (Kim et al., 
2015), raising another plausible explanation for the enhanced EGFR signaling in MASTL 
depleted cells. In any case, these results should be taken into account for future anti-tumoral 
therapies targeting MASTL kinase, as combined treatments of MASTL inhibitors along with RTK 
inhibitors, which are already use in clinics, may help for finding synergies and enhance 
therapeutic response in tumors. 
Implications of MASTL in AKT-driven metabolism could also be relevant to find metabolic 
dependencies to MASTL inhibition in tumor cells. For instance, MASTL depleted cells might rely 
more on glucose metabolism and, as such, be more sensitive to glucose availability.  
 
Figure 46. MASTL is an essential mitotic 
regulator with metabolic implications. MASTL is 
a recently discovered mitotic kinase with critical 
implications in proliferation and cancer. Other 
functions of MASTL and its physiological relevance 
are just starting to emerge. We have described a 
new role of MASTL in the control of AKT and 
mTORC1 signaling and its metabolic implications. 
This dual role of MASTL might be exploited for 
treating glucose intolerance disorders and might 
contribute to find more effective antitumoral 
therapies. 
  Discussion  
	   134	  
Altogether, the work herein presented supports a new role of MASTL in the modulation of 
mTORC1/S6K1-dependent feedback loop to potentiate PI3K/AKT inhibition and contributed to 
further understand the role of MASTL kinase in mammals. Given that MASTL is a druggable 
kinase whose deletion presents low toxicity in adult mice, these findings might hopefully expand 
its potential therapeutic applicability for the treatment of glucose intolerance, and contribute to the 
development of more accurate antitumoral responses (Figure 46).  
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1. MASTL is an essential mitotic kinase required for proper chromosome condensation and 
segregation in mammals. MASTL prevents premature dephosphorylation of CDK-
dependent phosphosites in mitosis through inhibition of the PP2A/B55 phosphatase. 
2. Mastl is not essential for S-phase entry from quiescence, neither for entry or 
maintenance of cellular quiescence. 
3. MASTL-ENSA/ARPP19-PP2A/B55 pathway participates in the mTORC1/S6K1-
dependent negative feedback loop that limits AKT activity.  
4. MASTL, through ENSA/ARPP19-mediated inhibition of PP2A/B55, prevents the 
dephosphorylation of two targets of the feedback, the adaptor proteins IRS and GRB10, 
to allow fine-tune of PI3K/AKT pathway in response to nutrients (e.g. glucose) and 
growth factors. Deregulation of this axis has metabolic consequences in glucose uptake 
in cells. 
5. MASTL activity is positively modulated in feedback conditions downstream of the 
mTORC1/S6K1 pathway. 
6.  Mastl plays a physiological role in proliferation in vivo. Whereas ablation of Mastl in 
young mice leads to severe proliferative defects that compromise survival, adult mice are 
more tolerant to Mastl depletion. However, Mastl ablation impaired tissue regeneration 
and altered tissue homeostasis in the long term, eventually leading to premature death. 
7. Mastl controls glucose homeostasis in vivo, and improves glucose tolerance in conditions 
of high fat diet-induced obesity, in a PI3K-dependent manner, without affecting glucose-
stimulated-insulin secretion.  
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Álvarez-Fernández, M., Sanz-Flores, M., Sanz, B., Salazar-Roa, M., Partida, D., Ali, H. R., 
Manchado, E., Lowe, S., VanArsdale, T., Shields, D., Caldas, C., & Quintela-Fandino, 
Miguel Malumbres, M. (n.d.). MASTL/Greatwall kinase activity as a new therapeutic target 
in breast cancer. Submitted. 
Anania, M., Gasparri, F., Cetti, E., Fraietta, I., Todoerti, K., Miranda, C., Mazzoni, M., Re, C., 
Colombo, R., Ukmar, G., Camisasca, S., Pagliardini, S., Pierotti, M., … Greco, A. (2015). 
Identification of thyroid tumor cell vulnerabilities through a siRNA-based functional 
screening. Oncotarget, 6(33), 34629–34648. 
Annicotte, J.-S., Blanchet, E., Chavey, C., Iankova, I., Costes, S., Assou, S., Teyssier, J., Dalle, 
S., Sardet, C., & Fajas, L. (2009). The CDK4-pRB-E2F1 pathway controls insulin secretion. 
Nature Cell Biology, 11(8), 1017–1023. 
Archambault, V., Zhao, X., White-Cooper, H., Carpenter, A. T. C., & Glover, D. M. (2007). 
Mutations in Drosophila Greatwall/scant reveal its roles in mitosis and meiosis and 
interdependence with polo kinase. PLoS Genetics, 3(11), 2163–2179. 
Bai, L., Wang, Y., Fan, J., Chen, Y., Ji, W., Qu, A., Xu, P., James, D. E., & Xu, T. (2007). 
Dissecting Multiple Steps of GLUT4 Trafficking and Identifying the Sites of Insulin Action. 
Cell Metabolism, 5(1), 47–57. 
Bai, Y., Xuan, B., Liu, H., Zhong, J., Yu, D., & Qian, Z. (2015). Tuberous Sclerosis Complex 
Protein 2-Independent Activation of mTORC1 by Human Cytomegalovirus pUL38. J Virol, 
89(15), 7625–7635. 
Bernal-Mizrachi, E., Fatrai, S., Johnson, J. D., Ohsugi, M., Otani, K., Han, Z., Polonsky, K. S., & 
Permutt, M. A. (2004). Defective insulin secretion and increased susceptibility to 
experimental diabetes are induced by reduced Akt activity in pancreatic islet  ?? cells. 
Journal of Clinical Investigation, 114(7), 928–936. 
Bernard, A., Jin, M., González-Rodríguez, P., Füllgrabe, J., Delorme-Axford, E., Backues, S. K., 
Joseph, B., & Klionsky, D. J. (2015). Rph1/KDM4 mediates nutrient-limitation signaling that 
  References 
	   143	  
leads to the transcriptional induction of autophagy. Current Biology, 25(5), 546–555. 
Betz, C., & Hall, M. N. (2013). Where is mTOR and what is it doing there? Journal of Cell Biology, 
203(4), 563–574. 
Blake-hodek, K. A., Williams, B. C., Zhao, Y., Castilho, P. V, Chen, W., Mao, Y., & Yamamoto, T. 
M. (2012). Determinants for Activation of the Atypical AGC Kinase Greatwall. Molecular and 
Cellular Biology, 1337–1353. 
Blake-Hodek, K. a, Williams, B. C., Zhao, Y., Castilho, P. V, Chen, W., Mao, Y., Yamamoto, T. 
M., & Goldberg, M. L. (2012). Determinants for activation of the atypical AGC kinase 
Greatwall during M phase entry. Molecular and Cellular Biology, 32(8), 1337–53. 
Bontron, S., Jaquenoud, M., Vaga, S., Talarek, N., Bodenmiller, B., Aebersold, R., & De Virgilio, 
C. (2013). Yeast Endosulfines Control Entry into Quiescence and Chronological Life Span 
by Inhibiting Protein Phosphatase 2A. Cell Reports, 3(1), 16–22. 
Bradley, H., Shaw, C. S., Worthington, P. L., Shepherd, S. O., Cocks, M., & Wagenmakers, A. J. 
M. (2014). Quantitative immunofluorescence microscopy of subcellular GLUT4 distribution 
in human skeletal muscle: effects of endurance and sprint interval training. Physiological 
Reports, 2(7), 1–16. 
Briaud, I., Dickson, L. M., Lingohr, M. K., McCuaig, J. F., Lawrence, J. C., & Rhodes, C. J. 
(2005). Insulin receptor substrate-2 proteasomal degradation mediated by a mammalian 
target of rapamycin (mTOR)-induced negative feedback down-regulates protein kinase B-
mediated signaling pathway in  ??-cells. Journal of Biological Chemistry, 280(3), 2282–2293. 
Brugarolas, J., Lei, K., Hurley, R. L., Manning, B. D., Reiling, J. H., Hafen, E., Witters, L. A., 
Ellisen, L. W., Kaelin, W. G., & Jr, W. G. K. (2004). Regulation of mTOR function in 
response to hypoxia by REDD1 and the TSC1 / TSC2 tumor suppressor complex. Genes 
and Development, 18(23), 1–12. 
Brunet, A., Bonni, A., Zigmond, M. J., Lin, M. Z., Juo, P., Hu, L. S., Anderson, M.J., Arden, K. C., 
Blenis, J., & Greenberg, M. E. (1999). Akt promotes cell survival by phosphorylating and 
inhibiting a Forkhead transcription factor. Cell, 96, 857–868. 
Burgess, A., Vigneron, S., Brioudes, E., Labbé, J.-C., Lorca, T., & Castro, A. (2010). Loss of 
human Greatwall results in G2 arrest and multiple mitotic defects due to deregulation of the 
cyclin B-Cdc2/PP2A balance. Proceedings of the National Academy of Sciences of the 
United States of America, 107(28), 12564–9. 
Cameroni, E., Hulo, N., Roosen, J., Winderickx, J., & De Virgilio, C. (2004). The novel yeast PAS 
kinase Rim15 orchestrates G0-associated antioxidant defense mechanisms. Cell Cycle, 
3(4), 462–468. 
  References 
	   144	  
Carlson, C. J., White, M. F., & Rondinone, C. M. (2004). Mammalian target of rapamycin 
regulates IRS-1 serine 307 phosphorylation. Biochemical and Biophysical Research 
Communications, 316(2), 533–539. 
Carracedo, A., Ma, L., Rojo, F., Teruya-Feldstein, J., Salmena, L., Alimonti, A., Egia, A., Sasaki, 
A. T., Thomas, G., Kozma, S. C., Papa, A., Nardella, C., Cantley, L. C., … Pandolfi, P. P. 
(2008). Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K- 
dependent feedback loop in human cancer. Journal of Clinical Investigation, 118(9), 3065–
3074. 
Castilho, P. V., Williams, B. C., Mochida, S., Zhao, Y., & Goldberg, M. L. (2009). The M Phase 
Kinase Greatwall (Gwl) Promotes Inactivation of PP2A/B55?, a Phosphatase Directed 
Against CDK Phosphosites. Molecular Biology of the Cell, 20, 4777–4789. 
Chen, R. Q., Yang, Q. K., Lu, B. W., Yi, W., Cantin, G., Chen, Y. L., Fearns, C., Yates, J. R., & 
Lee, J. D. (2009). CDC25B mediates rapamycin-induced oncogenic responses in cancer 
cells. Cancer Research, 69(6), 2663–2668. 
Chica, N., Rozalén, A. E., Pérez-Hidalgo, L., Rubio, A., Novak, B., & Moreno, S. (2016). 
Nutritional control of cell size by the greatwall-endosulfine-PP2A·B55 pathway. Current 
Biology, 26(3), 319–330. 
Choi, E., Zhang, X., Xing, C., & Yu, H. (2016). Mitotic Checkpoint Regulators Control Insulin 
Article Mitotic Checkpoint Regulators Control Insulin Signaling and Metabolic Homeostasis. 
Cell, 1–15. 
Clark, S. F., Molero, J. C., & James, D. E. (2000). Release of insulin receptor substrate proteins 
from an intracellular complex coincides with the development of insulin resistance. Journal 
of Biological Chemistry, 275(6), 3819–3826. 
Clarke, J. F., Young, P. W., Yonezawa, K., Kasuga, M., & Holman, G. D. (1994). Inhibition of the 
translocation of GLUT1 and GLUT4 in 3T3-L1 cells by the phosphatidylinositol 3-kinase 
inhibitor, wortmannin. The Biochemical Journal, 300 ( Pt 3, 631–5. 
Cross, D. A., Alessi, D. R., Cohen, P., Andjelkovich, M., & Hemmings, B. A. (1995). Inhibition of 
glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature, 378, 785–789. 
Cross, D. A., Alessi, D. R., Vandenheede, J. R., McDowell, H. E., Hundal, H. S., & Cohen, P. 
(1994). The inhibition of glycogen synthase kinase-3 by insulin or insulin-like growth factor 1 
in the rat skeletal muscle cell line L6 is blocked by wortmannin, but not by rapamycin: 
evidence that wortmannin blocks activation of the mitogen-activated protein kin. The 
Biochemical Journal, 303 ( Pt 1(1994), 21–6. 
Cundell, M. J., Bastos, R., Zhang, T., Holder, J., Gruneberg, U., Novak, B., & Barr, F. A. (2013). 
  References 
	   145	  
The BEG (PP2A-B55/ENSA/Greatwall) Pathway Ensures Cytokinesis follows Chromosome 
Separation. Molecular Cell, 52(3), 393–405. 
Curtis, C., Shah, S., SF, C., G, T., OM, R., MJ, D., D, S., AG, L., S, S., Y, Y., S, G., G, H., Haffari 
G, Bashashati A, Russell R, McKinney S; METABRIC Group, Langerød A, Green A, 
Provenzano E, Wishart G, Pinder S, Watson P, M. F., … S., A. (2012). The genomic and 
transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature, 486, 
346–352. 
Dahlhaus, M., Burkovski, A., Hertwig, F., Mussel, C., Volland, R., Fischer, M., Debatin, K., 
Kestler, H., & Beltinger, C. (2016). Boolean modeling identifies Greatwall/MASTL as an 
important regulator in the AURKA network of neuroblastoma. Cancer Letters, 371, 79–89. 
de Cárcer, G., Wachowicz, P., Sara Marti ́nez-Marti ́nez, J. O., Nerea Me ́ndez-Barbero, Beatriz 
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